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ABSTRACT OF THE DISSERTATION  
MOLECULAR RISK FACTORS OF PULMONARY ARTERIAL HYPERTENSION 
by  
Hamza Assaggaf 
Florida International University, 2017 
Miami, Florida  
Professor Quentin Felty, Co-Major Professor 
Professor ChangwonYoo, Co-Major Professor 
The overall objective of the research presented in this dissertation was to investigate 
molecular risk factors of susceptibility to estrogenic chemicals, polychlorinated biphenyls 
(PCBs), hormone replacement therapy, and oral contraceptives and how that leads to the 
development of pulmonary arterial hypertension (PAH). Environmental and molecular risk 
factors for PAH are not clearly understood. This is a major hurdle for the development of 
new therapy against PAH as well as understanding individual susceptibility to this disease. 
Gender has been shown to impact the prevalence of PAH. Although controversial, 
estrogens have been implicated to be a risk factor for PAH. Thus, we hypothesize that 
women exposed to estrogenic chemicals are at increased risk of developing PAH when 
endocrine disrupting chemicals interact with unopposed estrogen to worsen pulmonary 
arterial disease. In support of this hypothesis, we have accomplished the following: 
Microarray data on PAH were collected and subsequent meta-analysis was conducted using 
genome-wide association and environment-wide association approaches on published 
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studies as well as GEO and NHANES data. All PCB geometric mean concentrations found 
higher levels in people at risk of PAH than people not at risk of PAH. The sum of non-
dioxin-like PCBs and the sum of dioxin-like PCBs were significantly higher in people at 
risk of PAH than people not at risk of PAH. Also, different levels of LOD (including PCBs 
concentration >LOD, > 50th percentile, 50th-75th percentile, and ≥75th percentile) were 
significantly higher in people at risk of PAH than people not at risk of PAH. We reported 
that females used estrogen pills and oral contraceptive were associated with risk of PAH. 
However, females used progestin and estrogen/progestin pills were not at risk of PAH. 
Molecular risk factor analysis using machine learning approaches revealed that VAMP2, 
LAMA5, POLR2C, VEGFB, and PRKCH genes are causal genes of PAH pathogenesis. 
Gene ontology and pathway analysis of PAH showed that genes involved in the apoptosis 
pathway, p53 pathway, Ras Pathway, T-cell activation, TGF-beta pathway, VEGF 
pathway, and Wnt pathway appear to be significantly associated with PAH. Documenting 
the exposure to estrogenic chemicals among the general U.S. population, and identifying 
agents and molecular risk factors associated with PAH have the potential to fill research 
gaps and facilitate our understanding of the complex role environmental chemicals play in 
producing toxicity in the lungs. 
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CHAPTER 1 
INTRODUCTION 
Exposure to toxic environmental chemicals have been known to cause many health 
effects over a period of time. Pulmonary arterial hypertension (PAH) is a rare, complex 
disease that affects the vascular system and leads to increases in pulmonary artery pressure 
and causes thickness of their walls. This thickness has been associated with different 
mechanisms including angiogenesis and vasculogenesis (Tofovic, 2010). Pathogenesis of 
PAH has been associated with many pathways that interact at different molecular levels 
(Tuder, Marecki, Richter, Fijalkowska, & Flores, 2007). Some molecular level interactions 
that are involved in PAH pathogenesis include: inflammation, uncontrolled vascular 
growth, and formation of obliterative vascular lesion (Irey & Norris, 1973). Females are 
associated with PAH and are reported to be at higher risk to the disease than males. This 
has been suggested to be a result of the higher exposure to estrogen (Austin et al., 2009). 
Moreover, many IPAH registries report such differences between females and males 
including REVEAL and French PAH registry with 4.1:1 and 1.9:1, respectively (Badesch 
et al., 2010; Humbert et al., 2006). Estrogen causes multiple effects in PAH-associated 
pathways such as alveologenesis (through estrogen α and β receptors, ERα, ERβ) (Massaro, 
Clerch, & Massaro, 2007; Patrone et al., 2003). Furthermore aromatase and mutation of 
BMPR2 are also associated with the exposure to estrogen and the formation of the 
plexiform lesion and cause PAH (Cakan, Aldemir, Topcuoglu, & Altuğ, 2009; Machado et 
al., 2009).     
Vascular changes are known to be associated with the exposure to different 
endocrine disrupting chemicals which are available in the environment in different 
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products. Also, they can be found in plastic products, pesticides, and flame retardants; and 
different routes of exposure were reported for PCB including inhalation, ingestion, and 
absorption through skin (Balabanič, Rupnik, & Klemenčič, 2011; J. R. Roy, Chakraborty, 
& Chakraborty, 2009). Even though EDCs are presented in small quantities in the 
environment, there were reported to accumulate in the body and causing many health and 
side effects including cancer, neurological and immunological effect, and reducing fertility. 
High exposure in household products was suggested to cause embryonic exposure to EDCs 
as well as during breast feeding (Yang, Kim, Weon, & Seo, 2015). Overall, the effect of 
these compounds on estrogen activity were suggested through many pathways, which all 
lead to increased levels of circulating estrogens; such as the inhibition of sulfotransferase 
by PCBs leads to elevation of estradiol in circulation (Kester et al., 2000). The combined 
effect of EDCs and estrogen reported to have about 1000 times higher synergic effect than 
the individual effect (Kortenkamp & Altenburger, 1998).       
Many researchers reported synergic effect either through direct or indirect effect, 
starting from ingestion, and exposure to EDC such as PCBs to molecular gene expression 
alteration. High exposure levels to PCBs cause lung toxicity and hypertension (Andersson 
& Brittebo, 2012). Furthermore pathways-associated with PAH such as inflammation 
reported modification of a number of genes due to EDC exposure. For example, PCB 153 
modified AHR, IL6, and IL1B; while PCB 126 modified CXCL2, SOD2, and TNF. BPA-
modified inflammation genes are PARP1, TNF, and IFNG; and Dibutyl phthalate, diethyl-
hexyl phthalate modified genes are PARP1, MIF, CSF2, MMP9 and HMOX1 (D. Roy, 
Cai, Felty, & Narayan, 2007). 
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Notably, EDCs showed association with estrogen receptors on disease pathways. 
For example, activation of mitogen-activated protein kinase pathway resulted from high 
levels of exposure to BPA which activate ERs in breast cancer (Li, Zhang, & Safe, 2006). 
Some data suggested that obesity, which is a risk factor of PAH, is linked to EDC exposure 
(Grün & Blumberg, 2009). Also, adipogenesis is a known risk factor of obesity, and PCBs 
were reported to increase adipogenesis (Arsenescu, Arsenescu, King, Swanson, & Cassis, 
2008). BPA exposure showed an association with a high risk of breast cancer, asthma, and 
different neurological effects (Rezg, El-Fazaa, Gharbi, & Mornagui, 2014). Phthalates 
were associated with an increased risk of cardiovascular disease, through alteration of 
PPAR gene expression (Yang et al., 2015).         
Pathways associated with PAH induce estrogen activity, and effects of exposure to 
EDCs have not been reviewed. However, it is suggested that reviewing common associated 
pathways would provide better understanding in disease pathogenesis. Different 
expressions of a number of genes were associated with PAH and its multiple pathways and 
their associated genes. TGF-β family receptors which cause BMPR2 mutation is known to 
be associated with FPAH (Thomson et al., 2000). Also, mutation in Bax, angiopoietin-1, 
and Smads are associated with a high risk of PAH (Rajkumar et al., 2010). Moreover, many 
pathways are associated with PAH and its pathogenesis including: MAPK signaling 
pathway, Apoptosis signaling pathway, VEGF signaling pathway, and Wnt signaling 
pathway (Sitbon & Morrell, 2012).  
Common PAH associated pathways and genes were collected from literature and 
from GEO microarray gene expression datasets. Using this information, we will perform 
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Bayesian network analysis and gene ontology search to find common pathways and genes 
associated with PAH. This will result in a markov blanket network with a number of genes 
could be plausible pathway of PAH.  
Using NHANES survey data will help us to better understand the association 
between exposure to EDC and how this exposure would affect subjects identified at risk of 
PAH. The National Health and Nutrition Examination Survey (NHANES) provide 
information about the U.S population in demographic, dietary, physical examination, 
laboratory, and questionnaire data (CDC Centers for Disease Control and Prevention, 
2017). NHANES reports data in 2-years cycles since 1999 with an average of 5,000 
participants each year. We will evaluate the effect of different PCBs including PCB 74, 99, 
118, 138, 153, and 180 on population ≥ 20 years old at identified risk of PAH. We will 
compare different LODs to evaluate what concentrations of PCB would affect the risk of 
PAH. We will evaluate the effect of use of estrogen pills only, use of progestin pills only, 
use of estrogen/ progestin combo pills, and use of birth controls on females ≥ 20 years old 
at identified risk of PAH. We used REVEAL scoring methods to create new variable “risk 
of PAH” to include subjects at risk of PAH since it was not available in NHANES (Benza 
et al., 2012). We used available variables hypertension, diabetes, thyroid problems, uric 
acid level, and insulin status. 
The main objective of this research was to use NHANES data from 1999-2004 and 
perform statistical analysis to evaluate the associations between EDCs concentrations, 
hormone replacement therapy, and oral contraceptives among subjects identified at risk of 
PAH. Also, we will support this finding with the plausible genes resulted from the meta-
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analysis preformed using GEO datasets of microarray gene expressions of PAH. We will 
provide an overall evaluation of the effect of EDC on estrogen, effect of different genes 
and pathways on risk PAH, and how these different analyses would lead to increased 
identified risk of PAH. 
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CHAPTER 2 
LITERATURE REVIEW 
GENDER, ESTROGEN, AND OBLITERATIVE LESIONS IN THE LUNG 
Abstract 
Gender has been shown to impact the prevalence of several lung diseases such as 
cancer, asthma, chronic obstructive pulmonary disease, and pulmonary arterial 
hypertension (PAH). Controversy over the protective effects of estrogen on the 
cardiopulmonary system should be of no surprise as clinical trials of hormone replacement 
therapy have failed to show benefits observed in experimental models. Potential 
confounders to explain these inconsistent estrogenic effects include the dose, cellular 
context, and systemic versus local tissue levels of estrogen. Idiopathic PAH is 
disproportionately found to be up to 4 times more common in females than in males, 
however, estrogen levels cannot explain why males develop PAH sooner and have poorer 
survival. Since the sex steroid hormone 17β-estradiol is a mitogen, obliterative processes 
in the lung such as cell proliferation and migration may impact the growth of pulmonary 
tissue or vascular cells. We have reviewed evidence for biological differences of sex 
specific lung obliterative lesions and highlighted cell-context specific effects of estrogen 
in the formation of vessel lumen-obliterating lesions. Based on this information, we 
provide a biological based mechanism to explain the sex difference in PAH severity as well 
as propose a mechanism for the formation of obliterative vascular lesions by estrogens. 
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CHAPTER 2 
LITERATURE REVIEW 
GENDER, ESTROGEN, AND OBLITERATIVE LESIONS IN THE LUNG 
INTRODUCTION 
 Lung disease is not only responsible for more than 349,000 deaths per year in the 
United States, but also is a chronic condition with more than 35 million Americans living 
with chronic lung disease according to the American Lung Association. The increased 
prevalence in women of certain lung diseases such as asthma, cystic fibrosis (CF), and 
chronic obstructive pulmonary disease (COPD) suggest that sex specific hormones have 
detrimental effects on the lung (Tam et al., 2011). The lung is a target tissue of estrogen. 
Since the lung expresses estrogen receptor (ER) subtypes, ERα and ERβ, estrogen has been 
implicated as a risk factor. The controversy over whether estrogen is protective or 
detrimental to the cardiopulmonary system should be of no surprise as clinical trials have 
failed to show cardiovascular benefits from hormone therapies. The Women’s Health 
Initiative, reported that long-term use of estrogen may have increased, risk of 
cardiovascular disease while a significant increase of coronary heart disease was observed 
among men receiving estrogens in The Coronary Drug Project (JAMA, 1970, 1973; 
Rossouw, 2005). Since the sex hormone 17β-estradiol (E2) is a mitogen, a possible 
explanation may be that exposure to E2 contributed to atherosclerotic lesions, which have 
been proposed to occur as a result of the monoclonal expansion of a mutated vascular cell 
(Benditt & Benditt, 1973). 
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 The dose of estrogens reportedly used in experimental models and clinically may 
offer a potential explanation for the estrogen paradox. On the one hand, estrogen at low 
doses acts as a pro-oxidant whereas higher doses act to suppress oxidative stress (Felty, 
Xiong, et al., 2005; Felty & Roy, 2005; Felty, Singh, & Roy, 2005; Konings et al., 2017; 
Parkash, Felty, & Roy, 2006). In order to understand the actions of estrogen in lung cells, 
it is important that we understand estrogen actions which we have summarized in brief. 
The classical paradigm of estrogen mechanism of action is through the ER which have 
been extensively reviewed; therefore we have limited our discussion in this area. Estrogen 
supports cell growth via interaction with estrogen receptors alpha and beta (ERα and ERβ) 
by directly binding to estrogen response elements, or through non-genomic pathways. The 
non-genomic action of estrogen very often includes ligand-dependent activation of GPR30 
at the plasma membrane and leads to the activation of signaling pathways such as 
ERK/MAPK, protein kinases A and C, and calcium pathways (Marino, Galluzzo, & 
Ascenzi, 2006). Together these genomic and non-genomic pathways can contribute to 
obliterative lesions via cell proliferation. Alternatively, reactive oxygen species (ROS) 
generated from redox cycling of both stilbene and catechol estrogens can act as signaling 
messengers also that are also involved in cell growth (Felty, Xiong, et al., 2005; Liehr & 
Roy, 1990; D. Roy & Liehr, 1988). We have shown that physiologically achievable E2 
concentrations, corresponding to the estrogenic menstrual peak, induces formation of ROS. 
Importantly, the ROS produced as a result of estrogen stimulation does not require estrogen 
receptors, as the ER-negative cell line produces a similar amount of ROS as the ER-positive 
cell lines (Felty, Xiong, et al., 2005). These studies suggest that estrogen induces oxidative 
stress, in part, by both ER-dependent and ER-independent pathways. Therefore, estrogen-
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induced ROS through influencing cell signaling pathways may contribute to the growth of 
estrogen exposed lung cells.  
 Clinically, estrogen is given at a “low dose” to minimize thrombotic risk and 
hormone-dependent malignancies. Few in vitro and in vivo studies have studied the adverse 
effects of low dose estrogen exposure. For example, high concentrations of E2 (10 μM) 
have been shown to act as antioxidants in vitro (Behl et al., 1997), which may explain 
certain beneficial effects. Also, the exogenous administration of estrogen may not mimic 
the endogenous estrogen response because of differences in pulsatile versus continuous 
cell exposure. It has been argued that estrogens perhaps through antioxidant activity 
scavenges lipid peroxyl radicals and thus interrupting lipid peroxidation. Estrogen has been 
suggested to scavenge hydroxyl radicals at higher doses, and inhibit superoxide radical 
generation (Abplanalp et al., 2000). Estrogen can also produce its antioxidant actions 
through suppressing inflammatory cytokines or modulating antioxidant enzyme status. For 
instance, the apoptotic oxidative effects of cytokine TNF-α which include ROS generation, 
lipid peroxidation, antioxidant enzyme consumption, and disruption of mitochondrial 
membrane potential may be countered by estrogen (Mok et al., 2006). The chemical 
structure of estrogens contain a phenolic ring. In the presence of an oxidant-generating 
environment, the phenolic hydroxyl group present at the C3 position of the A ring of 
estrogens or catechol estrogens accept electrons, and gets oxidized by either accepting 
these electrons or losing a proton (Liehr & Roy, 1990; D. Roy & Liehr, 1988). This may 
help explain the antioxidant function of estrogens or estrogenic chemicals. In contrast to 
antioxidant effects, estrogens have been described to induce an inflammatory response with 
an increase of chemokines such as IL-8 (P. Comeglio et al., 2014). On the contrary, 
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androgens have been demonstrated to have potent anti-inflammatory effects, reducing 
secretion of cytokines and chemokines which are related to Th1 inflammatory response 
(Vignozzi et al., 2013). Testosterone was able to blunt the inflammatory response induced 
by potent pro-inflammatory stimuli such as TNFα, LPS, activated CD4 (+) lymphocytes 
(Vignozzi et al., 2012). Hence, the counteractive effects of these two sex steroid hormones 
might justify the relative increased incidence of pulmonary diseases in females as 
compared to males as well as help to explain the paradoxical effects of estrogens. 
 Besides the dose, the capability of lung tissue to biosynthesize estrogen from 
circulatory testosterone by the cytochrome P-450 enzyme aromatase (CYP19) raises the 
question of whether a local imbalance between testosterone and E2 levels influences the 
development of lung disease. Lastly, cell-context specific effects may also determine 
whether physiological or pharmacological concentrations of E2 stimulates cell 
proliferation, hypertrophy, or survival of obliterative vascular leisons found in severe 
pulmonary arterial hypertension (PAH). Understanding the biological and biochemical 
differences of sex specific lung diseases poses a major challenge in clinical research 
because of the predominant use of male cell lines and animals models. This has garnered 
the attention of NIH which has implemented an initiative to reduce sex bias in research 
(Clayton & Collins, 2014). This review will discuss the general state of knowledge of 
estrogens in lung disease with a focus on vessel-lumen obliterative lesions that are found 
in PAH. This will include a description of estrogens and xenoestrogens in lung tissue and 
disease, review of sex bias in obliterative lung disease, explanation for the sex differences 
in PAH, and a proposed mechanism for the formation of obliterative vascular lesions by 
estrogenic stress. 
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Estrogens and the lung 
 Three major steroidal estrogens in women: estrone (E1), estradiol (E2), and estriol 
(E3) are produced by the ovary from cholesterol. The steroidogenesis pathway also 
produces ovarian androgens, specifically testosterone and androstenedione, which are 
aromatized to E2 by the enzyme aromatase. The cytochrome P-450 enzymes CYP1A1 and 
CYP1B1 metabolize E2 into two catechol estrogens, 4-hydroxyestradiol (4-OHE2) and 2-
hydroxyestraidol (2-OHE2) which are further metabolized to methoxyestrogens via 
catechol-O-methyltransferase (Liehr & Roy, 1990; D. Roy & Liehr, 1988). Out of the three 
estrogens, E2 has the highest estrogenic activity and is the most abundant in the 
bloodstream during reproductive years. Women experience normal fluctuations in estrogen 
throughout their lifetime and in their reproductive years. Premenopausal circulating E2 
levels range 40-400 pg/ml with a considerable drop after menopause to approximately 10-
20 pg/ml (DiMarco, 2000). During the menstrual cycle E2 increases in the follicular phase 
(days 0-14) in the range of 40-100 pg/ml that ends with a surge of E2 ranging from 100-
400 pg/ml on day 14. Estradiol levels lower during the luteal phase 40-250 pg/ml and return 
to lower levels prior to menstruation. Men also produce estrogen, but at lower levels than 
women. The adult testis convert testosterone to E2 by aromatase in Leydig cells and germ 
cells (Hess, 2003). Once in the bloodstream estrogen can exist in two forms, bound or 
unbound to a protein carrier. Between 20-40% of circulating estradiol is bound to sex 
hormone-binding globulin (SHBG) which retains them in the circulation where they are 
considered to be inactive (Dunn, Nisula, & Rodbard, 1981). Estradiol that is unbound can 
diffuse directly through the cell membrane where it binds to estrogen receptors to regulate 
transcriptional processes. In addition, membrane-bound estrogen receptors mediate both 
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genomic and non-genomic effects on target cells. Sex differences in fetal lung development 
and maturation of adult lung tissue have been attributed to estrogen (Becklake & 
Kauffmann, 1999). The formation of alveoli in females depends on estrogens which 
modulate alveologeneiss by ERα and ERβ (Massaro, Clerch, & Massaro, 2007; Patrone et 
al., 2003). The production of surfactant in the fetal lung can be increased by E2 treatment 
(Chu & Rooney, 1985), which may contribute to more rapid lung maturation in female 
fetuses than in the male fetus (Torday & Nielsen, 1987). Although alveolar volume and 
number of alveoli per unit area do not differ between male and female, males develop larger 
lungs with larger conducting airways in adulthood (Martin, Castile, Fredberg, Wohl, & 
Mead, 1987). 
 Several lung diseases are more common in women than in men; and estrogen has 
been implicated as a risk factor. Since the most biologically active estrogen is E2; we 
reviewed concentrations of E2 reported in pathological conditions of the human lung. In 
patients with PAH, it has been recommended to avoid pregnancy. Levels of E2 tend to rise 
in the bloodstream up to 7,200 pg/ml during pregnancy which may exacerbate lung 
pathology (Carranza-Lira et al., 1998). A recent study reported a significantly higher level 
of circulatory E2 [42 pg/ml] and E2/testosterone ratio in men with PAH (Ventetuolo et al., 
2016). Aromatase was shown to be expressed by human pulmonary arterial smooth muscle 
cells in both PAH patients and controls(Mair et al., 2014). Since E2/testosterone ratio has 
been considered to be correlated with aromatase activity (Cakan, Aldemir, Topcuoglu, & 
Altuğ, 2009), it is possible that the localized expression of aromatase may elevate E2 in 
the pulmonary artery. With regard to local E2 concentrations, lung tissue concentrations of 
20 pg/g in non-small cell lung cancer (NSCLC) have been reported to be 2.2-fold higher 
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than those found in corresponding non-neoplastic lung tissues (Niikawa et al., 2008). E2 
concentration of 79 pg/g was reported in interstitial pneumonia (IP) which was 2.8-fold 
higher than in normal lung (Taniuchi et al., 2014). A significant immunolocalization of 
aromatase in IP tissues implicate a role of local metabolism in causing local estrogen 
overexposure in the lung. In pre-menopausal women, the major sources of circulatory 
estrogens are the ovaries. However, estrogens are produced locally in various reproductive 
and non-reproductive tissues in both post-menopausal women and men by enzymatic 
conversions of serum androgens and adrenal-cortex steroids. The production of E2, the 
most potent estrogen, from the precursor E1 is a major conversion pathway dependent on 
the enzyme 17-beta-hydroxysteroid dehydrogenases (17β-HSDs) (Labrie, 2003). The 
enzyme CYP19A1 aromatase, mentioned previously, also catalyzes the aromatization of 
androstenedione to E1 and testosterone to E2. Evidence from a recent study of COPD 
showed that the local production of E2 in the lung had increased levels of enzymes involved 
in local estradiol synthesis (Konings et al., 2017). Since chronic inflammation is a major 
hall mark of lung diseases such as COPD and pulmonary hypertension we provide a 
summary of pro-inflammatory effects as it pertains to estrogen in the following section. 
Pro-inflammatory effects of estrogen in the lung:  
 The function of estrogen in inflammation is complex because on one hand, 
suppression of inflammation with increased estrogen occurs in chronic inflammatory 
diseases while on the other hand estrogen produces pro-inflammatory effects in some 
chronic autoimmune diseases. Estrogen induces pro-inflammatory cytokines, such as 
interleukin-1β (IL-1β) and tumor necrosis factor alpha (TNF-α), and a number of other 
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inflammation associated genes, which were also associated with exposure to endocrine 
disrupting chemicals (EDCs) (Deodutta Roy et al., 2015). How estrogen induced 
inflammation may play a role in lung disease is not clear. One of the mechanisms includes 
inflammation-mediated oxidative stress. For example, inflammatory genes are associated 
among estrogen, EDCs, and several chronic diseases. Polychlorinated biphenyls (PCBs) 
congener 126 and congener 153 modify the following inflammation related genes—AHR, 
CXCL2, HMOX1, IFNG, IL6, PTGS2, SOD2, and TNF; AHR, CXCL8, HMOX1, IL1B, 
IL6, MMP9, NOS2, NOS3, PARP1, PTGS2, and TNF; and AHR, IFNG, IL1B, PARP1, 
PTGS2, and TNF, respectively. Dibutyl phthalate, diethyl-hexyl phthalate and BPA-
modified inflammation genes are AHR, CXCL8, HMOX1, IL1B, IL6, MIF, MMP9, 
PARP1, SOD2, TFRC, and TNF; AHR, CSF2, CXCL8, IFNG, LEP, MMP9, SOD2, and 
TNF; and AHR, CSF2, HMOX1, IFNG, IL1B, IL6, LEP, MIF, MMP9, NOS2, NOS3, 
PARP1, PTGS2, SOD2, and TNF, respectively. In addition to the direct effect of estrogen 
on mitochondria and the redox cycling of catechol estrogen, estrogen-induced pro-
inflammatory cytokines, such as IL-1β, IL-6 and TNF-α can also generate reactive oxygen 
and nitrogen species (RO/NS) (Deodutta Roy, Cai, Felty, & Narayan, 2007). In the 
pathogenesis of estrogen-dependent lung diseases, the role of IL-6 and IL-1β are implicated 
in cell proliferation, angiogenesis and cell adhesion. The concentration of the peptide IL-
1β  seems to determine its stimulatory or inhibitory paracrine and/or autocrine signals that 
regulate the growth of estrogen dependent disease (Deodutta Roy, Sarkar, & Felty, 2006). 
IL-6 is an important cytokine involved in the pathogenesis of PAH. Clinical data showed 
an association between higher levels of IL-6 in PAH patients that also correlated with 
patient survival (Groth et al., 2014). Furthermore, IL-6 has been shown to impact the 
17 
 
development of pulmonary hypertension in COPD patients (Chaouat et al., 2009). In the 
transgenic mouse model, overexpression of IL-6 resulted in obliterative neointimal lesions 
consisting of endothelial cells (Steiner et al., 2009). It is important to note that estrogen 
differentially regulates IL-6 production in various cell types, however, estrogen has been 
shown to stimulate IL-6 production in mice and humans (Isse et al., 2010). Taken together 
these evidences support the pro-inflammatory contribution of estrogens to obliterative lung 
lesions in chronic disease. 
Xenoestrogens, endocrine disruptors, and the lung: 
 Endogenous estrogens are known to strongly regulate angiogenesis and vascular 
modeling by influencing the growth of both vascular endothelial and smooth muscle cells. 
Exogenous estrogen exposures may also be important factors to consider in sex specific 
lung diseases. Pharmacological exposure to hormone replacement therapy (HRT) or oral 
contraceptives have been shown to exacerbate PAH (Irey & Norris, 1973; Kleiger, Boxer, 
Ingham, & Harrison, 1976; Morse, Horn, & Barst, 1999; Sweeney & Voelkel, 2009), LAM 
(Shen, Iseman, Waldron, & King, 1987; Wahedna et al., 1994), and NSCLC (Chlebowski 
et al., 2016). There is also a growing body of evidence in support of estrogenic endocrine 
disruptors including occupational exposure to chlorinated solvents in PAH (Montani et al., 
2015). High levels of PCBs have been reported in human lung tissue (Rallis et al., 2014). 
Inhalation exposure to vapor-phase PCBs was demonstrated to be even more important 
than ingestion under some circumstances (Carpenter, 2015). Epidemiological studies have 
shown that chronic exposure to PCBs including its estrogenic congeners are associated 
with lung toxicity (Hansen et al., 2016) and hypertension (Kreiss et al., 1981). Prenatal 
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exposures to PCBs have been associated with decreased lung function in 20-year old 
offspring (Hansen et al., 2016). Moreover, population-based studies have provided 
evidence that PCBs are damaging to the vascular system (Goncharov et al., 2008; 
Gustavsson & Hogstedt, 1997; Sergeev & Carpenter, 2005; Tokunaga & Kataoka, 2003). 
In vivo animal studies have shown that PCBs produce placental vascular lesions and 
trophoblastic lesions (Bäcklin, Persson, Jones, & Dantzer, 1998). We have reported that 
physiological levels of E2 and estrogenic PCB153 [1ng/ml] at a level found in human 
serum [0.60 - 1.63 ng/ml] (Charlier, Albert, Zhang, Dubois, & Plomteux, 2004), altered 
pulmonary endothelial as well as smooth muscle cell phenotypes (Charlier et al., 2004). 
PCB153’s effects on both endothelial cells are even more pronounced than E2 with respect 
to vasculosphere formation and vasculogenesis. Another endocrine disrupting chemical, 
4,4′-methylenedianiline, used in the synthesis of polyurethanes has been shown to increase 
hyperplasia of pulmonary arteries exclusively in female rats (Carroll-Turpin et al., 2015). 
In vitro, human pulmonary smooth muscle cells were shown to proliferate when exposed 
to 4,4′-methylenedianiline and this was inhibited by treatment with the estrogen receptor 
antagonist ICI 182,780. Another well-known xenoestrogen, bisphenol A, has been reported 
to enhance development of asthma (Midoro-Horiuti, Tiwari, Watson, & Goldblum, 2010). 
Environmentally relevant concentrations of bisphenol A have been shown to elicit 
proangiogenic effects in human endothelial cells (Andersson & Brittebo, 2012). Taken 
together, these studies suggest that exposure to xenoestrogens and/or endocrine disruptors 
as a potential risk factor for obliterative lung lesions. 
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Sex bias in lung disease: 
Asthma: Gender has been shown to play a role in the diseased lung. We will summarize 
sex differences in major lung diseases at times highlighting how estrogens contribute to 
obliterative processes in the lung such as cell proliferation and migration. Female hormones 
in allergic disease have been extensively studied in asthma. After puberty the prevalence 
of asthma is greater in girls than boys (Akinbami, Moorman, & Liu, 2011). The prevalence 
of asthma is greater in women than men during early to middle adulthood (Leynaert et al., 
2012). Severity of asthma is also more severe in women with a higher likelihood of death 
compared to men (Tam et al., 2011). Modulation of lung inflammation by estrogen may 
partly explain this association. In asthma, inflammation enhances airway smooth muscle 
cell contractility, proliferation, and extracellular matrix production. Estrogens are known 
to modulate immune cells such as macrophages, lymphocyte, and mast cells some of which 
express ERs and the estrogen membrane receptor GPR30 (Bonds & Midoro-Horiuti, 2013), 
which may contribute to smooth muscle hyperplasia that obliterate the airway. 
Chronic obstructive pulmonary disease (COPD): Chronic obstructive pulmonary disease is 
a progressive disease that includes emphysema and chronic bronchitis. The incidence of 
COPD in women has been reported to be increasing (Han et al., 2007). For example, 
smoking is a major risk factor for COPD, but females tend to develop COPD faster than 
males even though they smoke less cigarettes (Gold et al., 1996). In nonsmokers, females 
make up two-thirds of cases with COPD (Salvi & Barnes, 2009). Cell proliferation has 
been shown to contribute to the intimal thickening of pulmonary arteries in both smokers 
and patients with mild COPD (Harness-Brumley, Elliott, Rosenbluth, Raghavan, & Jain, 
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2014). The early appearance of obliterative vascular lesions in COPD suggest that the 
pathology is not a late complication of pulmonary hypertension. Rather the growth 
promoting effects of estrogen on smooth muscle cells may be involved in the early 
development of COPD. Besides receptor mediated pathways, oxidative stress from 
estrogen metabolism in the lung may contribute to the growth of these cells. Estrogens have 
been shown to be hydroxylated to catechol estrogens, and catechol estrogens participate as 
a substrate in cytochrome P450 catalyzed redox reactions (Liehr & Roy, 1990; D. Roy & 
Liehr, 1988). Thus, estrogen potentiation of oxidative stress may confer susceptibility of 
female smokers to COPD. Cystic fibrosis is a rare genetic disorder that affects both men 
and women; and is characterized by a buildup of mucus in the lungs. This abnormal level 
of mucus leads to repeated, serious lung infections that over time severely damage lungs. 
Women have shown a higher prevalence of severe cystic fibrosis and exacerbations 
coincide with estrogen peak in the menstrual cycle (Chotirmall et al., 2012; Harness-
Brumley et al., 2014). Estrogen has been demonstrated to upregulate the MUC5B gene, a 
major mucin in the human airway (Choi et al., 2009). A potential mechanism by which 
estrogen may exacerbate cystic fibrosis in women may be by increasing MUC5B 
expression. 
Lymphangioleiomyomatosis (LAM): Pulmonary lymphangioleiomyomatosis (LAM) is a 
progressive and eventually fatal disease that primarily affects premenopausal women and 
can be exacerbated by pregnancy (Henske & McCormack, 2012). Estrogen can be 
considered a risk factor for LAM because disease severity worsens with estrogen therapy 
(Yano, 2002). LAM is associated with abnormal proliferation and invasion of smooth 
muscle cells that destroys the lung parenchyma. Small clusters of cells characterize lung 
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lesions in LAM which are located along pulmonary bronchioles, blood vessels, and 
lymphatics. Clumps of LAM cells in lymph vessels leads to thickening of the vessel wall 
and obliteration of the lumen. Immunohistochemical data has also shown higher levels of 
estrogen synthesizing enzyme aromatase in LAM cells (Adachi et al., 2015). Lung cancer 
is a leading cause of cancer related deaths in women (Jemal, Siegel, Xu, & Ward, 2010). 
A greater female predominance of NSCLC in both smokers and nonsmokers suggests that 
differences in sex hormones contribute to its pathogenesis (Shim et al., 2013). A worse 
prognosis in women with lung cancer has been associated with the expression of aromatase 
(Mah et al., 2007). Hence, the pro-proliferative effects of estrogen along with its known 
genotoxic effects may explain the sex bias observed in both LAM and NSCLC.  
Pulmonary arterial hypertension (PAH): Pulmonary arterial hypertension is clinically 
classified as Group 1 in the World Health Organization (WHO) system. Uncontrolled 
vascular cell growth has been postulated as the major mechanism involved in PAH 
pathogenesis (Rubin M. Tuder, Marecki, Richter, Fijalkowska, & Flores, 2007), which 
results in vessel obliteration. Most epidemiological studies have determined the effect of 
gender on prevalent PAH cases. Group 1 PAH includes idiopathic PAH, heritable PAH, 
drug- and toxin-induced PAH, and PAH associated with conditions such as connective 
tissue disease (CTD)-PAH, HIV-PAH, congenital heart disease (CHD)-PAH, and 
schistosomiasis. The Registry to Evaluate Early and Long-term PAH Disease Management 
(REVEAL) is a database used in an ongoing observational cohort study of PAH designed 
to enroll prevalent and/or incident patients in the United States with Group 1 PAH. This 
study reported the highest female to male ratio of 4.1:1 in IPAH patients as compared to 
the French registry (1.9:1) and the National Institutes of Health registry (1.7:1) (Badesch 
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et al., 2010; Humbert et al., 2006; Rich et al., 1987). A female bias was also reported in 
other sub-categories of Group 1 PAH which include CHD-PAH (2.8:1), CTD-PAH (9.1:1), 
and Drugs/toxins-PAH (5.4:1) (Badesch et al., 2010). We have provided a descriptive table 
of female to male ratios reported from these PAH registries (Table 1.). 
Table 1: Summary of PAH Registry Female to Male Ratios 
Registry Time Cohort No. 
Patients 
Female : Male 
Ratio 
References 
REVEAL 2006-
2007 
Mean age 53 yr 
IPAH, HPAH, APAH, 
Drug/toxin-induced 
PAH 
2525 4.1:1 IPAH 
3.8:1 APAH 
5.4:1 
Drug/toxin-PAH 
(Badesch 
et al., 
2010)  
French 2002-
2003 
Mean age 50 yr 
IPAH, HPAH, 
Drug/toxin-induced 
PAH 
674 1.9:1 (Humbert 
et al., 
2006)  
NIH 1981-
1985 
Mean age 36 yr 
IPAH, HPAH 
187 1.7:1 (Rich et al., 
1987)  
IPAH, idiopathic PAH; HPAH, heritable PAH; APAH, associated PAH 
 
Estrogen as a risk factor in PAH: 
 In human studies, pulmonary hypertension (Kleiger et al., 1976) and vessel lumen-
obliterating lesions (Irey & Norris, 1973) have been associated with oral contraceptives. 
Hormone replacement therapy has also been associated with severe PAH in post-
menopausal women (Taraseviciute & Voelkel, 2006). While these hormone therapies 
contain estrogens, the contribution of estrogen to PAH has been debated because of 
paradoxical gender effects observed in animal models. The chronic hypoxia-induced 
pulmonary hypertension model showed that male rats are more susceptible than females 
while estrogen treatment was shown to protect against monocrotaline (MCT)-induced 
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pulmonary hypertension [88,89]. In contrast, there are reports of chronic E2-induced 
hypoxic pulmonary hypertension in ovariectomized female rats (Artem’eva, Kovaleva, 
Medvedev, & Medvedeva, 2015; Kovaleva, Artem’eva, Medvedev, & Medvedeva, 2013a, 
2013b). The contradictory effects of E2 in the MCT-induced model may be partly due to 
differences in pulsatile versus continuous E2 exposure which cannot fully recapitulate what 
occurs in the human body. Another factor that may complicate our understanding comes 
from the assumption that exogenous and endogenous E2 act similarly on the pulmonary 
vasculature. Recently, a study has shown that reduction of endogenous E2 by ovariectomy 
or aromatase inhibitor treatment, decreased vessel muscle thickening or vessel obliterative 
lesions (Mair et al., 2014). This study used both the hypoxic mouse and the Sugen 5416 
plus chronic hypoxia (SuHx) rat model of PAH. In the SuHx model, rats are given a single 
injection of the VEGF receptor blocker Sugen 5416 and exposed to hypoxia for several 
weeks (Abe et al., 2010). The protection observed with the anastrazole treatment of the 
previous study was corroborated by a study with metformin treatment which reversed PAH 
and decreased pulmonary vascular remodeling via aromatase inhibition (Dean, Nilsen, 
Loughlin, Salt, & MacLean, 2016). E2 treatment was reported to improve heart function in 
the SuHx model (Frump et al., 2015), but its effect on the development of plexiform 
lesions, a hallmark of human PAH reproduced in the SuHx rat model, was not reported. 
Further studies on the development of obliterative intimal lesions in a chronic E2 treated 
SuHx model would be helpful because of the previously mentioned reports of chronic E2-
induced pulmonary hypertension in ovariectomized female rats. 
 Other rodent models of PAH have reported a female bias toward PAH. Anorectic 
drugs such as dexfenfluramine (Dfen) have been shown to induce PAH in only female mice 
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(Dempsie et al., 2013). Treatment of rats with 4, 4'-methylenedianiline (DAPM) induced 
female specific smooth muscle hyperplasia of the pulmonary vessels (Carroll-Turpin et al., 
2015). Genetic based mouse models have also shown sex differences in PAH susceptibility. 
Female mice overexpressing calcium binding protein S100A4/Mts1 (Mts1) were more 
susceptible to develop PAH and developed plexiform-like lesions (Dempsie et al., 2011). 
In mice overexpressing the serotonin transporter (SERT), only female SERT+ mice 
developed PAH (White et al., 2011). Since E2 treatment increased the severity of PAH in 
female SERT+ mice, it is plausible that estrogen is a significant risk factor for the 
development of PAH. Furthermore, the inhibition of obliterative vascular lesions by 
aromatase inhibitor anastrozole in the SuHx model supports the idea that E2 mediates its 
adverse effects by increasing the formation of plexiform lesions in PAH. We have provided 
a summary table of the discussed in vivo models that support a role of female sex and/or 
estrogen in PAH (Table 2). 
Table 2: Models of PAH that support female sex bias and/or detrimental effect of estrogen 
Model Species Findings References 
Chronic Hx + E2 rat Female develop hypoxic 
pulmonary hypertension; E2 
detrimental 
(Kovaleva et al., 
2013a, 2013b)  
SuHx rat, 
mouse 
Male and female develop 
PAH 
Aromatase inhibition 
protective 
(Abe et al., 2010; 
Dean et al., 2016; 
Mair et al., 2014)  
Dexfenfluramine mouse Female only develop PAH; 
Ovx protective 
(Dempsie et al., 
2013)  
4,4'-
methylenedianilin
e  
rat Female only develop PAH (Carroll-Turpin et al., 
2015)  
Mts1+ mouse PAH in female > male 
Ovx protective 
(Dempsie et al., 
2011)  
SERT+ mouse Female only develop PAH (White et al., 2011)  
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Ovx protective; E2 
detrimental 
Hx, hypoxia; E2, 17β-estradiol; SuHx, Sugen 5416 plus hypoxia; Mts1+, 
overexpression of calcium binding protein S100A4/Mts1; SERT+, overexpression of 
serotonin transporter; Ovx, ovariectomized.  
Biological based mechanisms for sex differences in PAH 
Circulatory levels of E2 cannot explain why males who have lower levels of E2 than 
females develop PAH much sooner and have poorer survival. A potential explanation may 
lie in different characteristics of the vascular pathology which obliterate the pulmonary 
artery. Blood vessels are composed of an outer layer of adventitial fibroblasts, a middle 
layer of smooth muscle cells (SMC), and an inner layer of endothelial cells (EC). The 
medial thickening of pulmonary arteries is considered the earliest pathological change in 
PAH (Rubin, 1997). Chronic hypoxia-induced PAH is characterized by medial thickening 
(Meyrick & Reid, 1980; M. Rabinovitch et al., 1986). Experimental data from rodent 
models attribute the 
thickening to 
pulmonary arterial 
SMC hypertrophy and 
extracellular matrix 
deposition in proximal 
pulmonary arteries 
(Kobs, Muvarak, 
Eickhoff, & Chesler, 2005; Pak, Aldashev, Welsh, & Peacock, 2007; Stenmark, Fagan, & 
Frid, 2006). In contrast, severe IPAH is characterized by clustered proliferation of EC that 
results in concentric obliteration of the lumina by vascular structures called plexiform 
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lesions, which consist of the monoclonal proliferation of EC and are reported in the late 
stages of PAH (R. M. Tuder, Groves, Badesch, & Voelkel, 1994). Three-dimensional 
analysis of the plexiform lesion indicated that plexiform lesion is functionally important in 
pathogenesis because blood flow is severely obstructed along the entire length of a vessel 
affected by a single plexiform lesion (Cool et al., 1999). Although both human pulmonary 
arterial SMCs and ECs have been shown to proliferate when exposed to E2 (Tofovic et al., 
2008; White et al., 2011), a difference between these cell types from PAH patients has been 
shown with the expression of an estrogen synthesizing enzyme. Pulmonary arterial SMC 
were shown to highly express aromatase in PAH patients, but it was absent in human 
pulmonary arterial EC (Cakan et al., 2009). Thus, the cell-context specific difference in 
aromatase expression can help to explain why men have more severe PAH. Since men are 
ill equipped to defend against a higher body burden of E2 when compared to women, we 
propose that the local concentration of E2 in pulmonary arteries is higher in men with PAH. 
This difference in lung concentration of E2 contributes to the reported faster progression 
and severity of PAH in men. Although proliferative changes in pulmonary arteries play a 
significant role in the development of PAH, evidence from the SuHx model of PAH suggest 
that fibrosis is a determining factor in the poor survival rate of male patients with PAH 
(Rafikova et al., 2015). In this study, female rats with PAH primarily showed 
vasculoproliferative changes in the pulmonary artery while males showed severe fibrosis 
in the adventitia and media of the pulmonary artery. Severe fibrosis observed in male 
pulmonary arteries including myocardial fibrosis was associated with impaired heart 
function and lower survival rates compared to females. 
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 Unlike SMCs exposed to the local synthesis of E2 by aromatase, the proximity of 
EC to the bloodstream allows these cells to be directly exposed to circulatory E2. The 
possibility that estrogen is involved in the growth of EC in the plexiform lesion is suggested 
by the increased incidence (2.8-fold) in female PAH patients of plexiform lesions 
compared to their male counterparts (Stacher et al., 2012). A plausible mechanism for 
estrogen’s involvement in plexiform lesion growth comes from evidence that infantile 
hemangiomas, a different type of vascular lesion, are reported with increased incidence in 
females with elevated levels of circulating E2 (Sasaki, Pang, & Wittliff, 1984). The 
combination of hypoxia and estrogen has been demonstrated in vitro to synergistically 
enhance EC proliferation (Kleinman et al., 2007), which we postulate also contribute to the 
growth of plexiform lesions. Higher circulatory E2 may therefore explain the 
predominance of plexiform lesions in women with PAH because it acts directly on EC 
prolfieration. Plexiform lesions are considered to be a late pathological event compared to 
the much earlier pathology of pulmonary arterial SMC hypertrophy. This suggests that the 
plexiform lesions in women PAH patients can take more time to obstruct the pulmonary 
artery unlike the more rapid hypertrophy of SMCs that occurs in men, which can help to 
explain sex differences in disease severity. A summary scheme of the sex difference in 
vessel obliteration is shown in Fig. 1. 
Estrogen-induced obliterative vascular lesions: 
 Vessel obliterating lesions have been reported in female biased lung diseases 
including idiopathic interstitial pneumonia (Hallowell, Reed, Fraig, Horton, & Girgis, 
2012), COPD (Santos et al., 2002), and IPAH (R. M. Tuder et al., 1994). Eearly appearance 
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of obliterative vascular lesions observed in mild cases of COPD, mentioned previously, 
suggests that the growth of vascular lesions occurs much earlier than at the end stage of 
PAH. Uncontrolled vascular cell growth has been postulated as the major mechanism 
involved in PAH pathogenesis (Rubin M. Tuder et al., 2007). More specifically, the 
hypertrophic growth of SMC is responsible for progressive thickening of blood vessels of 
the lung that ends in obstruction (Marlene Rabinovitch, 2008). Proliferative endothelial 
lesions that result from a focal budding of EC are also reported to be an aggressive cell 
phenotype associated with a poor prognosis in NSCLC and severe IPAH (Rojiani & 
Dorovini-Zis, 1996; Tanaka et al., 2003; R. M. Tuder et al., 1994). Despite progress in 
understanding IPAH, current therapy (epoprostenol and derivatives, endothelin receptor 
antagonists, and phosphodiesterase type 5 inhibitors) has become a major clinical barrier 
for the treatment of patients with end-stage IPAH. Median survival for IPAH patients in 
the United States was reported to be only 2.8 years without treatment (D’Alonzo et al., 
1991). Although these drugs allow clinical, functional, and hemodynamic improvements, 
the prognosis of patients remains poor because a critical aspect of end-stage IPAH is the 
continual growth of vascular lesion cells which eventually obliterate the lumen. Anti-
proliferative agents such as tyrosine kinase inhibitors have been investigated in IPAH, 
however, safety concerns have restricted the clinical application of these drugs and 
therefore the need to identify new therapeutic targets has remained. 
 The molecular pathogenesis of vessel-lumen obliterating lesions in humans remains 
unknown. Largely the focus has been on loss-of-function mutations in the BMPR2 gene 
observed in approximately 80% of familial PAH and in 20% of patients with sporadic PAH 
(Machado et al., 2009). In addition to BMPR2, estrogen receptor signaling has been 
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implicated to be involved in the pathogenesis of obliterative vascular lesions. However, 
these studies have not been consistently focused on investigating target cells (vascular 
lesion “initiating” cells) that are susceptible to genetic and epigenetic instability and 
ultimately progress into the plexiform lesion. Investigators have conveniently used either 
adult EC or SMC without considering the in vivo plexiform lesion histopathology. 
Histopathology of both human and animal model obliterative vascular lesions suggests they 
are multicellular and just like solid tumors contain stem cells that may be involved in the 
pathogenesis of IPAH (Hanahan & Weinberg, 2011). Surprisingly, there are numerous 
clinical and experimental data of vessel stem cells in the blood and the lungs of various 
forms of PAH (Felty, Sakao, & Voelkel, 2015). Although several different cell types, 
including vascular SMCs, inflammatory cells, and fibroblasts are involved in the 
vasculoproliferative process; we recognize EC to be the initial site of injury. Previously we 
showed that E2 treatment leads to an increase in macrophage cell proliferation and 
secretion of TNF- (Felty & Roy, 2002; D. Roy & Cai, 2002) which could contribute to 
vascular lesion formation via paracrine effects with other cell types in the vessel wall. 
Estrogen involvement in immune responses in lung diseases described previously support 
an inflammatory role in PAH. 
 Endothelial and smooth muscle cells are directly involved in the pathology of 
plexiform lesions. Pulmonary arterial SMC express aromatase which allows for the local 
production of E2 whereas human pulmonary arterial microvascular EC do not possess this 
enzyme (Mair et al., 2014). Higher aromatase activity in pulmonary arterial SMCs may 
lead to locally produced estrogen that acts in an autocrine or paracrine manner, with 
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possible cross talk between SMC and EC. Besides estrogen synthesis, the metabolism of 
E2 by another enzyme CYP1B1 may contribute to the formation of lumen obliterating 
vascular lesions. CYP1B1 
expression is increased in 
pulmonary arterial SMCs 
from patients with IPAH 
(White et al., 2012). 
Cytochrome P450 family 
member CYP1B1 is a key 
enzyme involved in the metabolism of E2 to catechol estrogens and expressed in the lung. 
Oxidation of E2 produces 2 catechol estrogens that, in turn, are further oxidized to the 
quinones, which can react with DNA resulting in depurinating adducts that can lead to 
mutagenesis. Genetic instability usually associated with pathological disorders and 
referring to a range of genetic alterations from mutations to chromosome rearrangements 
may contribute to the quasi-malignant vascular lesions observed in PAH patients. In 
support of this concept, chromosomal abnormalities and increased DNA damage have been 
observed in vessel-lumen obliterating lesions from PAH patients (Federici et al., 2015) and 
we have shown a positive correlation of oxidative DNA damage (8-OHdG) in benign and 
malignant vascular tissues (Das & Felty, 2014). In vivo experimental evidence in support 
of genotoxic damage in PAH was shown in the SERT+ model of PAH, female SERT+ 
mice showed increased levels of 8-OHdG (Johansen et al., 2016). We have provided a 
hypothetical mechanism by which chronic estrogenic stress-induces genetic instability in 
stem cells that progresses to form the obliterative vascular lesion (Fig. 2). 
31 
 
Conclusion: 
 Mitogenic and genotoxic effects of estrogen may be a common pathogenic 
mechanism to explain the presence of obliterative lesions in lung tissue and vessels. 
Estrogen has been shown to promote lung disease in experimental models of PAH, lung 
cancer, LAM, and benign metastasizing leiomyoma (BML) (Mair et al., 2014; Márquez-
Garbán, Chen, Goodglick, Fishbein, & Pietras, 2009; Shim et al., 2013; Yu, Astrinidis, 
Howard, & Henske, 2004). Studies have reported associations between estrogen 
concentrations in lung disease. Lung tissues from interstitial pneumonia are reported with 
2.8-fold higher levels of E2 (Taniuchi et al., 2014), NSCLC has high intratumoral E2 
concentration associated with aromatase expression (Márquez-Garbán et al., 2009); and 
more recently, higher concentrations of E2 have been associated with the risk of PAH in 
men (Ventetuolo et al., 2016). Furthermore, higher aromatase activity and circulatory E2 
have been reported to increase the risk of PAH in patients with portopulmonary 
hypertension (Roberts et al., 2009). Based on the evidences discussed in this review, female 
gender bias towards obliterative lung disease may be attributed to the hormone estrogen. 
 Even though women have a 3-4 times higher prevalence than men of PAH, 
circulatory E2 levels cannot explain why men develop PAH much sooner and have poorer 
survival. Pulmonary arterial SMC hypertrophy that contributes to medial thickening is 
considered one of the earliest pathological changes observed in chronic hypoxia-induced 
PAH. We postulate that the severity of PAH in males is due to high local concentration of 
E2 produced by pulmonary arterial SMC, which leads to hypertrophy, vasoconstriction, 
and vessel obstruction. Since males cannot defend against a higher body burden of E2 
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unlike females, males succumb to a rapid and more severe progression of vascular 
obliteration in PAH. Females are more susceptible to develop pulmonary vascular disease 
characterized by obliterative hyper-proliferative vascular lesions because EC are directly 
exposed to circulatory E2 from the bloodstream. Higher circulatory E2 found in women 
can therefore explain the predominance of plexiform lesions in female PAH patients. The 
molecular mechanisms that underlie sex differences in vessel-lumen obliterating lesions 
remain largely unknown and this is a major hurdle to identifying novel sex-dependent 
molecular targets to treat obliterative vascular lesions. Understanding the molecular basis 
of this gender disparity in PAH may offer a new treatment paradigm in this devastating 
disease that currently has a high unmet clinical need. 
 Emerging evidence suggest that a local imbalance between testosterone and E2 
levels influences the development of lung disease in COPD and PAH.  In light of this 
information, we propose that novel therapies targeted against local tissue production of 
estrogen may be of clinical benefit and lead to novel therapeutic strategies in treating 
estrogen dependent lung diseases. The activation of the farnesoid X receptor (FXR) has 
been reported to inhibit aromatase at the level of mRNA, protein, and enzymatic activity 
(Catalano et al., 2010) and represents a novel therapeutic mechanism to reduce local tissue 
estrogen production in the lung. The potential inhibitory effect of FXR on aromatase is 
significant because a new class of drugs (FXR agonist, such as obeticholic acid, OCA) was 
recently shown to prevent monocrotaline-induced PAH (Vignozzi et al., 2017). Similar 
cardiopulmonary protective effects of OCA treatment have been demonstrated also in 
blemycin-induced pulmonary fibrosis (Paolo Comeglio et al., 2017). FXR activation by 
treatment with OCA was shown to protect against bleomycin-induced lung damage by 
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suppressing epithelial-to-mesenchymal transition (EMT), inflammation, and collagen 
deposition. This may be of major benefit in the treatment of PAH. Endothelial-to-
mesenchymal transition (EndMT) a process similar to EMT has been implicated to 
contribute to obliterative vascular remodeling in idiopathic PAH (Hopper et al., 2016). 
Furthermore, the release of cytokines IL-1β, IL-6, TNF-alpha, and IL-10 by macrophages 
present in pulmonary lesions are suggested to play an important role in the pathogenesis of 
PAH [41]. Since FXR activation was shown to suppress EMT as well as cause a dose-
dependent reduction of proinflammatory cytokines, the FXR class of drugs are highly 
innovative therapeutic agents for the treatment of estrogen dependent obliterative lung 
diseases including PAH.  
Hypothesis 
Estrogenic chemicals influencing ID3 target genes contribute to susceptibility of PAH   
Specific Aims 
Specific Aim 1: Collect retrospective environmental exposure data from NHANES 
database and gene expression data from the GEO database. 
Specific Aim 2:  Investigate the association between exposure to estrogenic chemicals 
and subjects at risk for PAH.  
Specific Aim 3: Identify ID3 regulated molecular gene networks within PAH pathways.   
 
  
34 
 
REFERENCES: 
Abe, K., Toba, M., Alzoubi, A., Ito, M., Fagan, K. A., Cool, C. D., … Oka, M. (2010). 
Formation of plexiform lesions in experimental severe pulmonary arterial 
hypertension. Circulation, 121(25), 2747–2754. 
https://doi.org/10.1161/CIRCULATIONAHA.109.927681 
Abplanalp, W., Scheiber, M. D., Moon, K., Kessel, B., Liu, J. H., & Subbiah, M. T. 
(2000). Evidence for the role of high density lipoproteins in mediating the 
antioxidant effect of estrogens. European Journal of Endocrinology, 142(1), 79–
83. 
Adachi, K., Miki, Y., Saito, R., Hata, S., Yamauchi, M., Mikami, Y., … Sasano, H. 
(2015). Intracrine steroid production and mammalian target of rapamycin 
pathways in pulmonary lymphangioleiomyomatosis. Human Pathology, 46(11), 
1685–1693. https://doi.org/10.1016/j.humpath.2015.02.019 
Akinbami, L. J., Moorman, J. E., & Liu, X. (2011). Asthma prevalence, health care use, 
and mortality: United States, 2005-2009. National Health Statistics Reports, (32), 
1–14. 
Andersson, H., & Brittebo, E. (2012). Proangiogenic effects of environmentally relevant 
levels of bisphenol A in human primary endothelial cells. Archives of 
Toxicology, 86(3), 465–474. https://doi.org/10.1007/s00204-011-0766-2 
Artem’eva, M. M., Kovaleva, Y. O., Medvedev, O. S., & Medvedeva, N. A. (2015). 
Effect of Chronic Administration of Estradiol on Responsiveness of Isolated 
Systemic and Pulmonary Blood Vessels from Ovariectomized Wistar Rats with 
Hypoxic Pulmonary Hypertension. Bulletin of Experimental Biology and 
Medicine, 159(4), 427–430. https://doi.org/10.1007/s10517-015-2982-x 
Bäcklin, B. M., Persson, E., Jones, C. J., & Dantzer, V. (1998). Polychlorinated biphenyl 
(PCB) exposure produces placental vascular and trophoblastic lesions in the mink 
(Mustela vison): a light and electron microscopic study. APMIS: Acta 
Pathologica, Microbiologica, et Immunologica Scandinavica, 106(8), 785–799. 
Badesch, D. B., Raskob, G. E., Elliott, C. G., Krichman, A. M., Farber, H. W., Frost, A. 
E., … McGoon, M. D. (2010). Pulmonary arterial hypertension: baseline 
characteristics from the REVEAL Registry. Chest, 137(2), 376–387. 
https://doi.org/10.1378/chest.09-1140 
Becklake, M., & Kauffmann, F. (1999). Gender differences in airway behaviour over the 
human life span. Thorax, 54(12), 1119–1138. 
Behl, C., Skutella, T., Lezoualc’h, F., Post, A., Widmann, M., Newton, C. J., & Holsboer, 
F. (1997). Neuroprotection against oxidative stress by estrogens: structure-activity 
relationship. Molecular Pharmacology, 51(4), 535–541. 
35 
 
Benditt, E. P., & Benditt, J. M. (1973). Evidence for a monoclonal origin of human 
atherosclerotic plaques. Proceedings of the National Academy of Sciences of the 
United States of America, 70(6), 1753–1756. 
Bonds, R. S., & Midoro-Horiuti, T. (2013). Estrogen effects in allergy and asthma. 
Current Opinion in Allergy and Clinical Immunology, 13(1), 92–99. 
https://doi.org/10.1097/ACI.0b013e32835a6dd6 
Cakan, M., Aldemir, M., Topcuoglu, M., & Altuğ, U. (2009). Role of 
testosterone/estradiol ratio in predicting the efficacy of tamoxifen citrate 
treatment in idiopathic oligoasthenoteratozoospermic men. Urologia 
Internationalis, 83(4), 446–451. https://doi.org/10.1159/000251186 
Carpenter, D. O. (2015). Exposure to and health effects of volatile PCBs. Reviews on 
Environmental Health, 30(2), 81–92. https://doi.org/10.1515/reveh-2014-0074 
Carranza-Lira, S., Hernández, F., Sánchez, M., Murrieta, S., Hernández, A., & Sandoval, 
C. (1998). Prolactin secretion in molar and normal pregnancy. International 
Journal of Gynaecology and Obstetrics: The Official Organ of the International 
Federation of Gynaecology and Obstetrics, 60(2), 137–141. 
Carroll-Turpin, M., Hebert, V., Chotibut, T., Wensler, H., Krentzel, D., Varner, K. J., … 
Dugas, T. R. (2015). 4,4’-Methylenedianiline Alters Serotonergic Transport in a 
Novel, Sex-Specific Model of Pulmonary Arterial Hypertension in Rats. 
Toxicological Sciences: An Official Journal of the Society of Toxicology, 147(1), 
235–245. https://doi.org/10.1093/toxsci/kfv126 
Catalano, S., Malivindi, R., Giordano, C., Gu, G., Panza, S., Bonofiglio, D., … Andò, S. 
(2010). Farnesoid X receptor, through the binding with steroidogenic factor 1-
responsive element, inhibits aromatase expression in tumor Leydig cells. The 
Journal of Biological Chemistry, 285(8), 5581–5593. 
https://doi.org/10.1074/jbc.M109.052670 
Chaouat, A., Savale, L., Chouaid, C., Tu, L., Sztrymf, B., Canuet, M., … Adnot, S. 
(2009). Role for interleukin-6 in COPD-related pulmonary hypertension. Chest, 
136(3), 678–687. https://doi.org/10.1378/chest.08-2420 
Charlier, C. J., Albert, A. I., Zhang, L., Dubois, N. G., & Plomteux, G. J. (2004). 
Polychlorinated biphenyls contamination in women with breast cancer. Clinica 
Chimica Acta; International Journal of Clinical Chemistry, 347(1–2), 177–181. 
https://doi.org/10.1016/j.cccn.2004.04.025 
Chlebowski, R. T., Wakelee, H., Pettinger, M., Rohan, T., Liu, J., Simon, M., … 
Wactawski-Wende, J. (2016). Estrogen Plus Progestin and Lung Cancer: Follow-
up of the Women’s Health Initiative Randomized Trial. Clinical Lung Cancer, 
17(1), 10–17.e1. https://doi.org/10.1016/j.cllc.2015.09.004 
36 
 
Choi, H. J., Chung, Y.-S., Kim, H. J., Moon, U. Y., Choi, Y. H., Van Seuningen, I., … 
Yoon, J.-H. (2009). Signal pathway of 17beta-estradiol-induced MUC5B 
expression in human airway epithelial cells. American Journal of Respiratory Cell 
and Molecular Biology, 40(2), 168–178. https://doi.org/10.1165/rcmb.2007-
0377OC 
Chotirmall, S. H., Smith, S. G., Gunaratnam, C., Cosgrove, S., Dimitrov, B. D., O’Neill, 
S. J., … McElvaney, N. G. (2012). Effect of estrogen on pseudomonas mucoidy 
and exacerbations in cystic fibrosis. The New England Journal of Medicine, 
366(21), 1978–1986. https://doi.org/10.1056/NEJMoa1106126 
Chu, A. J., & Rooney, S. A. (1985). Estrogen stimulation of surfactant synthesis. 
Pediatric Pulmonology, 1(3 Suppl), S110-114. 
Clayton, J. A., & Collins, F. S. (2014). Policy: NIH to balance sex in cell and animal 
studies. Nature News, 509(7500), 282. https://doi.org/10.1038/509282a 
Comeglio, P., Morelli, A., Cellai, I., Vignozzi, L., Sarchielli, E., Filippi, S., … Maggi, M. 
(2014). Opposite effects of tamoxifen on metabolic syndrome-induced bladder 
and prostate alterations: a role for GPR30/GPER? The Prostate, 74(1), 10–28. 
https://doi.org/10.1002/pros.22723 
Comeglio, Paolo, Filippi, S., Sarchielli, E., Morelli, A., Cellai, I., Corcetto, F., … 
Vignozzi, L. (2017). Anti-fibrotic effects of chronic treatment with the selective 
FXR agonist obeticholic acid in the bleomycin-induced rat model of pulmonary 
fibrosis. The Journal of Steroid Biochemistry and Molecular Biology, 168, 26–37. 
https://doi.org/10.1016/j.jsbmb.2017.01.010 
Cool, C. D., Stewart, J. S., Werahera, P., Miller, G. J., Williams, R. L., Voelkel, N. F., & 
Tuder, R. M. (1999). Three-dimensional reconstruction of pulmonary arteries in 
plexiform pulmonary hypertension using cell-specific markers. Evidence for a 
dynamic and heterogeneous process of pulmonary endothelial cell growth. The 
American Journal of Pathology, 155(2), 411–419. https://doi.org/10.1016/S0002-
9440(10)65137-1 
D’Alonzo, G. E., Barst, R. J., Ayres, S. M., Bergofsky, E. H., Brundage, B. H., Detre, K. 
M., … Kernis, J. T. (1991). Survival in patients with primary pulmonary 
hypertension. Results from a national prospective registry. Annals of Internal 
Medicine, 115(5), 343–349. 
Das, J. K., & Felty, Q. (2014). PCB153-induced overexpression of ID3 contributes to the 
development of microvascular lesions. PloS One, 9(8), e104159. 
https://doi.org/10.1371/journal.pone.0104159 
Dean, A., Nilsen, M., Loughlin, L., Salt, I. P., & MacLean, M. R. (2016). Metformin 
Reverses Development of Pulmonary Hypertension via Aromatase Inhibition. 
Hypertension (Dallas, Tex.: 1979), 68(2), 446–454. 
https://doi.org/10.1161/HYPERTENSIONAHA.116.07353 
37 
 
Dempsie, Y., MacRitchie, N. A., White, K., Morecroft, I., Wright, A. F., Nilsen, M., … 
MacLean, M. R. (2013). Dexfenfluramine and the oestrogen-metabolizing 
enzyme CYP1B1 in the development of pulmonary arterial hypertension. 
Cardiovascular Research, 99(1), 24–34. https://doi.org/10.1093/cvr/cvt064 
Dempsie, Y., Nilsen, M., White, K., Mair, K. M., Loughlin, L., Ambartsumian, N., … 
Maclean, M. R. (2011). Development of pulmonary arterial hypertension in mice 
over-expressing S100A4/Mts1 is specific to females. Respiratory Research, 12, 
159. https://doi.org/10.1186/1465-9921-12-159 
DiMarco, C. S. (2000). Clinical Gynecologic Endocrinology and Infertility. In Speroff L, 
Glass RH, Kase NG, editors. Clinical Gynecologic Endocrinology and Infertility. 
(6th ed., Vol. 74, pp. 425–426). Baltimore: Lippincott: Williams & Wilkins. 
Retrieved from http://www.fertstert.org/article/S0015-0282(00)00647-6/abstract 
Dunn, J. F., Nisula, B. C., & Rodbard, D. (1981). Transport of steroid hormones: binding 
of 21 endogenous steroids to both testosterone-binding globulin and 
corticosteroid-binding globulin in human plasma. The Journal of Clinical 
Endocrinology and Metabolism, 53(1), 58–68. https://doi.org/10.1210/jcem-53-1-
58 
Federici, C., Drake, K. M., Rigelsky, C. M., McNelly, L. N., Meade, S. L., Comhair, S. 
A. A., … Aldred, M. A. (2015). Increased Mutagen Sensitivity and DNA Damage 
in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical 
Care Medicine, 192(2), 219–228. https://doi.org/10.1164/rccm.201411-2128OC 
Felty, Q., & Roy, D. (2002). Potential use of J774A. 1 macrophage cells to biomonitor 
estrogenic activity in non-estrogen dependent tissue. Vitro Cell Dev Biol, 38, 13. 
Felty, Q., & Roy, D. (2005). Estrogen, mitochondria, and growth of cancer and non-
cancer cells. Journal of Carcinogenesis, 4, 1. https://doi.org/10.1186/1477-3163-
4-1 
Felty, Q., Sakao, S., & Voelkel, N. F. (2015). Pulmonary Arterial Hypertension: A Stem 
Cell Hypothesis. In Lung Stem Cells in the Epithelium and Vasculature (pp. 289–
306). Springer, Cham. https://doi.org/10.1007/978-3-319-16232-4_16 
Felty, Q., Singh, K. P., & Roy, D. (2005). Estrogen-induced G1/S transition of G0-
arrested estrogen-dependent breast cancer cells is regulated by mitochondrial 
oxidant signaling. Oncogene, 24(31), 4883–4893. 
https://doi.org/10.1038/sj.onc.1208667 
Felty, Q., Xiong, W.-C., Sun, D., Sarkar, S., Singh, K. P., Parkash, J., & Roy, D. (2005). 
Estrogen-induced mitochondrial reactive oxygen species as signal-transducing 
messengers. Biochemistry, 44(18), 6900–6909. https://doi.org/10.1021/bi047629p 
Frump, A. L., Goss, K. N., Vayl, A., Albrecht, M., Fisher, A., Tursunova, R., … Lahm, 
T. (2015). Estradiol improves right ventricular function in rats with severe 
38 
 
angioproliferative pulmonary hypertension: effects of endogenous and exogenous 
sex hormones. American Journal of Physiology. Lung Cellular and Molecular 
Physiology, 308(9), L873-890. https://doi.org/10.1152/ajplung.00006.2015 
Gold, D. R., Wang, X., Wypij, D., Speizer, F. E., Ware, J. H., & Dockery, D. W. (1996). 
Effects of cigarette smoking on lung function in adolescent boys and girls. New 
England Journal of Medicine, 335(13), 931–937. 
https://doi.org/10.1056/NEJM199609263351304 
Goncharov, A., Haase, R. F., Santiago-Rivera, A., Morse, G., Akwesasne Task Force on 
the Environment, McCaffrey, R. J., … Carpenter, D. O. (2008). High serum PCBs 
are associated with elevation of serum lipids and cardiovascular disease in a 
Native American population. Environmental Research, 106(2), 226–239. 
https://doi.org/10.1016/j.envres.2007.10.006 
Groth, A., Vrugt, B., Brock, M., Speich, R., Ulrich, S., & Huber, L. C. (2014). 
Inflammatory cytokines in pulmonary hypertension. Respiratory Research, 15, 47. 
https://doi.org/10.1186/1465-9921-15-47 
Gustavsson, P., & Hogstedt, C. (1997). A cohort study of Swedish capacitor 
manufacturing workers exposed to polychlorinated biphenyls (PCBs). American 
Journal of Industrial Medicine, 32(3), 234–239. 
Hallowell, R. W., Reed, R. M., Fraig, M., Horton, M. R., & Girgis, R. E. (2012). Severe 
pulmonary hypertension in idiopathic nonspecific interstitial pneumonia. 
Pulmonary Circulation, 2(1), 101–106. https://doi.org/10.4103/2045-8932.94842 
Han, M. K., Postma, D., Mannino, D. M., Giardino, N. D., Buist, S., Curtis, J. L., & 
Martinez, F. J. (2007). Gender and chronic obstructive pulmonary disease: why it 
matters. American Journal of Respiratory and Critical Care Medicine, 176(12), 
1179–1184. https://doi.org/10.1164/rccm.200704-553CC 
Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 
144(5), 646–674. https://doi.org/10.1016/j.cell.2011.02.013 
Hansen, S., Strøm, M., Olsen, S. F., Dahl, R., Hoffmann, H. J., Granström, C., … 
Halldorsson, T. I. (2016). Prenatal exposure to persistent organic pollutants and 
offspring allergic sensitization and lung function at 20 years of age. Clinical and 
Experimental Allergy: Journal of the British Society for Allergy and Clinical 
Immunology, 46(2), 329–336. https://doi.org/10.1111/cea.12631 
Harness-Brumley, C. L., Elliott, A. C., Rosenbluth, D. B., Raghavan, D., & Jain, R. 
(2014). Gender Differences in Outcomes of Patients with Cystic Fibrosis. Journal 
of Women’s Health, 23(12), 1012–1020. https://doi.org/10.1089/jwh.2014.4985 
Henske, E. P., & McCormack, F. X. (2012). Lymphangioleiomyomatosis - a wolf in 
sheep’s clothing. The Journal of Clinical Investigation, 122(11), 3807–3816. 
https://doi.org/10.1172/JCI58709 
39 
 
Hess, R. A. (2003). Estrogen in the adult male reproductive tract: A review. Reproductive 
Biology and Endocrinology, 1, 52. https://doi.org/10.1186/1477-7827-1-52 
Hopper, R. K., Moonen, J.-R. A. J., Diebold, I., Cao, A., Rhodes, C. J., Tojais, N. F., … 
Rabinovitch, M. (2016). In Pulmonary Arterial Hypertension, Reduced BMPR2 
Promotes Endothelial-to-Mesenchymal Transition via HMGA1 and Its Target 
Slug. Circulation, 133(18), 1783–1794. 
https://doi.org/10.1161/CIRCULATIONAHA.115.020617 
Humbert, M., Sitbon, O., Chaouat, A., Bertocchi, M., Habib, G., Gressin, V., … 
Simonneau, G. (2006). Pulmonary arterial hypertension in France: results from a 
national registry. American Journal of Respiratory and Critical Care Medicine, 
173(9), 1023–1030. https://doi.org/10.1164/rccm.200510-1668OC 
Irey, N. S., & Norris, H. J. (1973). Intimal vascular lesions associated with female 
reproductive steroids. Archives of Pathology, 96(4), 227–234. 
Isse, K., Specht, S. M., Lunz, J. G., Kang, L.-I., Mizuguchi, Y., & Demetris, A. J. (2010). 
Estrogen stimulates female biliary epithelial cell interleukin-6 expression in mice 
and humans. Hepatology (Baltimore, Md.), 51(3), 869–880. 
https://doi.org/10.1002/hep.23386 
JAMA, J. (1970). The Coronary Drug ProjectInitial Findings Leading to Modifications of 
Its Research Protocol. JAMA, 214(7), 1303–1313. 
https://doi.org/10.1001/jama.1970.03180070069012 
JAMA, J. (1973). The Coronary Drug ProjectFindings Leading to Discontinuation of the 
2.5-mg/day Estrogen Group. JAMA, 226(6), 652–657. 
https://doi.org/10.1001/jama.1973.03230060030009 
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010). Cancer statistics, 2010. CA: A Cancer 
Journal for Clinicians, 60(5), 277–300. https://doi.org/10.3322/caac.20073 
Johansen, A. K. Z., Dean, A., Morecroft, I., Hood, K., Nilsen, M., Loughlin, L., … 
MacLean, M. R. (2016). The serotonin transporter promotes a pathological 
estrogen metabolic pathway in pulmonary hypertension via cytochrome P450 
1B1. Pulmonary Circulation, 6(1), 82–92. https://doi.org/10.1086/685023 
Kleiger, R. E., Boxer, M., Ingham, R. E., & Harrison, D. C. (1976). Pulmonary 
hypertension in patients using oral contraceptives. A report of six cases. Chest, 
69(2), 143–147. 
Kleinman, M. E., Greives, M. R., Churgin, S. S., Blechman, K. M., Chang, E. I., 
Ceradini, D. J., … Gurtner, G. C. (2007). Hypoxia-induced mediators of 
stem/progenitor cell trafficking are increased in children with hemangioma. 
Arteriosclerosis, Thrombosis, and Vascular Biology, 27(12), 2664–2670. 
https://doi.org/10.1161/ATVBAHA.107.150284 
40 
 
Kobs, R. W., Muvarak, N. E., Eickhoff, J. C., & Chesler, N. C. (2005). Linked 
mechanical and biological aspects of remodeling in mouse pulmonary arteries 
with hypoxia-induced hypertension. American Journal of Physiology. Heart and 
Circulatory Physiology, 288(3), H1209-1217. 
https://doi.org/10.1152/ajpheart.01129.2003 
Konings, G. F. J., Reynaert, N. L., Delvoux, B., Verhamme, F., Bracke, K., Brusselle, G., 
… Vernooy, J. H. J. (2017). Increased levels of enzymes involved in local 
estradiol synthesis in chronic obstructive pulmonary disease. MOLECULAR 
AND CELLULAR ENDOCRINOLOGY, (doi:10.1016/j.mce.2016.12.001). 
https://doi.org/http://dx.doi.org/10.1016/j.mce.2016.12.001 
Kovaleva, I. O., Artem’eva, M. M., Medvedev, O. S., & Medvedeva, N. A. (2013a). 
[Chronic administration of estradiol to ovariectomized female Wistar rats causes 
development of hypoxic pulmonary hypertension]. Eksperimental’naia I 
Klinicheskaia Farmakologiia, 76(5), 7–9. 
Kovaleva, I. O., Artem’eva, M. M., Medvedev, O. S., & Medvedeva, N. A. (2013b). 
[Chronic administration of estrogen receptors antagonist reduces degree of 
hypoxia-induced pulmonary hypertension caused by chronic injections of 
estrogen in ovariectomised female Wistar rats]. Eksperimental’naia I 
Klinicheskaia Farmakologiia, 76(7), 15–18. 
Kreiss, K., Zack, M. M., Kimbrough, R. D., Needham, L. L., Smrek, A. L., & Jones, B. 
T. (1981). Association of blood pressure and polychlorinated biphenyl levels. 
JAMA, 245(24), 2505–2509. 
Labrie, F. (2003). Extragonadal synthesis of sex steroids: intracrinology. Annales 
D’endocrinologie, 64(2), 95–107. 
Leynaert, B., Sunyer, J., Garcia-Esteban, R., Svanes, C., Jarvis, D., Cerveri, I., … 
Neukirch, F. (2012). Gender differences in prevalence, diagnosis and incidence of 
allergic and non-allergic asthma: a population-based cohort. Thorax, 67(7), 625–
631. https://doi.org/10.1136/thoraxjnl-2011-201249 
Liehr, J. G., & Roy, D. (1990). Free radical generation by redox cycling of estrogens. 
Free Radical Biology & Medicine, 8(4), 415–423. 
Machado, R. D., Eickelberg, O., Elliott, G., Geraci, M. W., Hanaoka, M., Loyd, J. E., … 
Chung, W. K. (2009). Genetics and Genomics of Pulmonary Arterial 
Hypertension. Journal of the American College of Cardiology, 54(1 0), S32–S42. 
https://doi.org/10.1016/j.jacc.2009.04.015 
Mah, V., Seligson, D. B., Li, A., Márquez, D. C., Wistuba, I. I., Elshimali, Y., … 
Goodglick, L. (2007). Aromatase expression predicts survival in women with 
early-stage non small cell lung cancer. Cancer Research, 67(21), 10484–10490. 
https://doi.org/10.1158/0008-5472.CAN-07-2607 
41 
 
Mair, K. M., Wright, A. F., Duggan, N., Rowlands, D. J., Hussey, M. J., Roberts, S., … 
MacLean, M. R. (2014). Sex-dependent influence of endogenous estrogen in 
pulmonary hypertension. American Journal of Respiratory and Critical Care 
Medicine, 190(4), 456–467. https://doi.org/10.1164/rccm.201403-0483OC 
Marino, M., Galluzzo, P., & Ascenzi, P. (2006). Estrogen signaling multiple pathways to 
impact gene transcription. Current Genomics, 7(8), 497–508. 
Márquez-Garbán, D. C., Chen, H.-W., Goodglick, L., Fishbein, M. C., & Pietras, R. J. 
(2009). Targeting aromatase and estrogen signaling in human non-small cell lung 
cancer. Annals of the New York Academy of Sciences, 1155, 194–205. 
https://doi.org/10.1111/j.1749-6632.2009.04116.x 
Martin, T. R., Castile, R. G., Fredberg, J. J., Wohl, M. E., & Mead, J. (1987). Airway size 
is related to sex but not lung size in normal adults. Journal of Applied Physiology 
(Bethesda, Md.: 1985), 63(5), 2042–2047. 
Massaro, D., Clerch, L. B., & Massaro, G. D. (2007). Estrogen receptor-alpha regulates 
pulmonary alveolar loss and regeneration in female mice: morphometric and gene 
expression studies. American Journal of Physiology. Lung Cellular and Molecular 
Physiology, 293(1), L222-228. https://doi.org/10.1152/ajplung.00384.2006 
Meyrick, B., & Reid, L. (1980). Hypoxia-induced structural changes in the media and 
adventitia of the rat hilar pulmonary artery and their regression. The American 
Journal of Pathology, 100(1), 151–178. 
Midoro-Horiuti, T., Tiwari, R., Watson, C. S., & Goldblum, R. M. (2010). Maternal 
bisphenol a exposure promotes the development of experimental asthma in mouse 
pups. Environmental Health Perspectives, 118(2), 273–277. 
https://doi.org/10.1289/ehp.0901259 
Mok, Y.-Y. P., Shen, M., Shimizu, I., Wei, M., Huang, R. H., Urata, M. M., … Fukuno, 
H. (2006). Effects of estradiol and progesterone on tumor necrosis factor alpha-
induced apoptosis in human hepatoma HuH-7 cells. Life Sciences. 
https://doi.org/10.1016/j.lfs.2006.06.044 
Montani, D., Lau, E. M., Descatha, A., Jaïs, X., Savale, L., Andujar, P., … Humbert, M. 
(2015). Occupational exposure to organic solvents: a risk factor for pulmonary 
veno-occlusive disease. European Respiratory Journal, 46(6), 1721–1731. 
https://doi.org/10.1183/13993003.00814-2015 
Morse, J. H., Horn, E. M., & Barst, R. J. (1999). Hormone replacement therapy: a 
possible risk factor in carriers of familial primary pulmonary hypertension. Chest, 
116(3), 847. 
Niikawa, H., Suzuki, T., Miki, Y., Suzuki, S., Nagasaki, S., Akahira, J., … Sasano, H. 
(2008). Intratumoral estrogens and estrogen receptors in human non-small cell 
lung carcinoma. Clinical Cancer Research: An Official Journal of the American 
42 
 
Association for Cancer Research, 14(14), 4417–4426. 
https://doi.org/10.1158/1078-0432.CCR-07-1950 
Pak, O., Aldashev, A., Welsh, D., & Peacock, A. (2007). The effects of hypoxia on the 
cells of the pulmonary vasculature. The European Respiratory Journal, 30(2), 
364–372. https://doi.org/10.1183/09031936.00128706 
Parkash, J., Felty, Q., & Roy, D. (2006). Estrogen exerts a spatial and temporal influence 
on reactive oxygen species generation that precedes calcium uptake in high-
capacity mitochondria: implications for rapid nongenomic signaling of cell 
growth. Biochemistry, 45(9), 2872–2881. https://doi.org/10.1021/bi051855x 
Patrone, C., Cassel, T. N., Pettersson, K., Piao, Y.-S., Cheng, G., Ciana, P., … Nord, M. 
(2003). Regulation of postnatal lung development and homeostasis by estrogen 
receptor beta. Molecular and Cellular Biology, 23(23), 8542–8552. 
Rabinovitch, M., Bothwell, T., Hayakawa, B. N., Williams, W. G., Trusler, G. A., Rowe, 
R. D., … Cutz, E. (1986). Pulmonary artery endothelial abnormalities in patients 
with congenital heart defects and pulmonary hypertension. A correlation of light 
with scanning electron microscopy and transmission electron microscopy. 
Laboratory Investigation; a Journal of Technical Methods and Pathology, 55(6), 
632–653. 
Rabinovitch, Marlene. (2008). Molecular pathogenesis of pulmonary arterial 
hypertension. The Journal of Clinical Investigation, 118(7), 2372–2379. 
https://doi.org/10.1172/JCI33452 
Rafikova, O., Rafikov, R., Meadows, M. L., Kangath, A., Jonigk, D., & Black, S. M. 
(2015). The sexual dimorphism associated with pulmonary hypertension 
corresponds to a fibrotic phenotype. Pulmonary Circulation, 5(1), 184–197. 
https://doi.org/10.1086/679724 
Rallis, G. N., Boumba, V. A., Sakkas, V. A., Fragkouli, K., Siozios, G., Albanis, T. A., & 
Vougiouklakis, T. (2014). Residues of selected polychlorinated biphenyls (PCB) 
and organochlorine pesticides (OCP) in postmortem lungs from Epirus, 
northwestern Greece. Journal of Toxicology and Environmental Health. Part A, 
77(13), 767–775. https://doi.org/10.1080/15287394.2014.892447 
Rich, S., Dantzker, D. R., Ayres, S. M., Bergofsky, E. H., Brundage, B. H., Detre, K. M., 
… Koerner, S. K. (1987). Primary pulmonary hypertension. A national 
prospective study. Annals of Internal Medicine, 107(2), 216–223. 
Roberts, K. E., Fallon, M. B., Krowka, M. J., Brown, R. S., Trotter, J. F., Peter, I., … 
Pulmonary Vascular Complications of Liver Disease Study Group. (2009). 
Genetic risk factors for portopulmonary hypertension in patients with advanced 
liver disease. American Journal of Respiratory and Critical Care Medicine, 
179(9), 835–842. https://doi.org/10.1164/rccm.200809-1472OC 
43 
 
Rojiani, A. M., & Dorovini-Zis, K. (1996). Glomeruloid vascular structures in 
glioblastoma multiforme: an immunohistochemical and ultrastructural study. 
Journal of Neurosurgery, 85(6), 1078–1084. 
https://doi.org/10.3171/jns.1996.85.6.1078 
Rossouw, J. E. (2005). Coronary heart disease in menopausal women: implications of 
primary and secondary prevention trials of hormones. Maturitas, 51(1), 51–63. 
https://doi.org/10.1016/j.maturitas.2005.02.015 
Roy, D., & Cai, Q. (2002). Estrogen, immunoactivation, gene damage, and development 
of breast, endometrial, ovarian, prostate, and testicular cancers. Recent Res Devel 
Steroid Biochem Mol Biol, 3, 1–32. 
Roy, D., & Liehr, J. G. (1988). Temporary decrease in renal quinone reductase activity 
induced by chronic administration of estradiol to male Syrian hamsters. Increased 
superoxide formation by redox cycling of estrogen. The Journal of Biological 
Chemistry, 263(8), 3646–3651. 
Roy, Deodutta, Cai, Q., Felty, Q., & Narayan, S. (2007). Estrogen-induced generation of 
reactive oxygen and nitrogen species, gene damage, and estrogen-dependent 
cancers. Journal of Toxicology and Environmental Health. Part B, Critical 
Reviews, 10(4), 235–257. https://doi.org/10.1080/15287390600974924 
Roy, Deodutta, Morgan, M., Yoo, C., Deoraj, A., Roy, S., Yadav, V. K., … Doke, M. 
(2015). Integrated Bioinformatics, Environmental Epidemiologic and Genomic 
Approaches to Identify Environmental and Molecular Links between 
Endometriosis and Breast Cancer. International Journal of Molecular Sciences, 
16(10), 25285–25322. https://doi.org/10.3390/ijms161025285 
Roy, Deodutta, Sarkar, S., & Felty, Q. (2006). Levels of IL-1 beta control 
stimulatory/inhibitory growth of cancer cells. Frontiers in Bioscience: A Journal 
and Virtual Library, 11, 889–898. 
Rubin, L. J. (1997). Primary pulmonary hypertension. The New England Journal of 
Medicine, 336(2), 111–117. https://doi.org/10.1056/NEJM199701093360207 
Salvi, S. S., & Barnes, P. J. (2009). Chronic obstructive pulmonary disease in non-
smokers. Lancet (London, England), 374(9691), 733–743. 
https://doi.org/10.1016/S0140-6736(09)61303-9 
Santos, S., Peinado, V. I., Ramírez, J., Melgosa, T., Roca, J., Rodriguez-Roisin, R., & 
Barberà, J. A. (2002). Characterization of pulmonary vascular remodelling in 
smokers and patients with mild COPD. The European Respiratory Journal, 19(4), 
632–638. 
Sasaki, G. H., Pang, C. Y., & Wittliff, J. L. (1984). Pathogenesis and treatment of infant 
skin strawberry hemangiomas: clinical and in vitro studies of hormonal effects. 
Plastic and Reconstructive Surgery, 73(3), 359–370. 
44 
 
Sergeev, A. V., & Carpenter, D. O. (2005). Hospitalization rates for coronary heart 
disease in relation to residence near areas contaminated with persistent organic 
pollutants and other pollutants. Environmental Health Perspectives, 113(6), 756–
761. 
Shen, A., Iseman, M. D., Waldron, J. A., & King, T. E. (1987). Exacerbation of 
pulmonary lymphangioleiomyomatosis by exogenous estrogens. Chest, 91(5), 
782–785. 
Shim, B., Pacheco-Rodriguez, G., Kato, J., Darling, T. N., Vaughan, M., & Moss, J. 
(2013). Sex-specific lung diseases: effect of oestrogen on cultured cells and in 
animal models. European Respiratory Review: An Official Journal of the 
European Respiratory Society, 22(129), 302–311. 
https://doi.org/10.1183/09059180.00002813 
Stacher, E., Graham, B. B., Hunt, J. M., Gandjeva, A., Groshong, S. D., McLaughlin, V. 
V., … Tuder, R. M. (2012). Modern age pathology of pulmonary arterial 
hypertension. American Journal of Respiratory and Critical Care Medicine, 
186(3), 261–272. https://doi.org/10.1164/rccm.201201-0164OC 
Steiner, M. K., Syrkina, O. L., Kolliputi, N., Mark, E. J., Hales, C. A., & Waxman, A. B. 
(2009). Interleukin-6 overexpression induces pulmonary hypertension. Circulation 
Research, 104(2), 236–244, 28p following 244. 
https://doi.org/10.1161/CIRCRESAHA.108.182014 
Stenmark, K. R., Fagan, K. A., & Frid, M. G. (2006). Hypoxia-induced pulmonary 
vascular remodeling: cellular and molecular mechanisms. Circulation Research, 
99(7), 675–691. https://doi.org/10.1161/01.RES.0000243584.45145.3f 
Sweeney, L., & Voelkel, N. F. (2009). Estrogen exposure, obesity and thyroid disease in 
women with severe pulmonary hypertension. European Journal of Medical 
Research, 14(10), 433–442. https://doi.org/10.1186/2047-783X-14-10-433 
Tam, A., Morrish, D., Wadsworth, S., Dorscheid, D., Man, S. F. P., & Sin, D. D. (2011). 
The role of female hormones on lung function in chronic lung diseases. BMC 
Women’s Health, 11, 24. https://doi.org/10.1186/1472-6874-11-24 
Tanaka, F., Oyanagi, H., Takenaka, K., Ishikawa, S., Yanagihara, K., Miyahara, R., … 
Wada, H. (2003). Glomeruloid microvascular proliferation is superior to 
intratumoral microvessel density as a prognostic marker in non-small cell lung 
cancer. Cancer Research, 63(20), 6791–6794. 
Taniuchi, S., Fujishima, F., Miki, Y., Abe, K., Nakamura, Y., Sato, S., … Sasano, H. 
(2014). Tissue concentrations of estrogens and aromatase immunolocalization in 
interstitial pneumonia of human lung. Molecular and Cellular Endocrinology, 
392(1–2), 136–143. https://doi.org/10.1016/j.mce.2014.05.016 
45 
 
Taraseviciute, A., & Voelkel, N. F. (2006). Severe pulmonary hypertension in 
postmenopausal obese women. European Journal of Medical Research, 11(5), 
198–202. 
Tofovic, S. P., Zhang, X., Zhu, H., Jackson, E. K., Rafikova, O., & Petrusevska, G. 
(2008). 2-Ethoxyestradiol is antimitogenic and attenuates monocrotaline-induced 
pulmonary hypertension and vascular remodeling. Vascular Pharmacology, 48(4–
6), 174–183. https://doi.org/10.1016/j.vph.2008.02.001 
Tokunaga, S., & Kataoka, K. (2003). [A longitudinal analysis on the association of serum 
lipids and lipoproteins concentrations with blood polychlorinated biphenyls level 
in chronic “Yusho” patients]. Fukuoka Igaku Zasshi = Hukuoka Acta Medica, 
94(5), 110–117. 
Torday, J. S., & Nielsen, H. C. (1987). The sex difference in fetal lung surfactant 
production. Experimental Lung Research, 12(1), 1–19. 
Tuder, R. M., Groves, B., Badesch, D. B., & Voelkel, N. F. (1994). Exuberant endothelial 
cell growth and elements of inflammation are present in plexiform lesions of 
pulmonary hypertension. The American Journal of Pathology, 144(2), 275–285. 
Tuder, Rubin M., Marecki, J. C., Richter, A., Fijalkowska, I., & Flores, S. (2007). 
Pathology of Pulmonary Hypertension. Clinics in Chest Medicine, 28(1), 23–vii. 
https://doi.org/10.1016/j.ccm.2006.11.010 
Ventetuolo, C. E., Baird, G. L., Barr, R. G., Bluemke, D. A., Fritz, J. S., Hill, N. S., … 
Kawut, S. M. (2016). Higher Estradiol and Lower Dehydroepiandrosterone-
Sulfate Levels Are Associated with Pulmonary Arterial Hypertension in Men. 
American Journal of Respiratory and Critical Care Medicine, 193(10), 1168–
1175. https://doi.org/10.1164/rccm.201509-1785OC 
Vignozzi, L., Cellai, I., Santi, R., Lombardelli, L., Morelli, A., Comeglio, P., … Maggi, 
M. (2012). Antiinflammatory effect of androgen receptor activation in human 
benign prostatic hyperplasia cells. The Journal of Endocrinology, 214(1), 31–43. 
https://doi.org/10.1530/JOE-12-0142 
Vignozzi, L., Gacci, M., Cellai, I., Santi, R., Corona, G., Morelli, A., … Maggi, M. 
(2013). Fat boosts, while androgen receptor activation counteracts, BPH-
associated prostate inflammation. The Prostate, 73(8), 789–800. 
https://doi.org/10.1002/pros.22623 
Vignozzi, L., Morelli, A., Cellai, I., Filippi, S., Comeglio, P., Sarchielli, E., … Maggi, M. 
(2017). Cardiopulmonary protective effects of the selective FXR agonist 
obeticholic acid in the rat model of monocrotaline-induced pulmonary 
hypertension. The Journal of Steroid Biochemistry and Molecular Biology, 165(Pt 
B), 277–292. https://doi.org/10.1016/j.jsbmb.2016.07.004 
46 
 
Wahedna, I., Cooper, S., Williams, J., Paterson, I. C., Britton, J. R., & Tattersfield, A. E. 
(1994). Relation of pulmonary lymphangio-leiomyomatosis to use of the oral 
contraceptive pill and fertility in the UK: a national case control study. Thorax, 
49(9), 910–914. 
White, K., Dempsie, Y., Nilsen, M., Wright, A. F., Loughlin, L., & MacLean, M. R. 
(2011). The serotonin transporter, gender, and 17β oestradiol in the development 
of pulmonary arterial hypertension. Cardiovascular Research, 90(2), 373–382. 
https://doi.org/10.1093/cvr/cvq408 
White, K., Johansen, A. K., Nilsen, M., Ciuclan, L., Wallace, E., Paton, L., … MacLean, 
M. R. (2012). Activity of the estrogen-metabolizing enzyme cytochrome P450 
1B1 influences the development of pulmonary arterial hypertension. Circulation, 
126(9), 1087–1098. https://doi.org/10.1161/CIRCULATIONAHA.111.062927 
Yano, S. (2002). Exacerbation of pulmonary lymphangioleiomyomatosis by exogenous 
oestrogen used for infertility treatment. Thorax, 57(12), 1085–1086. 
https://doi.org/10.1136/thorax.57.12.1085 
Yu, J., Astrinidis, A., Howard, S., & Henske, E. P. (2004). Estradiol and tamoxifen 
stimulate LAM-associated angiomyolipoma cell growth and activate both 
genomic and nongenomic signaling pathways. American Journal of Physiology. 
Lung Cellular and Molecular Physiology, 286(4), L694-700. 
https://doi.org/10.1152/ajplung.00204.2003 
 
  
47 
 
CHAPTER 3 
MANUSCRIPT 1  
EXPOSURE TO POLYCHLORINATED BIPHENYLS AND RISK OF 
PULMONARY ARTERIAL HYPERTENSION IN THE UNITED STATES 
POPULATION: ANALYSES OF NHANES DATA 1999-2004 
ABSTRACT 
 
Background:   
Pulmonary arterial hypertension (PAH) is a disease with higher risk in women. Endocrine 
disrupting chemicals (EDC) are associated with increase of estrogen activity and 
metabolism which leads to increase the risk of PAH. Polychlorinated biphenyls (PCBs) 
are known to be endocrine disrupters and to alter estrogenic activity in human.  
Objectives: 
The objective of this study was to evaluate the association between exposure to PCBs and 
risk of PAH among U.S. population. 
Methods:   
Using Centers for Disease Control and Prevention’s National Health and Nutrition 
Examination Survey (NHANES) data from 1999-2004, we selected subjects identified at 
risk of PAH and ≥ 20 years old with available blood samples data. We used lipid adjusted 
serum levels of six PCBs congeners (including PCB 74, 99, 118, 138, 153, and 180), the 
sum of non-dioxin-like PCBs (PCB 099 + 138 + 153+187), and the sum of dioxin-like 
PCBs (PCB 074 + 118) along with other variables provided from different health 
examinations. We included gender, age, BMI, and race and confounders in our analysis.  
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PCB concentration geometric means were analyzed in subjects identified ≥ 20 years old 
at risk of PAH and not at risk of PAH.     
Results:  
Different analysis showed that all PCBs congeners were significantly higher in subjects 
identified at risk of PAH than subjects identified not at risk of PAH. Multiple limit of 
detections (LODs) were used to evaluate PCBs associations with the risk of PAH. All 
LOD showed higher association of PCBs congeners concentrations in subjects identified 
at risk of PAH including (PCBs concentrations >LOD, > 50th percentile, 50th-75th 
percentile, and ≥75th percentile).   
Conclusions:  
Using NHANES data from 1999-2004, we found that exposure to PCBs increases the risk 
of PAH in the U.S. population ≥ 20 years old. However, epidemiological studies need to 
be conducted to provide better explanation of PCBs association and other diseases. 
Keywords:  PCBs, NHANES, pulmonary arterial hypertension, PAH 
MANUSCRIPT 1 
EXPOSURE TO POLYCHLORINATED BIPHENYLS AND risk of 
PULMONARY ARTERIAL HYPERTENSION IN THE UNITED STATES 
POPULATION: ANALYSES OF NHANES DATA 1999-2004 
INTRODUCTION 
Pulmonary arterial hypertension (PAH) is a vascular disease that affects 
pulmonary arteries and causes increase in the mean arterial pressure (Rich et al., 1987). 
PAH has poor prognosis with duration time of 2.8 years, from the beginning of the 
symptoms (D’Alonzo et al., 1991). PH surveillance reported that prevalence of 5.4 
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/100,000 population which was reported for the year 2002 in the U.S. and the same report 
showed that the rate of death was decreased among men while increased among women, 
which reflect the higher incidence of PAH among women. Data from NCHS reported 
5.3% of deaths because of cardiopulmonary diseases in 2008 (NHLBI, 2012). However, 
women reported higher cases than men during the same period. Also, black race reported 
the highest death rates comparing with other race groups with 7.3 /100,000 population. 
Elderly, > 85 years was the highest age group with number of death with 63.2 /100,000 
population (CDC, 2005b).  
Besides gender, many risk factors were reported to be associated with increased 
risk of PAH including: hypertension, abnormal lung function, diabetes, uric acid level, 
age, insulin status, obesity, thyroid problems, and female sex hormones. Insulin 
resistance (IR) was reported to be associated with PAH and poor survival rate in females 
(Zamanian et al., 2009). Registry to Evaluate Early and Long-term PAH Disease 
Management (REVEAL) showed significant association between obesity (BMI > 30, P-
value=0.004) and PAH comparing with normal and underweight patients (Burger et al., 
2011). Zhang and colleagues showed that serum uric acid levels in PAH patients 
(405±130 μmol/L) were higher than control subjects (344±96 μmol/L; P<0.05). 
Reference values were 360 μmol/L and 420 μmol/L for females and males, respectively 
(Zhang, Ma, & Wang, 2013). Older age was reported to be a risk factor of PAH 
comparing with younger patients. Schachna reported that elderly > 60 years old had 2 
times higher risk of PAH than patients < 60 years old (OR, 2.30; 95% CI, 1.32 to 3.99) 
(Schachna et al., 2003). This also supports the finding of the age specific death rate for 
elderly by CDC in 2005 (CDC, 2005b). Many studies showed high prevalence of thyroid 
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problems and risk of PAH. In 2007, Li and colleagues reported that risk of PAH was 2 
times higher in people who had thyroid diseases than others (OR, 2.53; 95% confidence 
interval, 1.55 to 4.08; p < 0.001) (J. H. Li et al., 2007). Diabetes showed high prevalence 
in patients with PAH than control (OR, 1.53; 95% CI, 1.45 to 1.60; p < 0.001).  Gender 
difference was reported in France national registry that females had higher risk of PAH 
than males (OR 1.9; P <0.035) (Marc Humbert et al., 2006). Also, REVEAL study 
reported the highest female to male ratio of 4.1:1 in IPAH (Badesch et al., 2010). 
Moreover, oral contraceptives and hormone replacement therapies were reported to be 
associated with severity of PAH and formation of obliterative lesions in idiopathic-PAH 
(IPAH) (Irey & Norris, 1973; Taraseviciute & Voelkel, 2006).   
Polychlorinated biphenyls (PCBs) are group of complex chemical contaminants in 
the environment that have different effects on the human body including 
neurodevelopmental effects (Ribas-Fito, Sala, Kogevinas, & Sunyer, 2001). They were 
widespread into the industries by 1920’s as transformers of many products. PCBs were 
known to have high resistant of degradation by chemical and biological factors (Jensen, 
1987). Even though they were banned during the 1970’s, their exposure remained in the 
environment by many ways. Exposure to PCBs was reported in wildlife tissues, animal fat, 
and even in human serum with small amounts (Dewailly et al., 1999). PCBs are known to 
be endocrine disrupting chemicals (EDCs) which have different effects on health by 
altering cellular activity, pathways and metabolism. They can be found in plastic products, 
pesticides, and flame retardants (J. R. Roy et al., 2009).    
Estrogen and EDCs were associated with inducing many molecular level 
processes such as inflammation. Estrogen reported to have direct effect on inflammatory 
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cytokines such as TNF-α, IL-6, and IL-1β (D. Roy et al., 2007). Various EDCs such as 
PCB126 congener are associated with modifications of many induced-inflammation 
genes including IL6, TNF, and CXCL8; while PCB 153 is associated with modifications 
of SOD2, AHR, and IL6. Bisphenol A is shown to be associated with inflammatory 
induced genes including PARP1, MMP9, HMOX1, and IL1B. Nevertheless, PCB153 
was also reported to alter smooth muscle cell phenotypes and pulmonary endothelial 
(Charlier, Albert, Zhang, Dubois, & Plomteux, 2004).  
In this study, we evaluated the association between 6 PCB congeners, the sum of 
dioxin-like PCBs, and the sum of non-dioxin-like PCBs in subjects at risk of PAH in the 
National Health and Nutrition Examination Survey (NHANES) between the years 1999-
2004. We aimed to 1) describe the mean of PCB concentration in population ≥ 20 years 
of age who were identified at risk of PAH compared with subjects identified not at risk of 
PAH; and 2) use different LOD levels of PCBs’ to evaluate the higher concentration of 
PCBs and the risk of PAH.   
METHODS 
Study Design 
The main objective of this study was to investigate the association between 
exposure to EDCs such as PCB and risk of PAH and pulmonary diseases in the U.S. 
general population. To clarify and confirm the suggested role of EDCs, we used 
NHANES data from 1999-2004 provided by Centers for Disease Control and Prevention 
(CDC) to conduct a secondary statistical analysis. National Health and Nutrition 
Examination Survey (NHANES) is a program developed by National Center for Health 
Statistics (NCHS) to assess the nutritional and health status for children and adults in the 
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United States. NHANES started in the early 1960s producing different surveys for many 
health issues as well as many age groups. Since 1999, NHANES started producing 
annually continuous interviews and surveys targeting different health and nutritional 
measurements for evaluation purposes including demographic, dietary, health-related 
questions, socioeconomic, dental, medical, physiological measurements, and laboratory 
tests. An average of 5,000 participants enrolled every year and 15 counties across the 
nation are visited every year. To acquire a representative sampling of the population, 
many parameters needed to be taken into consideration for oversampling. Oversampling 
would be sub-grouped, stratified in strata’s and then divided into different locations. 
Oversampling includes age (adolescents (12-19 years), adults (≥ 60 years)) and 
ethnicity/race (non-Hispanic black and Mexican Americans). After being eligible, the 
participants undergo series of interviews and examinations in a specially equipped mobile 
evaluation clinic (MEC). MEC examination consist of collections of urine and blood 
samples, personal interviews, and dental and physical examinations. Urine is collected 
from participant if ≥ 6 years, and blood samples collected from participant if ≥ 1 year. 
CDC institutional board approved the study protocol and all participants signed a consent 
before joining the NHANES.  All data are strictly confident and coded in different 
identification factors to keep privacy. Transportation, personal care (baby/ elderly) and 
cash payment for participating are included (CDC, 2012).  
Laboratory Methods 
Exposure to environmental chemicals can be through different routes including 
dermal, ingestion, or inhalation. Thus, measurements of these chemicals or their 
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metabolites in blood and urine can reflects the amount enters the body. About 2,500 
subsamples participated in each 2-years cycle for blood serum and urine samples. CDC 
used many procedures to measure environmental chemical exposure including isotope 
dilution mass spectrometry, graphite furnace atomic absorption spectrometry, or 
inductively coupled plasma mass spectrometry. These procedures or protocols are 
provided by Division of Laboratory Sciences, National Center for Environmental Health, 
and CDC’s Environmental Health Laboratory. Serum blood samples are measured per 
whole weight or per gram of total lipid to reflect the amount of PCBs stored in body fat. 
During the MEC exam and transit location, both urine and blood serum samples are 
stored in 4 ◦C or froze at -20 ◦C before shipping to the Division of Laboratory Sciences, 
National Center for Environmental Health, CDC’s Environmental Health Laboratory 
(CDC, 2013b).   
Serum PCB  
One-third sampling procedure was used to measure PCB levels in blood serum 
samples of participant’s ≥ 12 years old in 1999-2000 and 2003-2004 survey cycles. In 
2001-2002 survey cycle, NHANES used age inclusion to be ≥ 20 years old. PCBs were 
analytically reported on a lipid-adjusted basis (ng/g or ppb) and a whole weight (ng/g or 
ppb).  
Questionnaire Methods 
Multiple time points included collection of demographic, reproductive health, and 
medical health data. Intensive two weeks training program including exercises, training 
interview, and training on personal audio computer interview was conducted and 
supervised by NCHS and accompanied staff.  Also, multiple quality control monitoring 
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procedure were conducted through full pilot test before starting questionnaire. During a 
household interview, people ≥ 16 years old provided demographic data. During the 
personal interview in Mobile Examination Center (MEC), females ≥ 12 years old 
provided reproductive health data. For both males and female (constriction by age and 
gender), medical health data was provided during the MEC interview (CDC, 2012).    
Selection of Participants 
Inclusion criteria used for the study included people during MEC were ≥ 20 years 
old who completed and provided, personal interview and urine and blood samples, 
respectively. A participant will be included in the study population if PCB measurements 
were available. In addition, people at risk of PAH were selected based on an inclusion 
criteria specifically for this variable. We created the Risk of PAH variable based on any 
risk factors that reported individually to be associated with PAH in literature. As 
mentioned earlier in introduction, these risk factors included hypertension, diabetes, 
thyroid problems, uric acid level, insulin status, and female hormone (only for female 
participants). Risk of PAH variable was created after sum of all risk factor scoring to be 
at risk of PAH if > 2 for male participants and to be 3 for female participants (CDC, 
2012). Participant will be deleted from the dataset if any of these risk factors answer or 
level were missing. 
Sample Weights and Limits of Detection 
Sample weight is required when merging NHANES complex survey data to avoid 
bias from non-response selection. As mentioned earlier PCB measurements were 
collected in one third selection procedure, so weighting these environmental chemical is 
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also required. The weight variable was provided in each 2-year cycle from 1999-2004 
“for all variables; and it was created for the environmental chemical based on NHANES 
analytic guidelines (CDC, 2013b). Detection limit for each of the environmental 
chemicals was divided into 0 if below detection limit and 1 if above detection limit for 
PCB. However, if PCB serum level was below the detection limit, it is required to be 
divided by the square root of 2. CDC improved their procedure and techniques yearly, 
which resulted in changing in the detection limit of the environmental chemicals (CDC, 
2013). Individual PCB congener has their own LOD because they have different sample 
volumes. Thus, calculations for each of the environmental chemicals is required based on 
sample volume for each serum and urine sample to be analytically sensitive. Serum 
samples environmental chemical LOD was calculated per amount of lipid and urine 
samples environmental chemical LOD was calculated per volume of urine (CDC, 2013b).   
EDC Exposure Assessment 
PCB Variables.   
Number of available PCB data was varied in different NHANES cycles (1999-
2000, 2001-2002, and 2003-2004) and to avoid bias of low detection limit samples, we 
selected 6 PCB congeners which had measurements above 60% of the population 
samples. Based on this inclusion criteria, the selected PCB congeners to find the 
association with the risk of PAH were: 2,4,4’,5-tetrachlorobiphenly (PCB 74), 2,2’4,4’,5-
pentachlorobiphenyl (PCB 99),  2,3’,4,4’,5-pentachlorobiphenyl (PCB 118), 
2,2’,3,4,4’,5-hexachlorobiphenyl  (PCB 138), 2,2’,4,4’,5,5’-hexachlorobiphenyl (PCB 
153), and 2,2’,3,4,4,5,5’-heptachlorobiphenyl (PCB 180). We also analyzed the sum of 
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dioxin-like PCBs (PCB 74 and PCB 118) and of non-dioxin-like PCBs (PCB 99, PCB 
138, PCB 153, PCB 180). Using complex survey NHANES data for 1999-2004 merged 
year cycles, we analyzed the association of these PCBs and the risk of PAH in ≥ 20 years 
old.  
  Reproductive and Medical Health Variables 
Data was collected from medical health questionnaire, reproductive health 
questionnaire, and laboratory data to analyze the association between serum PCB and the 
risk of PAH.    
Medical Health Questionnaire.   
Using medical health questionnaire, the participant > 20 years old had to provide 
a response to risk factors of PAH including “have you ever been told by a doctor or 
health professional that you have diabetes?”, “Has a doctor or other health professional 
ever told that you had a thyroid disease?” Diabetes risk factor was scored 0 if answer was 
NO, and scored 1 if answer was YES. Thyroid problem risk factor was scored 0 if answer 
was NO, and scored 1 if answer was YES. Each of these variables was transformed into 0 
if no risk of PAH and 1 if at risk of PAH. 
Reproductive Health Questionnaire.  
Using reproductive health questionnaire, female participants > 20 years old had to 
provide a response to risk factor of PAH “have you ever used female hormones such as 
estrogen and progesterone?” Female hormone risk factors (female participants only) was 
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scored 0 in the female participant answered No, and scored 1 if the female participant 
answered YES. 
Laboratory data.  
Using laboratory data measurements, uric acid level should be available for the 
included participant, as well as measurements of both (triglycerides and HDL-
Cholesterol) to calculate insulin status (insulin sensitive or insulin resistance). Uric acid 
risk factor is a continuous variable, so males and females have different references. Males 
participants scored 0 if any had uric acid level < 419 mmol/L, and scored 1 if any male 
participant had uric acid level > 420 mmol/L. Females participants scored 0 if any had 
uric acid level < 359 mmol/L, and scored 1 if any male participant had uric acid level > 
360 mmol/L. Insulin status was calculated by dividing triglycerides level by HDL-
cholesterol level to be < 1.99 “insulin sensitive (IS)” or > 2.00 “insulin resistance (IR)”. 
Insulin status scored 0 if IS and scored 1 if IR. Risk of PAH variable was created after 
sum of all risk factor scoring to be at risk of PAH if > 2 for male participants and to be 3 
for female participants (CDC, 2012). Participant will be deleted from the dataset if any of 
these risk factors answer or level were missing.  
Statistical Analysis 
We selected people > 20 years old and had available data for PCBs, medical 
health, and reproductive health to be included in the analysis to find the association with 
the risk of PAH. Because non-normal distribution of the PCBs measurements, they were 
log transformed before the analysis. Also, data was weighted using the required weight 
by the National Center for Health Statistics guidelines to be representative to the whole 
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population. We used stratum and PSA to estimate variance of the demographic data. We 
calculated geometric means (GM), geometric standard errors (GSE), and proportions for 
all PCBs and their associated with the risk of PAH. We used Student’s t-test GM to 
compare PCBs level’s mean and the association with the risk of PAH. To find the 
associated risk of PAH with each of the PCBs’, we used logistic regression models to 
calculate the odds ratios (ORs) and their 95 % confidence intervals (CI).  
Because of small number of participants who had risk of PAH, we used NCHS guidelines 
to categorize the limit of detection (LOD) into many levels to perform different analysis 
based on the LOD (51). These LOD including 1) < LOD vs. ≥ LOD; 2) < LOD to 50th 
percentile (reference) vs. ≥ 50th percentile, and 3). < LOD to 50th percentile vs. 50th 
percentile to 75th percentile vs. ≥ 75th percentile. Statistical analysis were performed 
using SPSS software (release 20) for windows and SAS software for windows (release 
9.4; SAS Institute Inc. Cary, N.C.). We used 5% (P ≤0.05) as significance level for all 
analysis.     
Potential Confounding Variables. 
We included many potential confounding variables as categorical variables which 
are gender, age, body mass index (BMI, kg/m2), annual family income, smoking status, 
alcohol consumption, race, and education level. Gender were categorized into male (1) 
and female (2), age was categorized into three age groups including 20-59 years (1), 60-
74 years (2) and ≥ 75 years (3). BMI was categorized into > 25 kg/m2 (1), 25-30 kg/m2 
(2), and ≥ 30 kg/m2 (3). Annual family income was categorized into 0-$24,999 (1), 
$25,000-$54,999 (2), $55,000-$74,999 (3), and ≥ $75,000 (4). Smoking status was 
categorized into smokers (1) and non-smokers (2), and alcohol consumption was 
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categorized into consumers (1) non-consumers (2). Race was categorized into non-
Hispanic White (1) and others (2), and education level was categorized into three 
categories < 12th grade (1), 12th grade (2), and > 12th grade (3). All confounding variable 
data included in the analysis to find the association of PCB and risk of PAH was used 
from the demographic file. Categorization of age and race into specific ranges was to 
avoid bias in the results due to low number of people at risk of PAH in younger ages and 
other races.  
RESULTS 
Descriptive Statistics. 
The study population who completed medical health questionnaire, reproductive 
health questionnaire; and had available laboratory data to analyze the association between 
serum PCB and the risk of PAH were 4,495 participants ≥ 20 years old. Among the 
included population, 166 (3.7%) of them identified at risk to PAH and 4,329 (96.3) of 
them were not at risk of PAH (Table 3). Males reported 25 (0.41%) of them identified at 
risk to PAH, while 141 (2.96%) females were identified at risk to PAH. However, 2092 
(47.78%) males and 2237 (48.86%) females were not at risk of PAH, respectively (Table 
3). Race distribution reported 94 (2.72%) of people at risk of PAH to be non-Hispanic 
white and 69 (0.65%) were others. However, people not at risk of PAH were 2197 
(69.13%) non-Hispanic white and 2132 (27.5%) were others (Table 3). Age was 
categorized into 3 group; where 47 (1.45%) of people at risk of PAH and 2888 (76.09%) 
of people not at risk of PAH were in 20-59 years old group. Most participants at risk of 
PAH among all age groups were in 60-74 years old group with 78 (1.28%), while same 
age group reported 906 (13.67%) participant not to be at risk of PAH. Elderly > 75 years 
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old were the smallest number among all age groups with 41 (0.63%) at risk of PAH and 
535 (6.86%) not at risk of PAH (Table 3). Obese participant reported the highest number 
among people at risk of PAH with 83 (2.32%), followed by 54 (1.39%) and 19 (0.58%) 
for overweight and normal weight, respectively. However, people not at risk of PAH 
were 1079 (35%), 1149 (33.35%), and 970 (27.35%) for normal weight, overweight, and 
obese, respectively (Table 3). Annual family income reported 0-$24,999 group to 
represent the highest number of population in both risk of PAH 81 (1.29%) and 1692 
(28.12%) not at risk of PAH. In the group of $25,000-$54,999, there were 47 (1.17%) at 
risk of PAH and 1242 (28.66%). However, $55,000-74,999 group reported the lowest 
number of people at risk of PAH and people not at risk of PAH with 10 (0.39%) and 390 
(11.01%), respectively (Table 3). No significant difference in distribution of people at 
risk of PAH in education variable, however, people with high education level ≥ 12th 
grade reported to be the highest not at risk of PAH with 1943 (53.28%) (Table 3). Most 
subjects at risk of PAH were not smokers with 62 (3.24%), while 29 (1.52%) were 
smokers. Subjects not at risk pf PAH reported 711 (46.64%) to be smokers and 899 
(48.59%) were not smokers (Table 3). Alcohol users, 20 (0.77%) were not at risk of 
PAH, while no cases reported to be at risk of PAH. Non-alcohol users were 165 (4.41%) 
at risk of PAH and 3258 (94.82%) were not at risk of PAH (Table 3).  
Individual PCB geometric mean (GM) for people at risk of PAH and not at risk of PAH 
was represented in (Table 4) with their geometric standard error (GSE). An average 
number of people at risk of PAH was 153 in all PCB included in the analysis which were 
above LOD concentration (Table 4). Generally, people at risk of PAH reported 
significant higher GM for all PCBs than people not at risk. Among GM of all PCB for 
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people at risk of PAH, GM of PCB 153 was the highest concentration with 51.28 ng/g,  
while PCB 99 reported the lowest GM concentration among all PCB in people at risk of 
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PAH with 8.79 ng/g (Table 4). As well, people not at risk of PAH reported lowest GM in 
PCB 99 with 6.06 ng/g and the highest GM was in PCB 153 with 33.02 ng/g (Table 4). 
 
We analyzed the association between our study population by different age groups and all 
PCBs GM > LOD. All GM PCBs, in people at risk of PAH and with no risk of PAH, 
were markedly increased with age with some exceptions in PCBs 99, 153, and 180 in age 
group 60-74 years, and PCB 180 an age group of ≥ 75 (Table 5). However, people at risk 
of PAH reported that PCB 153 had the highest GM while PCB 99 reported the lowest 
GM among all PCBs in the age group of 20-59 years old with 36.89 ng/g and 6.90 ng/g, 
respectively (Table 5). No significant difference was reported within GM of PCB in the 
study population in the other age groups 60-74 years old and ≥ 75 years old (Table 5).  
 
We analyzed the association between age adjusted PCB concentrations in study 
population race groups. Using lipid adjusted PCB concentration, participants categorized 
as “non-Hispanic white” had higher GM concentrations of all PCBs than people 
categorized as “other” for not at risk of PAH population (Table 6). However, population 
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at risk of PAH reported that people categorized as “other” had higher concentrations of 
PCB 99, 138, 153, and 180, while non-Hispanic white category had higher PCB 74 and 
118 (Table 6). 
 
For all 6 PCB congeners, there were 150 participants at risk of PAH, 154 
participants at risk of PAH in dioxin-like PCBs (74+ 118) (Table 7), and non-dioxin-like 
PCBs (99+138+153+180) (Table 8). We analyzed the Dioxin-like PCBs (74+118) serum 
concentration to evaluate their association with the risk of PAH in our study population 
(Table 7). Dioxin-like PCB concentration in serum was significantly higher in people at 
risk of PAH with 3.58 ng/g, than people not at risk of PAH with 2.81 ng/g  (Table 7). We 
categorized limit of detection of dioxin –like PCBs into < LOD to 50 % and > 50%. 
People not at risk of PAH reported mean of dioxin-like PCB < LOD to be 2.59 ng/g, 
while LOD ≥ 50% with 3.53 ng/g (Table 7). However, people at risk of PAH reported 
mean of dioxin-like PCB < LOD to be 2.61 ng/g, while LOD ≥ 50% with 3.81 ng/g 
(Table 7). 
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All covariates reported higher mean dioxin-like PCBs in population at risk of PAH than 
population not at risk of PAH except in race covariate, people categorized as “other” 
reported higher dioxin-like PCB mean to be lower in people at risk of PAH (Table 7). 
Overall, the highest mean of dioxin-like PCB was reported in people ≥ 75 with risk of 
PAH, while the lowest mean of dioxin-like PCBs was in race categorized as “others” in 
people at risk of PAH (Table 7). 
Non-dioxin-like PCB included the sum of PCBs (99+138+153+180) was analyzed 
to evaluate the association with the risk of PAH by mean of concentration and 95% CI 
(Table 8). People at risk of PAH reported higher mean of non-dioxin-like PCBs that 
people not at risk of PAH with 4.87 ng/g and 4.41 ng/g, respectively (Table 8). We also 
evaluated the association of covariates with risk of PAH and their association with mean 
concentration of non-dioxin-like PCBs including gender, race, age, BMI, annual family 
income, education level, smoking, and alcohol use. Most covariates reported higher mean 
of non-dioxin-like PCBs in people at risk of PAH than people not at risk of PAH. 
However, concentration < LOD to 50% of non-dioxin-like PCBs was higher in people 
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not at risk of PAH (Table 8). Nevertheless, concentration of non-dioxin-like PCBs 
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remained the same in age groups 60-74 and > 75 with 5.10 ng/g and 5.33, respectively, 
for both risk of PAH groups of non-dioxin-like PCBs. Overall, the highest concentration 
of non-dioxin-like PCBs was reported in age group > 75 years with 5.33 ng/g, while the 
lowest concentration was reported in people at risk of PAH at < LOD to 50% with 4.16 
ng/g (Table 8).  
We analyzed the LOD for all PCBs concentrations with the study population to evaluate 
their association with the risk of PAH with different LOD. Small number of people at risk 
of PAH was reported with all PCBs concentration < LOD comparing to number of people 
not at risk of PAH (Table 9). We reported GM with 95% CI for LOD level of each PCB 
and all PCB concentrations > LOD were higher in people at risk of PAH than people not 
at risk of PAH (Table 9). However, PCB concentration < LOD remained the same among 
people at risk and not at risk of PAH (Table 9).  
People at risk of PAH reported PCB > LOD concentration GM at 16.94 ng/ng for PCB 
74, 11.5 ng/ng for PCB99, 22.87 ng/ng for PCB118, 40.56 ng/ng for PCB138, 54.02 
ng/ng for PCB153, and 42.66 ng/ng for PCB180 (Table 9). However, people not at risk of 
PAH reported PCB > LOD concentration GM at 11.54 ng/ng for PCB 74, 8.41 ng/ng for 
PCB99, 15.36 ng/ng for PCB118, 33.89 ng/ng for PCB138, 47.33 ng/ng for PCB153, and 
38.31 ng/ng for PCB180 (Table 9).  
We also analyzed all PCBs concentration with another division of LOD because 
small number of people at risk in table 1.7, and we used < LOD to 50% and > 50% 
percentiles to be reported in (Table 10). Also, small number of people at risk of PAH was 
reported for all PCB with concentration < LOD to 50 % with 4, 11, 11, 15, 22, and 21 for 
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PCBs 74, 99, 118, 138, 153, and 180, respectively (Table 10). All GM for different levels 
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of PCB LOD concentrations were higher in people at risk of PAH than people not at risk 
of PAH, except PCB118 > 50% and PCB180 (Table 10).  
People at risk of PAH reported PCB > 50% concentration GM at 18.03 ng/ng for 
PCB 74, 12.74 ng/ng for PCB99, 25.69 ng/ng for PCB118, 47.49 ng/ng for PCB138, 
64.89 ng/ng for PCB153, and 48.37 ng/ng for PCB180 (Table 10). However, people not 
at risk of PAH reported PCB > LOD to 50% concentration GM at 15.22 ng/ng for PCB 
74, 10.58 ng/ng for PCB99, 7.22 ng/ng for PCB118, 43.87 ng/ng for PCB138, 63.86 
ng/ng for PCB153, and 49.90 ng/ng for PCB180 (Table 10). 
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Overall, no significance difference was reported between GM PCB concentrations of 
people at risk of PAH and people not at risk of PAH (Table 10).  
To get more accurate LOD, we performed another analysis with more divided 
LOD for PCB concentrations using < LOD to 50th percentile, 50th percentile to 75th 
percentile, and ≥ 75th percentile (Table 11). Higher number of people at risk of PAH were 
reported among LOD ≥ 75th percentile than < LOD to 50th percentile and 50th percentile 
to 75th percentile (Table 11). All LOD of PCB concentration were higher in people at risk 
of PAH than people not at risk of PAH, except GM of PCB 138 < LOD to 50th percentile, 
GM of PCB180 50th percentile to 75th percentile, and ≥ 75 % percentile (Table 11). 
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The most significant GM was reported in PCB 118 of LOD ≥ 75 % percentile with 33.89 
for people not at risk of PAH and 39.02 for people at risk of PAH (Table 11).  
We calculated estimated odds ratio (OR) and 95% confidence intervals to 
evaluated all PCBs concentration association with risk of PAH (Table 12). Because of 
low number of subjects at risk of PAH, we used < LOD to 50th percentile (reference 
group) and ≥ 50th percentile. We calculated unadjusted OR; gender adjusted OR; age, 
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race, and BMI adjusted OR; and age, race, BMI, and gender adjusted OR. In Unadjusted 
OR, all PCBs were significantly associated with identified risk of PAH in (≥ 50th 
percentile) when we compare it to the reference group (< LOD to 50th percentile) (Table 
12). After gender adjusting, all PCB concentration were significantly associated with risk 
of PAH. The highest OR was found in PCB 74 with [OR of 4.00; 95% CI: 3.98-4.01] 
(Table 12).  
We calculated estimated OR and 95% confidence intervals for PAH with PCB 
concentrations divided into < LOD to 50th percentile (reference group), 50th to 75th 
percentile, and ≥ 75th percentile (Table 13). In unadjusted calculated OR, all PCB 
concentrations were significantly associated with identified risk of PAH. The highest OR 
was reported with PCB 74 with [OR of 4.32; 95% CI: (4.31-4.34)]. In gender adjusted 
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OR model, all PCB concentrations were higher than un adjusted model except for PCB 
180 reported lower OR than in unadjusted model (Table 13). In age, race, and BMI 
adjusted OR; and age, race, BMI, and gender adjusted OR, all PCB concentration were 
associated with identified risk of PAH. However, no significant difference was reported 
within the two models (Table 13). 
   
We calculated estimated OR and 95% confidence intervals for PAH and dioxin-
like and non-dioxin-like PCBs < LOD to 50th percentile (reference group) and ≥ 50th 
percentile (Table 14). In unadjusted calculated OR, dioxin-like and non-dioxin-like PCBs 
were significantly associated with identified risk of PAH [OR of 2.64; 95% CI: (2.63-
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2.66)] and 1.58 (1.79-1.59), respectively. In the age, race, and BMI adjusted model; and 
age, race, BMI, and gender adjusted OR, non-dioxin-like PCBs at levels ≥ 50th percentile 
and levels ≥ 75th percentile were not associated with identified risk of PAH (Table 14).  
DISCUSSION 
The fact that EDCs can affect estrogen activity in different tissue in human body, 
encouraged us to evaluate PCBs and their effect on the risk of PAH. It is known that 
estrogen, oral contraceptive, and female bias has been suggested to be risk factors in the 
pathogenesis of PAH. This is the first cross-sectional study that evaluate the exposure of 
PCBs and their association with the risk of PAH. We represented the significant 
association of exposure to 6 PCB 74, 99, 118, 138, 153, and 180 congeners individually 
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and high risk of PAH in the U.S. population > 20 years old using NHANES data 1999-
2004. Furthermore, we demonstrated the sum of dioxin-like PCBs (PCB 74 and 118), and 
non-dioxin-like PCBs (PCB 118, 138, 153, and 180) and their association with high risk 
of PAH.  
Our results are supported with the known association between PAH and its risk 
factors which is high estrogen activity, as well the bias in female gender (Badesch et al., 
2010). Females were six times significantly higher in population at risk of PAH than 
males. We found that PRKCH is a gene resulted from the meta-analysis of gene 
expression of PAH might have plausible role in pathogenesis of PAH. Also it was 
reported that PRKCH induce ERs transcriptional activity resulted from exposure to high 
levels of EDCs (Cho & Katzenellenbogen, 1993). Also, adipogenesis is known risk factor 
of obesity, and EDCs were reported to increase the PPAR and promote adipogenesis 
(Charlier et al., 2004). Obese people were at higher risk of PAH than normal and 
overweight people. This result is also supported by REVEAL results that reported 
significant association between obese people and PAH (BMI > 30, P-value=0.004 
(Burger et al., 2011). GM of all individual PCB levels was significantly increased in 
people at risk of PAH than people not at risk of PAH. Another NHANES study of PCBs 
association with hypertension reported 11 PCBs to risk factor including PCBs (PCBs 
126, 74, 118, 99, 138/158, 170, and 187) (Everett, Mainous, Frithsen, Player, & 
Matheson, 2008). Nevertheless, PCBs reported to promote vascular endothelial cell 
activity and increase the risk of cardiovascular diseases (Ha, Lee, & Jacobs, 2007; Lim, 
Smart, Toborek, & Hennig, 2007).   
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GM of all PCBs concentration in people at risk of PAH was higher in different 
age groups than people not at risk of PAH with some exception such as GM of PCB 180 
was lower in people at risk of PAH in age groups 60-74 years old and > 75 years old. 
Also, GM of all PCBs at people at risk of PAH was significantly higher in both races 
(non-Hispanic white and other) than people not at risk. However, there is no significant 
difference in GM of PCBs concentration within non-Hispanic white and others. Sum of 
Dioxin-like PCBs (74+118) and non-Dioxin-like PCBs (99+138+153+180) concentration 
were higher in people at risk of PAH than people not at risk of PAH. All confounders 
including gender, age, BMI, annual family income, educational level, smoking, and 
alcohol use reported higher concentration of Dioxin-like PCBs and non-Dioxin-like PCBs 
in people at risk of PAH than people not at risk of PAH, except race. GM of PCBs > 
LOD were significantly higher in people at risk of PAH than people not at risk of PAH. 
Also, GM of all PCBs LOD > 50%, 50-75%, and > 75% were higher in people at risk of 
PAH than people not at risk of PAH, except PCB 180. Risk of PAH appeared to be the 
highest in subjects identified at risk of PAH with the highest PCB concentrations in 
unadjusted models. PCB 74 reported the highest association among all PCBs in all 
models. However, some exception for higher concentrations of dioxin like PCBs and 
non-dioxin like PCBs were found no associated risk with PAH age, race, and BMI 
adjusted model; and age, race, BMI, and gender adjusted model.  
There is limited on data of PCB and its association with PAH. However, estrogen 
has high affinity to the lung because of high ER receptors activity. Although, sex 
hormone 17β-estradiol (E2) is associated with the formation of atherosclerotic lesions 
and vascularization (Benditt & Benditt, 1973). As well, estrogen toxicity is significantly 
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associated with high levels of inflammatory cytokine, which indeed lead to PAH (D. Roy 
et al., 2007). High levels pf PCB were reported in the human lung (Rallis et al., 2014).  
Although, lung toxicity and hypertension are associated with high levels of PCBs and 
their estrogenic congeners (Hansen et al., 2016; Kreiss et al., 1981). Moreover, PCBs are 
associated with damaging of cardiovascular system (Goncharov et al., 2008; Sergeev & 
Carpenter, 2005). Given that pulmonary smooth muscle and endothelial cells reported 
human serum level of E2 was found at [0.60 - 1.63 ng/ml] of estrogenic PCB 153 
[1ng/ml] (Charlier et al., 2004).  
There are some limitations in our study including that we created a variable 
named risk of PAH because there was no PAH variable included in the NHANES survey 
data. This increases the risk of misclassification to people at risk and not at risk of PAH. 
Also, a low number of people at risk of PAH in the study population resulted in low 
significance comparison within different analysis. Given that limited data on PCBs 
exposure and their association with PAH affected our comparison and analysis of the 
results. However, using NHANES cross-sectional survey data including representative 
sample size, medical health data, reproductive health data, and laboratory data of the U.S. 
population provided us with strength in our study.   
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CHAPTER  4 
MANUSCRIPT 2 
HORMONE REPLACEMENT THERAPY AND ORAL CONTRACEPTIVES 
AND RISK OF PULMONARY ARTERIAL HYPERTENSION IN THE UNITED 
STATES FEMALES: ANALYSES OF NHANES 1999-2004 
ABSTRACT 
Background: Females are known to be predominant of pulmonary arterial hypertension 
(PAH). Estrogens and oral contraceptives were reported to be associated with PAH. In 
this study, we will evaluate the association between hormone replacement therapy and 
oral contraceptives with risk of PAH. 
Objectives: The objective of this study was to evaluate the association between hormone 
replacement therapy and oral contraceptives and risk of PAH among females ≥ 20 years 
old in U.S. population. 
Methods: We used Centers for Disease Control and Prevention’s National Health and 
Nutrition Examination Survey (NHANES) data from 1999-2004 for females ≥ 20 years 
old. We selected females identified at risk of PAH with available data on hormones and 
birth control. We used data on use of estrogen pills only, progestin pills only, 
estrogen/progestin pills combined, and birth control pills. We included age, race, and 
BMI as confounders in our analysis. We calculated odds ratios (OR) for the association 
between each variable and the risk of PAH.   
Results: We found 97 (3.7%) females at risk of PAH and 2,280 (96.295) not at risk of 
PAH. Females used hormone pill with estrogen reported [OR of 1.24; 95% CI 1.23-1.25]. 
Females used hormone pills with progestin and estrogen/progestin pills reported no risk 
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of PAH with [OR of 0.57; 95% CI 0.56-0.58] and [OR of 0.59; 95%CI 0.59-0.60], 
respectively. However, all variables (estrogen, progestin, and estrogen/ progestin) 
reported significant OR with risk of PAH in elderly and obese females. Also, females 
used birth control pills reported significant association with risk of PAH [OR of 2.47; 
95%CI 2.46-2.48], elderly [OR 5.84; 95% CI 5.81-5.88], and obese [OR 7.43; 95% CI 
7.38-7.48]. 
Conclusions:  
Using NHANES data from 1999-2004, we found that use of estrogen pills and birth 
controls have a significant association with risk of PAH in females ≥ 20 years old. 
However, progestin only pills and estrogen/progestin combo pills did not show any 
association with risk of PAH.  
Keywords: Hormone replacement therapy, Oral Contraceptives, NHANES, 
pulmonary arterial hypertension, PAH 
 
MANUSCRIPT 2 
HORMONE REPLACEMENT THERAPY AND ORAL CONTRACEPTIVES 
AND RISK OF PULMONARY ARTERIAL HYPERTENSION IN THE UNITED 
STATES FEMALES: ANALYSES OF NHANES 1999-2004 
INTRODUCTION 
Pulmonary arterial hypertension (PAH) is a progressive disease and is frequently 
fatal (Yuan & Rubin, 2005). PAH is known by an increase in pulmonary arterial pressure, 
proliferation and remodeling of vascular cells; which leads to right heart failure (Price et 
83 
 
al., 2012). PAH was known to be more dominant in females with ration of 1.9:1 to 4.1:1 
in various studies with no clear understanding of gender bias (Badesch et al., 2010; Rich 
et al., 1987). Thus, PAH patients were encouraged to avoid pregnancy. Multiple 
interactions are involved in the pathogenesis of PAH including environmental exposure 
(hypoxia and drugs), genetics, cellular interaction, and sex hormones (Pugh & Hemnes, 
2010). Although it was suggested that gender bias in PAH could be explained with 
testosterone acts as protective factor of pulmonary vasculature, estrogens acts as 
destroying factor. Estrogen is known to promote growth of smooth muscle cells and 
vascular endothelial cells by regulating vascular remodeling and angiogenesis. As well, 
estrogen is known to induce inflammatory chemokines such as IL-8 (Comeglio et al., 
2014). However, as we explained in our review, estrogen could have an antioxidant effect 
and be a protective factor for superoxide radical generation (Assaggaf & Felty, 2017). 
Hormonal changes usually comes with pregnancy and PAH pregnant reported high 
mortality rates as 50% (Weiss, Zemp, Seifert, & Hess, 1998). Usually, contraceptives are 
recommended for PAH females at childbearing age, but estrogen containing 
contraceptives are not recommended (Bonnin et al., 2005; Humbert et al., 2001). 
Progestin is known to prevent estrogen activity and expression. This was found in uterine 
cells and prevented their proliferation (Slayden, Hirst, & Brenner, 1993). Progestin was 
added to hormone replacement therapy (HRT) to mimic estrogen activity in breast cancer 
(Hirvonen, 1996). However, the mechanistic association between estrogen and progestin 
is not fully understood.  
Animal models with induced hypoxia and monocrotaline reported that estrogen 
acutely increased vasorelaxation of pulmonary artery (Lahm et al., 2007). Another PH 
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animal model showed that females have less vascular remodeling than males 
(Rabinovitch, Gamble, Miettinen, & Reid, 1981). Mutation in bone morphogenetic 
protein receptor type 2 (BMPR2) gene, is known as familial PAH. This type of PAH is 
significantly associated with females and specifically young females (35.8 ± 15.4, p < 
0.0001) (Eric D Austin et al., 2009).  In BMPR2 mutation, females reported 2.4 higher 
risk than males and it was suggested to be because of estrogen metabolism (E. D. Austin 
et al., 2009). Many studies reported that oral contraceptives and HRT worsen PAH 
(Morse, Horn, & Barst, 1999; Sweeney & Voelkel, 2009). Conversely, cohort HRT study 
reported that patients developed PAH at low rates (Beretta et al., 2006). Thus, oral 
contraceptives are contradicted with PAH and extensive research is recommended. Taken 
together, estrogen and sex hormones are suggested to play an unknown important role 
with risk of PAH. Thus, we hypothesized that estrogen to be risk factor of high risk of 
PAH in females.  
 In this study, we evaluated the association between use of hormone pills with 
estrogen, use of hormone pills with progestin, use of hormone pills with 
estrogen/progestin, and use of birth control pills in females at risk of PAH in the National 
Health and Nutrition Examination Survey (NHANES) between the years 1999-2004. We 
calculated Odd Ratio (OR) of each variable to evaluate its association with risk of PAH.  
METHODS 
Study Design. The main objective of this study was to investigate the association 
between hormone replacement therapy (estrogen, progestin, estrogen/progestin) and oral 
contraceptives and risk for PAH and pulmonary diseases in females > 20 years old in the 
U.S. To clarify and confirm the suggested role of hormone replacement therapy and oral 
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contraceptives, we used NHANES data from 1999-2004 provided by Centers for Disease 
Control and Prevention (CDC) to conduct a secondary statistical analysis. National 
Health and Nutrition Examination Survey (NHANES) is a program was developed by 
National Center for Health Statistics (NCHS) to assess the nutritional and health status 
for children and adults in the United States. NHANES started in the early 1960s 
producing different surveys for many health issues as well as many age groups. Since 
1999, NHANES started producing annually continuous interviews and surveys targeting 
different health and nutritional measurements for evaluation purposes including 
demographic, dietary, health-related questions, socioeconomic, dental, medical, 
physiological measurements, and laboratory tests. An average of 5,000 participants 
enrolled every year and 15 counties across the nation are visited every year. To acquire a 
representative sampling of the population, many parameters needed to be taken into 
consideration for oversampling. Oversampling would be sub-grouped, stratified in 
strata’s and then divided into different locations. Oversampling includes age (adolescents 
(12-19 years), adults (≥ 60 years)) and ethnicity/ race (non-Hispanics black and Mexican 
Americans). After being eligible, the participants undergo series of interviews and 
examinations in a specially equipped mobile evaluation clinic (MEC). MEC examination 
consist of collections of urine and blood samples, personal interviews, and dental and 
physical examinations. Urine is collected from participant if ≥ 6 years, and blood samples 
collected from participant if ≥ 1 year. CDC institutional board approved the study 
protocol and all participants signed a consent before joining the NHANES.  All data are 
strictly confident and coded in different identification factors to keep privacy. 
86 
 
Transportation, personal care (baby/ elderly) and cash payment for participating are 
included (CDC, 2012).  
Questionnaire Methods. Multiple time points included collection of demographic, 
reproductive health, and medical health data. Intensive two weeks training program 
including exercises, training interview, and training on personal audio computer 
interview was conducted and supervised by NCHS and accompanied staff.  Also, 
multiple quality control monitoring procedure were conducted through full pilot test 
before starting questionnaire. During a household interview, people ≥ 16 years old 
provided demographic data. During the personal interview in Mobile Examination Center 
(MEC), females ≥ 12 years old provided reproductive health data. For both males and 
female (constriction by age and gender), medical health data was provided during the 
MEC interview (CDC, 2012).    
Selection of Participants. Inclusion criteria used for the study included females during 
MEC were ≥ 20 years old who completed and provided personal interview. Subjects with 
defined risk of PAH were selected based on an inclusion criteria. We created the Risk of 
PAH variable based on any risk factors that reported individually to be associated with 
PAH in literature. As mentioned earlier in introduction, these risk factors included 
hypertension, abnormal lung function, diabetes, thyroid problems, uric acid level, insulin 
status, and female hormone. Risk of PAH variable was created after sum of all risk 
factors scoring to be at risk of PAH if > 3 for female participants (CDC, 2012). 
Participant will be deleted from the dataset if any of these risk factors answer or level 
were missing. 
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Sample Weights. Sample weight is required when merging NHANES complex survey 
data to avoid bias from non-response selection. The weight variable was provided in each 
2-year cycle from 1999-2004 “for all variables (CDC, 2013b).   
 Reproductive and Medical Health Variables. Data was collected from medical health 
questionnaire and reproductive health questionnaire to analyze the association between 
hormone replacement therapy and oral contraceptives and the risk of PAH.    
Medical Health Questionnaire. Using medical health questionnaire, females > 20 years 
old had to provide a response to risk factors of PAH including “have you ever been told by 
a doctor or health professional that you have diabetes?”, “Has a doctor or other health 
professional ever told that you had a thyroid disease?” Diabetes risk factor was scored 0 if 
answer was NO, and scored 1 if answer was YES. Thyroid problem risk factor was scored 
0 if answer was NO, and scored 1 if answer was YES. Each of these variables was 
transformed into 0 if no risk of PAH and 1 if at risk of PAH. 
Reproductive Health Questionnaire. Using reproductive health questionnaire, female 
participants > 20 years old had to provide a response to risk factor of PAH “have you ever 
used female hormones such as estrogen and progesterone?” Female hormone risk factor 
was scored 0 in the female participant answered NO, and scored 1 if the female participant 
answered YES. 
Hormone replacement therapy and Oral Contraceptives. We used 4 questions to 
evaluate the association between hormone replacement therapy and oral contraceptive and 
PAH. For hormone therapy, we used questions “{Have you/Has SP} ever taken female 
hormone pills containing estrogen only?”, “{Have you/Has SP} taken female hormone pills 
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containing progestin only?”, “{Have you/Has SP} taken female hormone pills containing 
both estrogen and progestin?”, and “Now I am going to ask you about {your/SP's} birth 
control history. {Have you/Has SP} ever taken birth control pills for any reason?” Use 
hormone pills w/estrogen only scored 1 if YES, and 2 if NO. Used hormone pills 
w/progestin only scored 1 if YES, and 2 if NO. Used estrogen/progestin combo pills scored 
1 if YES, and 2 if NO. Ever taken birth control pills scored 1 if YES, and 2 if NO.     
Laboratory data. Using laboratory data measurements of uric acid level should be 
available for the included participant, as well as measurements of both (triglycerides and 
HDL-Cholesterol) to calculate insulin status (insulin sensitive or insulin resistance). Uric 
acid risk factor is a continuous variable, so males and females should have different 
references. Thus, female participants scored 0 if any had uric acid level < 359 mmol/L, and 
scored 1 if any male participant had uric acid level > 360 mmol/L. Insulin status was 
calculated by dividing triglycerides level by HDL-cholesterol level to be < 1.99 “insulin 
sensitive (IS)” or > 2.00 “insulin resistance (IR)”. Insulin status scored 0 if IS and scored 
1 if IR. “Subjects at risk of PAH” variable was created after sum of all risk factor scoring 
to be “Subjects at risk of PAH” if > 3 for female participants (CDC, 2012). Participant will 
be deleted from the dataset if any of these risk factors answer or level were missing.  
Statistical Analysis. We selected females ≥ 20 years old and had available data for 
hormones and reproductive health to be included in the analysis to find the association with 
the risk of PAH. Data was weighted using the required weight by the National Center for 
Health Statistics guidelines to be representative to the whole population. We used stratum 
and PSA to estimate variance of the demographic data. To find the associated risk of PAH 
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with hormone therapy and oral contraceptives, we used logistic regression models to 
calculate the odds ratios (ORs) and their 95 % confidence intervals (CI). Statistical analysis 
was performed using SPSS software (release 20) for windows and SAS software for 
windows (release 9.4; SAS Institute Inc. Cary, N.C.). We used 5% (P ≤1.05) as significance 
level for all analysis.     
Potential Confounding Variables. We included many potential confounding variables as 
categorical variables which are age, body mass index (BMI, kg/m2), annual family income, 
smoking status, alcohol consumption, race, and education level. Age was categorized into 
three age groups including 20-59 years (1), 60-74 years (2) and ≥ 75 years (3). BMI was 
categorized into > 25 kg/m2 (1), 25-30 kg/m2 (2), and ≥ 30 kg/m2 (3). Annual family income 
was categorized into 0-$24,999 (1), $25,000-$54,999 (2), $55,000-$74,999 (3), and ≥ 
$75,000 (4). Smoking status was categorized into smokers (1) and non-smokers (2), and 
alcohol consumption was categorized into consumers (1) non-consumers (2). Race was 
categorized into non-Hispanic White (1) and others (2), and education level was 
categorized into three categories < 12th grade (1), 12th grade (2), and > 12th grade (3). All 
confounding variable data included in the analysis to find the association of hormones and 
oral contraceptives and subjects at risk of PAH was used from the demographic file. 
Categorization of age and race into specific ranges was to avoid bias in the results due to 
low number of people at risk of PAH in younger ages and other races.  
RESULTS 
Descriptive Statistics. The study population who completed medical health questionnaire, 
reproductive health questionnaire; and had available laboratory data to analyze the 
association between hormones and oral contraceptives and subjects at risk of PAH were 
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2,377 participants ≥ 20 years old. Among the included population, 97 (3.7%) of them 
identified at risk to PAH and 2,280 (96.3) of them were not at risk of PAH (Table 15). Race 
distribution reported 58 (2.97%) of people at risk of PAH to be non-Hispanic white and 39 
(0.73%) were others. However, people not at risk of PAH were 1129 (68.16%) non-
Hispanic white and 1151 (28.13%) were others. Age was categorized into 3 group; where 
26 (1.39%) of people at risk of PAH and 1550 (37.89%) of people not at risk of PAH were 
in 20-59 years old group. Most participants at risk of PAH among all age groups were in 
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60-74 years old group with 43 (1.48%), while same age group reported 467 (14.78%) 
participant not to be at risk of PAH. Elderly > 75 years old were 28 (0.82%) at risk of PAH 
and 263 (7.62%) not at risk of PAH. Obese participant reported the highest number among 
people at risk of PAH with 53 (2.83%), followed by 29 (1.37%) and 10 (0.54%) for 
overweight and normal weight, respectively. However, people not at risk of PAH were 608 
(40.28%), 519 (26.91%), and 577 (28.07%) for normal weight, overweight, and obese, 
respectively. Annual family income reported 0-$24,999 group to represent the highest 
number of population in both risk of PAH 48 (1.47%) and 944 (32.78%) not at risk of PAH. 
In the group of $25,000-$54,999, there were 24 (1.14%) at risk of PAH and 627 (27.98%). 
However, $55,000-74,999 group reported the lowest number of people at risk of PAH and 
people not at risk of PAH with 6 (0.42%) 198 (10.03%), respectively. No significant 
difference in distribution of people at risk of PAH in education variable, however, people 
with high education level ≥ 12th grade reported to be the highest not at risk of PAH with 
1018 (52.31%). Most Subjects at risk of PAH were not smokers with 37 (4.02%), while 17 
(2.16%) were smokers. Subjects not at risk of PAH reported 316 (47.02%) to be smokers 
and 372 (46.79%) were not smokers (Table 15). Alcohol users, 97 (4.81%) were not at risk 
of PAH, while no cases reported to be at risk of PAH. Non-alcohol users were 97 (4.81%) 
at risk of PAH and 1744 (94.54%) were not at risk of PAH (Table 15).  
Estimated ORs and 95% confidence intervals for the risk of PAH and the use of 
hormone pills with estrogen are shown in (Table 16). Results are presented for five logistic 
regression models: unadjusted, age-adjusted; BMI-adjusted; race-adjusted; and age, BMI, 
and race adjusted. In unadjusted model, use of hormone pills with estrogen was associated 
with higher risk of PAH [OR of 1.24; 95%CI 1.23-1.25]. After adjusting age, it remained 
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associated with risk of PAH but with less significant [OR 1.04; 95% CI 1.03-1.05]. 
However, when we adjusted for BMI, it was significantly associated with higher risk of 
PAH [OR 2.42; 95% CI 2.41-2.43]. After adjusting all variable (age, race, and BMI), use 
of hormone pills with estrogen was associated with higher risk of PAH [OR of 1.10; 95%CI 
1.09-1.11]. We further investigated the association between use of hormone pills with 
estrogen and risk of PAH within each group of adjusted variables age, race, and BMI. Age 
reported gradual increase in OR risk of PAH with older age. Age group 20-59 years old 
OR was [1.02; 95% CI 1.01-1.03], 60-74 years old {OR 2.15; 95% CI 1.14-2.16], and age 
group > 75 reported [OR 4.48; 95% CI 4.45-4.51]. Race was not associated with risk of 
PAH in Non-Hispanic white [OR 0.91; 95% CI 0.91-0.92]; however, race group “other” 
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was associated with high risk of PAH [OR 1.22; 95%CI 1.21-1.23]. All BMI groups were 
associated with risk of PAH. Normal BMI was [OR 1.28; 95% CI 1.28-1.30]; obese was 
[OR 6.25; 95% CI 6.21-6.29]; and overweight was [OR 3.01; 95% CI 2.99-3.04]. 
Estimated ORs and 95% confidence intervals for the risk of PAH and the use of 
hormone pills with progestin are shown in (Table 17). Results are presented for five logistic 
regression models: unadjusted, age-adjusted; BMI-adjusted; race-adjusted; and age, BMI, 
and race adjusted. All models, unadjusted and adjusted were not associated with risk of 
PAH. In unadjusted model, use of hormone pills with progestin was not associated with 
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risk of PAH [OR of 0.57; 95%CI 0.56-0.58]. After adjusting age, it remained not associated 
with risk of PAH [OR 0.74; 95% CI 0.74-0.75].  
We further investigated the association between use of hormone pills with progestin 
and risk of PAH within each group of the adjusted variables age, race, and BMI. Age was 
associated with age groups 60-74 and > 75 years old with [OR 2.04; 95% CI 2.03-2.05] 
and [OR 4.11; 95% CI 4.08-4.14], respectively. Race was not associated with risk of PAH 
in both groups Non-Hispanic white and other wit [OR 0.57; 95% CI 0.56-0.57] and [OR 
0.91; 95%CI 0.90-0.92], respectively. Subjects used hormone pills with progestin and had 
normal BMI were not associated with risk of PAH. However, subjects with obese and 
overweight BMI were associated with higher risk of PAH [OR 6.33; 95% CI 6.29-6.38] 
and [OR 2.92; 95% CI 2.89-2.94], respectively. 
Estimated ORs and 95% confidence intervals for the risk of PAH and the use of 
hormone pills with estrogen/progestin are shown in (Table 18). Results are presented for 
five logistic regression models: unadjusted, age-adjusted; BMI-adjusted; race-adjusted; 
and age, BMI, and race adjusted.  
All models, unadjusted and adjusted were not associated with risk of PAH. In unadjusted 
model, use of hormone pills with estrogen/progestin were not associated with risk of PAH 
[OR of 0.59; 95%CI 0.59-0.60]. After adjusting age, it remained not associated with risk 
of PAH [OR 0.65; 95% CI 0.65-0.66]. We further investigated the association between use 
of hormone pills with estrogen/progestin and risk of PAH within each group of the adjusted 
variables age, race, and BMI. Age was associated with age groups 60-74 and > 75 years 
old with [OR 2.05; 95% CI 2.04-2.06] and [OR 4.38; 95% CI 4.35-4.41], respectively. 
Race was not associated with risk of PAH in both groups Non-Hispanic white and other 
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white [OR 0.90; 95% CI 0.90-0.91] and [OR 0.60; 95%CI 0.60-0.61], respectively. 
Subjects used of hormone pills with estrogen/ progestin and had normal BMI were not 
associated with risk of PAH. However, subjects with obese and overweight BMI were 
associated with higher risk of PAH [OR 6.73; 95% CI 6.69-6.78] and [OR 3.17; 95% CI 
3.15-3.19], respectively.  
Estimated ORs and 95% confidence intervals for the risk of PAH and the use of 
birth control pills are shown in (Table 19). Results are presented for five logistic regression 
models: unadjusted, age-adjusted; BMI-adjusted; race-adjusted; and age, BMI, and race 
adjusted. All models, unadjusted and adjusted were associated with risk of PAH. In 
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unadjusted model, use of birth control pills was associated with higher risk of PAH [OR of 
2.47; 95%CI 2.46-2.48]. After adjusting age, it remained associated with risk of PAH [OR 
1.24; 95% CI 1.23-1.25]. However, when we adjusted for BMI, it was significantly 
associated with higher risk of PAH [OR 2.46; 95% CI 2.45-2.47]. The highest OR was 
reported after adjusting race [OR 2.56; 95% CI 2.55-2.57]. After adjusting all variable (age, 
race, and BMI), use of birth control pills was associated with higher risk of PAH [OR of 
1.23; 95%CI 1.22-1.24]. We further investigated the association between use of birth 
control pills and risk of PAH within each group of the adjusted variables age, race, and 
BMI. All age groups were associated with higher risk of PAH 20-59, 60-74 and > 75 years 
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old with [OR 1.18; 95% CI 1.18-1.19], [OR 5.14; 95% CI 5.12-5.17], and [OR 5.84; 95% 
CI 5.81-5.88], respectively.  
Race was associated with higher risk of PAH in both groups Non-Hispanic white 
and other wit [OR 1.86; 95% CI 1.86-1.87] and [OR 2.55; 95%CI 2.54-2.56], respectively. 
All BMI groups were associated with higher risk of PAH when use birth control pills. 
Subjects with normal and overweight BMI were associated with higher risk of PAH [OR 
2.44; 95% CI 2.43-2.45] and [OR 3.72; 95% CI 3.69-3.75], respectively. However, obese 
reported the highest [OR 7.43; 95% CI 7.38-7.48].  
DISCUSSION 
This is the first study to date that used NHANES data to evaluate hormone and oral 
contraceptive in subject with risk of PAH. Our results support the known high risk of PAH 
with estrogen exposure. We showed estrogen to be associated with OR of 1.24 in subjects 
at risk of PAH. This result support the hypothesis and confirm the known risk of estrogen 
in PAH. In fact, many studies reported high risk of PAH with high estrogen in circulation 
(Roberts et al., 2009). Also, it was suggested that estrogen induce pathogenesis of PAH (E. 
D. Austin et al., 2009; West et al., 2008). Proliferation of pulmonary artery smooth muscle 
cells is known in PAH; and Estrogen metabolites 16α-hydroxyestrone showed to increase 
PASMC proliferation (White et al., 2012). Estrogen is associated with higher risk of 
thromboembolism (Humbert et al., 2001). Moreover, this association was linked with up 
regulation of estrogen metabolizing enzyme cytochrome P450 1B1 (CYP1B1) (White et 
al., 2011).  
However, with BMI adjusting, the OR risk of PAH and estrogen exposure increase 
to 2.41, which reflect a key role of BMI in PAH. This finding support the significant 
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association between obesity and PAH (BMI > 30, P-value=0.004) in REVEAL (Burger et 
al., 2011).  We found elderly to be at higher risk of PAH with OD up to 4.48 when exposed 
to estrogen. Schachna reported that elderly > 60 years old had 2 times higher risk of PAH 
than patients < 60 years old (OR, 2.30; 95% CI, 1.32 to 3.99) (Schachna et al., 2003). This 
also supports the finding of the age specific death rate for elderly by CDC in 2005 (CDC, 
2005). 
Progestin is found in birth control and it have been recommended as a safe 
medication to prevent pregnancy for PAH females (Santiago-Munoz, 2011; Thorne et al., 
2006). Our result showed no risk of PAH in females used progestin pills only with OR of 
0.75. Thorne and colleagues found no association of progestin only use with PAH and it 
was recommended to use for risk of venous thrombotic (Thorne et al., 2006). However, 
age and BMI showed contradicted high OR of up to 4.11 and 6.33, respectively, in females 
used progestin pills only. This might explain the contradicted effect of progestin reported 
to increase thromboembolism in some PAH cases (Thorne et al., 2006).   
Combined estrogen/ progestin contraceptives are known to have contradicted effect 
on PAH (Montani et al., 2013). Our results showed OR of 0.59 for estrogen/ progestin pills 
use and risk of PAH. Combined therapy has been used for PAH, with some side effects of 
high risk of cardiovascular diseases (Lara et al., 2012). In MCT-induced PAH, combined 
estrogen/ progestin was reported to prevent development of PAH and right ventricular 
hypertrophy (Jones, Zhang, Jackson, & Tofovic, 2006). However, randomized clinical trial 
reported estrogen/ progestin may increase risk of coronary heart disease (CHD) in 
postmenopausal females (Manson et al., 2003). We reported OR of 4.38 for elderly using 
estrogen/ progestin pills. The same association of age was reported with estrogen/ progestin 
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use and risk of CHD. Also, we showed obese females using estrogen/ progestin pills to 
have the highest risk of PAH with OR of 6.73.  
Our results showed that use of birth control increase risk of PAH in females with 
OR of 2.47. PAH association with oral contraceptive been reported in pre- and 
postmenopausal females (Kleiger, Boxer, Ingham, & Harrison, 1976). We also showed 
birth control female users have high risk of PAH in all age groups, race, and BMI. No 
reports found for race and its association with PAH. Taken together, our study is the first 
cross-sectional study that use NHANES data to evaluate the association between hormone 
therapy and oral contraceptive. Our results support the known findings that females using 
estrogen and oral contraceptive are at higher risk of PAH.  
There are some limitations in our study including that we used scoring method for 
PAH risk factors such as REVEAL scoring methods (Benza et al., 2012). Because of 
limited data in NHANES, we used available variables hypertension, diabetes, thyroid 
problems, uric acid level, and insulin status. Thus, we created a variable named risk of 
PAH because there was not PAH variable included in the NHANES survey data. This may 
increase the risk of misclassification to people at risk and not at risk of PAH. However, 
using NHANES cross-sectional surveys including representative sample size, medical 
health data, and reproductive health data of the U.S. population provided us with strength 
in our study.   
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CHAPTER 5 
MANUSCRIPT 3 
Meta-analysis of Pulmonary Arterial Hypertension Microarray Expression Data 
Reveals Significant Aberrations of Gene Networks Involved in PAH Associated 
Pathways 
ABSTRACT 
Pulmonary arterial hypertension (PAH) causes many vascular changes including 
smooth-muscle cell and endothelial-cell proliferation, vasoconstriction, and thrombosis. 
PAH reported to associated with many genes such as BMPR2 and ALK1. It is important 
to understand the mechanism behind the onset of PAH to find an effective treatment and 
early diagnosis of the disease. Many disrupted pathways represented the complexity of 
PAH and difference in gene expression could prove the effect of how important to 
understand pathways elements. Thus, we performed meta-analysis on a published gene 
expression microarray datasets comparing gene expression in PAH samples and control 
samples. Six microarray datasets were included in our meta-analysis. Bioinformatics and 
Bayesian network analysis statistically identifies genes that are associated with PAH from 
our meta-analysis results, gene ontology databases, and literature. The most significant 
pathways associated with PAH were Apoptosis signaling pathway, p53 pathway, Ras 
Pathway, T-cell activation, TGF-beta signaling pathway, VEGF signaling pathway, Wnt 
signaling pathway. Using BN analysis, we found VAMP2, LAMA5, POLR2C, VEGFB, 
and PRKCH to be a plausible pathway of PAH.  
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MANUSCRIPT 3 
Meta-analysis of Pulmonary Arterial Hypertension Microarray Expression Data 
Reveals Significant Aberrations of Gene Networks Involved in PAH Associated 
Pathways 
Introduction 
Pulmonary arterial hypertension (PAH) is a disease that affects pulmonary arteries 
leading to increase in mean pulmonary arterial pressure. This increase in arterial pressure 
cause many vascular changes including smooth-muscle cell and endothelial-cell 
proliferation, vasoconstriction, and thrombosis (Rubin M. Tuder et al., 2007). Although, 
neointimal lesion formation cause intraluminal block which characterized by abnormal 
proliferation of smooth muscle cells (SMCs) (Marc Humbert et al., 2004). Human studies 
suggested that only women especially young women were more susceptible of developing 
PAH (Tofovic, 2010). Notably, familial PAH with mutated bone morphogenic protein 
receptor type 2 (BMPR2) had a higher penetration of disease in women because of the 
alteration in E2 metabolism (E. D. Austin et al., 2009). Recently, REVEAL reported that 
female-to-male ratio for IPAH is 4.1:1 (Badesch et al., 2010). In France, data were 
collected from 674 adults with PAH and followed up for 3 years from 2003-2006. This 
registry has confirmed that female are predominant in most PAH subtypes with a sex ratio 
(SR) female/ male of 1.9 for all PAH. 
Pulmonary hypertension can be caused by different medical conditions, majority of 
these conditions are demonstrated histopathologically by hypertrophy of the pulmonary 
arterioles (Rubin M. Tuder et al., 2009). Explanation of this high susceptibility remains 
unclear; however sex hormones and estrogen were reported to play a role in pathogenesis 
106 
 
of pulmonary hypertension. Indeed, females’ longer survival was referred to estrogen 
activity in PAH. On the other hand, mutations in Bone Morphogenic Protein (BMP) 
receptor type II (BMPR2) were reported in about 23% of all PAH cases (Newman, Phillips, 
& Loyd, 2008). Mutations in BMPR2 were associated with the increase vascular smooth 
muscle cells proliferation by downregulating of BMP signaling (Morrell et al., 2001).  
Genomic and non-genomic pathways were reported to have an effect on estrogen 
receptors α and β. For example, prostacyclin release and nitric oxidelo production were 
reported to be higher by rapid non-genomic mechanisms, which increase endothelial nitric 
oxide synthase activity and endothelial nitric oxide synthase messenger RNA (mRNA) 
levels and (Sherman et al., 2002). Notably, HIF-1α regulate several genes that have 
significant role in angiogenesis, vascular reactivity and remodeling, and cell proliferation 
(Tofovic, 2010). The importance of HIF-1α was linked to many human and experimental 
models including severe PAH in humans where HIF-1α was up regulated in obliterative 
endothelial lesions; and high levels of HIF-1α were associated with vascular remodeling 
and development of PAH. 
Murine models were studied by Mair and colleagues and they have reported 
overexpression of MTS1 and serotonin transporter gene (SERT1) in mice (Dempsie et al., 
2011). Pulmonary shunting, is the less oxygen in alveoli, was reported to cause alterations 
of the endothelin pathway in piglets and young lambs. These alterations resulted in high 
expression of endothelin-1 and endothelin-A receptor; and with chronic shunting, increase 
endothelial nitric oxide synthesis (eNOS). Indeed, these alterations were associated with 
increased blood flow in pulmonary arteries (Rondelet et al., 2012). Sugen/hypoxia rat 
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model showed that pulmonary shunts were associated with high expression of VEGF in 
IPAH (Geiger et al., 2000).  
Hypoxia and oxidative stress have a significant role in PAH, human and 
experimental. By down regulating expression of CYPIA, which control E2 metabolism, 
hypoxia and oxidative stress cause proliferation of pulmonary ECs and VSMCs, as well as 
pulmonary vascular remodeling (Kleinman et al., 2007). Hypoxia has been associated to 
decrease VEGF protein and gene expression, however, the down-regulation cause VEGFR 
blockade and endothelial cell injuries followed by plexiform lesion formation (Voelkel, 
Vandivier, & Tuder, 2006). Vascular endothelial growth factor (VEGF) has proliferative 
and high levels of VEGF and VEGF receptor-2 expressions have been reported in IPAH 
patients’ lung samples. VEGF and VEGFR2 are expressed by ECs within the plexiform 
lesions in lungs from patients with PAH (Malenfant et al., 2013). However, mutations in 
these molecules were linked with PAH pathogenesis and lesion formation. Plexiform lesion 
in IPAH showed up regulation in some genes including TGF-1, HIF1a, THBS1, MMP9, 
and cKIT (Jonigk et al., 2011). Jonigk and colleagues found a significant up regulation 
mediators in plexiform lesion such as THBS1, HIF1a, Ang-1, VEGF and its receptors 
(VEGFR1 and VEGFR2), and Tie-2 (Jonigk et al., 2011).   
Genetic mutation and risk of PAH have been reported with many genes and 
pathways. Transforming growth factor β (TGF-β) family receptors are the most known 
pathway to cause gene mutation in PAH. From the TGF-β, two genes were reported to 
cause PAH including BMPR2 and activin-receptor–like kinase 1 (ALK1) (Foletta et al., 
2003). More than 45 mutations have been identified in familial type of PAH patients 
because the inheritance role of BMPR2. However, BMPR2 mutation cannot express the 
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disease alone. Mutation in ALK1 is rare, however it was reported to cause IPAH (Farber 
& Loscalzo, 2004). 
Other somatic gene mutations linked to PAH development including prostacyclin, 
Bax, thromboxane, serotonin transporter, angiopoietin-1, plasminogen activator inhibitor, 
Smads, and Von Willebrand factor (Rajkumar et al., 2010). Moreover, molecular studies 
reported that down regulation of the voltage-gated K_ 1.5 potassium channel and up 
regulation of the transient receptor potential channel calcium channels were associated with 
PAH. These abnormal regulations cause pulmonary artery smooth muscle cells to 
proliferate, contract and resist to apoptosis (Bonnet et al., 2007). On the other hand, 
abnormal expression of NADPH oxidase 4 (NOX4) and interleukin-6, were reported to 
cause vasoconstriction and remodeling in PASMCs. In chronic hypoxia mice, 2.5-fold up 
regulation of NOX4 were reported to be associated with IPAH than controls (Mittal et al., 
2007). Moreover, supporting the role of vascular remodeling, NOX2 was reported to be as 
3.5-fold up regulated in human lung PAH (Rajkumar et al., 2010). Abnormal proliferation 
and growth of vascular smooth muscle cells in PAH were also associated with abnormal 
expression of PPP2CA and MYBL1 genes (Rajkumar et al., 2010). Although, Shelat  and 
colleagues reported that overexpression of E2F1 (a transcription factor which control cell 
cycle) and NCOA2 were associated with PAH (Shelat et al., 2001).   
Serotonin is a vasoconstrictor which stimulate smooth muscle cell hyperplasia and 
hypertrophy (Farber & Loscalzo, 2004). High levels of serotonin have been associated to 
increase the proliferation of cultured pulmonary vascular smooth-muscle cells in IPAH 
patients (S. Eddahibi et al., 2001). Furthermore anorexigens (appetite suppressants) such 
as aminorex, dexfenfluramine, and the fenfluramine and phentermine (fen/phen) have role 
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in plexiform lesions and serotonin pathogenesis (Wideman & Hamal, 2011). High 
incidence of IPAH was reported among patients who took dexfenfluramine elevate the 
secretion of serotonin from platelets and prevent its reuptake. Serotonin promotes cell 
growth and vasoconstriction; and in plexiform lesion formation, serotonin high levels 
affect signaling pathways downregulation of mutated BMPR2; which was observed in mice 
as well (X. Yang et al., 2005). Anorexigens trigger IPAH by: increasing serotonin release 
from cellular stores which stimulate plasma serotonin levels and serotonin receptors and 
trigger the formation of plexiform lesions (Saadia Eddahibi & Adnot, 2002)(Launay et al., 
2002). In up to 80% of IPAH patients, serotonin role cause rapid increase in PVR that lead 
to vasoconstriction followed remodeling in smooth muscle cell proliferation. This acute 
pulmonary vasoconstriction usually mediated by the expression of receptors on vascular 
smooth muscle cells including 5-HT2A, 5-HT2B, and 5- HT1B/1D (Rodat-Despoix, 
Crevel, Marthan, Savineau, & Guibert, 2008). 
It was reported that lack in expression of TGF-β receptor 1, TGF-β receptor 2, and 
their signaling smad(s) 1-4, including the phosphorylated smad 1/5/8 and 2 had a central 
role in plexiform lesions formation (Rubin M. Tuder et al., 2007). The lack of expression 
of these smads indicated the absence of their signaling through TGF-β or BMP as well, 
which allowed plexiform cells to abnormally proliferate (Richter et al., 2004). In general 
many signaling pathways when interrupted cause proliferation and angiogenesis, which are 
the leading cause of lesion formation. Many cellular and molecular mechanisms and 
pathways involve in the initiation and progression of IPAH. Different factors and 
molecules can cause plexiform lesion formation, either by increase proliferation or by 
decreasing apoptosis. Most of these mechanisms and pathways were applied on laboratory 
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experiments as animal models. Plexiform lesions have been defined as active angiogenic 
lesion caused by irregular or neoplastic-like endothelial proliferation and myofibroblast 
infiltration (Berger, Geiger, Hess, Bogers, & Mooi, 2001)(R. M. Tuder et al., 2001).  
Even though TGF-β signaling molecules are not expressed in the central core of 
plexiform lesion, they are actively expressed outside of the plexiform lesion (Abe et al., 
2010). Moreover, other pathways inducing vasoconstrictor production are over-expressed 
within the lesion including thromboxane, leukotrienes, and endothelin (Budhiraja, Tuder, 
& Hassoun, 2004); and vasodilator production by prostacyclin and nitric oxide (Berger et 
al., 2001).  
Plexiform lesion growth was reported to be caused by mononuclear inflammatory 
cells surround vascular sites (P. Dorfmüller, Perros, Balabanian, & Humbert, 2003). 
Moreover, high levels of pro-inflammatory cytokines were reported around plexifonn 
lesions in PAH including macrophages and B and T lymphocytes. Inflammatory processes 
on pulmonary endothelial cells can cause proliferative pulmonary vasculopathy. Pro-
inflammatory cytokines such as interleukin-6 and tumor necrosis factor alpha (TNF-a), as 
well as macrophages and lymphocytes were reported to increase aromatase activities and 
peripheral E2 synthesis (Tofovic, 2010). This linkage was associated with high levels of 
E2 as well as pulmonary vascular remodeling and progression of PAH (Peter Dorfmüller 
et al., 2011). 
It is important to understand the mechanism behind the onset of PAH to find an 
effective treatment and early diagnosis of the disease. Many disrupted pathways represent 
the complexity of PAH and difference in gene expression could prove the effect of how 
important to understand pathways elements. This study aims to show what is the effect of 
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the difference in gene expression on PAH using microarray expression data of PAH and 
non-PAH from published studies. We further extend our aim to investigate what genes 
make this difference and what pathways are associated with the disease and these genes. 
Moreover, to know how this combination of significant associated genes with PAH would 
lead us to discover new pathway of PAH. This will be applied using BN modeling of gene 
networks.  
Materials and Methods 
Microarray dataset 
National Center for Biotechnology Information (NCBI) Gene Expression Omnibus 
(GEO) was searched for gene expression profiles and datasets of Pulmonary Arterial 
Hypertension. Synonyms combination key terms were used for this comprehensive 
systematic search including: Pulmonary Arterial Hypertension (PAH), Idiopathic, case 
control, study. No language, subject, and/or period restriction were applied. All age period 
were included (pediatric, children, and adults); and both gender (males and females) were 
included. All types of pulmonary hypertension (pulmonary arterial hypertension (PAH), 
congenital heart disease (CHD-PAH), connective tissue disease (CTD-PAH), chronic 
thromboembolic pulmonary hypertension (CTEPH), idiopathic pulmonary arterial 
hypertension (IPAH), systemic sclerosis (Ssc-PAH), limited systemic sclerosis-PAH (lss-
PAH), portopulmonary hypertension (PoPH), and ventricular septal defect (VSD-PAH). 
Data extracted included study title, year of publication, disease of interest, study 
population, if the study included healthy controls, gender of participants (if available), 
mean age, age of each participant (if available). Sixteen datasets were found with different 
types of PAH (IPAH, Ssc-PAH, and Lss-PAH) and control subjects. The inclusion criteria 
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we used were: article to be published, PAH subjects, all datasets files available to download 
from GEO, clear information attached to submitted files, less than 50% missing gene 
expressions. All datasets were normalized and discretized using z-score normalization 
method (the value – mean / standard deviation), and (z<-1=0; -1<z<1=1; z=>1, 2), 
respectively.   
Datasets were tested for random distribution using 10% of genes in SPSS. Because 
we have different biological material locations, datasets were separated into blood and 
tissue samples. We combined all dataset to find out how many genes are common among 
all six datasets. We checked that ID1-4 gene expression are available, and we calculated 
their fold change as well. Statistical t-test was performed to identify genes that significantly 
expressed in PAH blood and tissue samples from GEO datasets, and we selected the first 
quartile of significant p-value of 0.05. Statistical correlation analysis was performed on 
ID3 correlated genes in blood and tissue from GEO datasets, and we selected the first 
quartile of correlated genes. We matched the common genes that were significantly 
expressed in PAH blood and tissue samples and ID3 correlated genes in blood and tissue 
from GEO datasets; and target gene list were created for blood and tissue.   
Gene ontology and pathway analysis 
We used (PANTHER, Protein ANalysis THrough Evolutionary Relationships, 
Classification System DataBase) for gene ontology analysis to understand the functions of 
the gene list. PANTHER provides comprehensive function information about genes, and 
was designed to also facilitate analysis of large numbers of gene associations 
(http://pantherdb.org/). Statistical enrichment test for each of biological process, molecular 
function, protein class, cellular component, and pathway were evaluated according to the 
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likelihood that their numerical values were drawn randomly from the overall distribution 
of values. The Mann-Whitney U Test (Wilcoxon Rank-Sum Test) was used to determine 
the P-value (the chromatin packaging and remodeling genes have random values relative 
to overall list of values that were input). 
Protein-protein interaction network construction 
We used STRING database (http:// string-db.org), which provides functional 
profile of each gene, to identify the association in the gene list. Also, to demonstrate 
functional and canonical pathway analysis associated with the list of genes provided in 
network maps. STRING provided data from published identified functions and 
interactions.  
Bayesian network analysis (Bene): 
The idea behind BN is to record how many times that different values of the variable (X) 
occur together with different vectors (V) in the data. In our analysis, X = variable (genes, 
disease, age, gender,...etc.), V= sample (patient or control) (Silander & Myllymaki, 2012). 
BN are directed acyclic graphs (DAGs) which represent an association among different 
variables, and variable can have more than one state (Heckerman, 1998). The association 
between these variables, which represented by the best BN, resulted through Bene software 
are based on five logical steps which (Silander and Myllynaki) explained in their published 
article (Silander & Myllymaki, 2012). “These five steps are: 1) Calculate the local scores 
for all n2n−1 different (variable, variable set)-pairs, 2) Using the local scores, find best 
parents for all n2n−1 (variable, parent candidate set)-pairs, 3) Find the best sink for all 2n 
variable sets, 4) Using the results from Step 3, find a best ordering of the variables, and 5) 
Find a best network using results computed in Steps 2 and 4”. Using discretized data, Bene 
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first constructed a best net using BDe score (with equivalent sample size 1.0) and a best 
net using the BIC score (Silander & Myllymaki, 2012) and (Yoo, 2012). The aim of using 
BN analysis is to develop a model which examine the association of gene expression levels 
in PAH samples and control samples. This might determine the risk of PAH with different 
expression of genes.  
Genie  
GeNIe 2.1 is a software used to validate and manipulate BN structure resulted from Bene. 
It helped us to find out what genes and expression affect PAH or control samples.  
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Figure 3 Flow chart summarizing the steps was carried out through this study 
 
116 
 
RESULTS 
Six PAH microarray datasets met our inclusion criteria and were included in the 
analysis (Table 20). Samples and controls were divided into two groups based on the 
biological material location, blood and tissue (Table 21). Common genes were matched 
among six datasets and 10,716 genes found to be common in all datasets (supplement1). 
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Table 21. Distribution of GEO samples included in the analysis (PAH, control, and 
gender), based on 2 biological material location (Tissue and Blood).  
 PAH Control Total 
Tissue 38 24 62 
Blood 84 54 138 
Total 122 78 200 
Male/ Female 29/ 82 17/ 49 46/ 131 
 
Statistical analysis t-test of the 10,716 common genes showed that 2,598 genes in 
blood samples and 2,542 genes in tissue samples were significantly expressed in PAH 
samples (P-value < 0.05). Correlation analysis of ID3 correlated genes showed that 2,679 
gene in blood samples and 2,699 genes in tissue samples, were in the first quartile of ID3 
correlated genes (Supplement 2).   
We matched the results of significant genes from the two statistical analysis tests, 
t-test and ID3 correlation. Matching results showed that 701 genes in blood and 573 genes 
in tissue, were common in t-test and ID3 correlation test (Table 22 and Table 23) (Figure 
1 and 2). Only 28 genes were common significantly expressed among blood and tissue 
samples (Table 24) (Figure 3 diagram). All Common genes represented in blood samples, 
tissue samples, t-test significant with PAH, and ID3 correlated genes showed in (Figure 4).   
                                  
Figure 4 Venn diagram represent number of ID3 correlated genes (2,679) and number of 
significantly expressed genes in PAH tissue samples from GEO datasets (2,679), in Blood 
samples. 700 genes are common between ID3 correlated genes and significantly 
expressed genes in PAH tissue samples from GEO datasets.  
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Figure 5 Venn diagram represent number of ID3 correlated genes (2,699) and number of 
significantly expressed genes in PAH tissue samples from GEO datasets (2,700), in 
Tissue samples. 572 genes are common between ID3 correlated genes and significantly 
expressed genes in PAH tissue samples from GEO datasets.    
 
 
Figure 6 Venn diagram represent number genes (27) are common between ID3 
correlated genes and number of significantly expressed genes in PAH from GEO 
datasets, blood samples (700) genes and tissue samples (572) genes. 
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Figure 7 Venn diagram represent overall number of genes are common between different 
list of correlate with ID3 and number of genes are significantly expressed in PAH blood 
and tissue samples from GEO datasets. Yellow represent number of genes are 
significantly expressed in PAH blood samples from GEO datasets (2,679). Green 
represent number of genes are ID3 correlated in PAH tissue samples from GEO datasets 
(2,699). Blue represent number of genes are ID3 correlated in PAH blood samples from 
GEO datasets (2,679). Red represent number of genes are significantly expressed in PAH 
tissue samples from GEO datasets (2,700).  
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Table 22. Genes that are significantly expressed in PAH samples; and significantly correlated with ID3 in blood samples (701 
genes) from the significant gene list provided from GEO PAH datasets 
Gene 
Symbol 
Gene Name 
KIFC2 kinesin family member C2 
LDHB lactate dehydrogenase B 
FHIT fragile histidine triad gene 
OXA1L oxidase (cytochrome c) assembly 1-like 
SLC2A4RG SLC2A4 regulator 
RPL19 ribosomal protein L19; ribosomal protein L19 
pseudogene 12 
TUBB2A tubulin, beta 2A 
H1FX H1 histone family, member X 
CLK1 CDC-like kinase 1 
MYLIP myosin regulatory light chain interacting 
protein 
ACBD6 acyl-Coenzyme A binding domain containing 
6 
WDR74 WD repeat domain 74 
BRPF1 bromodomain and PHD finger containing, 1 
SH3YL1 SH3 domain containing, Ysc84-like 1 (S. 
cerevisiae) 
WDR73 WD repeat domain 73 
MALL mal, T-cell differentiation protein-like 
MC1R tubulin, beta 3; melanocortin 1 receptor (alpha 
melanocyte stimulating hormone receptor) 
RPLP0 ribosomal protein, large 
CCR10 chemokine (C-C motif) receptor 10 
SH3BGR SH3 domain binding glutamic acid-rich 
protein 
FAU Finkel-Biskis-Reilly murine sarcoma virus 
(FBR-MuSV) ubiquitously expressed 
STAG3 stromal antigen 3 
LSM4 LSM4 homolog, U6 small nuclear RNA 
associated (S. cerevisiae) 
ZNF395 zinc finger protein 395 
DHX35 DEAH (Asp-Glu-Ala-His) box polypeptide 
35 
RPL12 ribosomal protein L12 pseudogene 2 
ADAM7 ADAM metallopeptidase domain 7 
CDCA4 cell division cycle associated 4 
GNG7 guanine nucleotide binding protein (G 
protein), gamma 7 
STAG1 stromal antigen 1 
KLRB1 killer cell lectin-like receptor subfamily B, 
member 1 
CGRRF1 cell growth regulator with ring finger domain 
1 
LIG1 ligase I, DNA, ATP-dependent 
ESPL1 extra spindle pole bodies homolog 1 (S. 
cerevisiae) 
RAD1 RAD1 homolog (S. pombe) 
UXT ubiquitously-expressed transcript 
NME3 non-metastatic cells 3, protein expressed in 
MAGEE1 melanoma antigen family E, 1 
CD320 CD320 molecule 
MAPK6 mitogen-activated protein kinase 6 
RPS17 ribosomal protein S17 
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RPS14 ribosomal protein S14 
SURF2 surfeit 2 
RPS11 ribosomal protein S11 
HSPBAP1 HSPB (heat shock 27kDa) associated protein 
1 
CRTC2 CREB regulated transcription coactivator 2 
RAD23B RAD23 homolog B (S. cerevisiae) 
WDR60 WD repeat domain 60 
DUSP12 dual specificity phosphatase 12 
ACP1 acid phosphatase 1, soluble 
PPP1R3D protein phosphatase 1, regulatory (inhibitor) 
subunit 3D 
ARIH1 ariadne homolog, ubiquitin-conjugating 
enzyme E2 binding protein, 1 (Drosophila) 
IL17D interleukin 17D 
SLC29A2 solute carrier family 29 (nucleoside 
transporters), member 2 
DUSP16 dual specificity phosphatase 16 
PABPC1 poly(A) binding protein, cytoplasmic 
pseudogene 5; poly(A) binding protein, 
cytoplasmic 1 
TCF3 transcription factor 3 (E2A immunoglobulin 
enhancer binding factors E12/E47) 
KIAA1683 KIAA1683 
SSSCA1 Sjogren syndrome/scleroderma autoantigen 1 
ZNF622 zinc finger protein 622 
MGAT4A mannosyl (alpha-1,3-)-glycoprotein beta-1,4-
N-acetylglucosaminyltransferase, isozyme A 
ZNF529 zinc finger protein 529 
TCF7 transcription factor 7 (T-cell specific, HMG-
box) 
ZC3H15 zinc finger CCCH-type containing 15 
KLF12 Kruppel-like factor 12 
KLF13 Kruppel-like factor 13 
NXF1 nuclear RNA export factor 1 
RPS5 ribosomal protein S5 
RPS7 ribosomal protein S7 
C1ORF64 chromosome 1 open reading frame 64 
PKP2 plakophilin 2 
RGS3 regulator of G-protein signaling 3 
HEBP2 heme binding protein 2 
PPRC1 peroxisome proliferator-activated receptor 
gamma, coactivator-related 1 
TGFBR3 transforming growth factor, beta receptor III 
DHX40 similar to DEAH (Asp-Glu-Ala-His) box 
polypeptide 40; DEAH (Asp-Glu-Ala-His) 
box polypeptide 40 
SYTL1 synaptotagmin-like 1 
SGSH N-sulfoglucosamine sulfohydrolase 
ELF2 E74-like factor 2 (ets domain transcription 
factor) 
BACH2 BTB and CNC homology 1, basic leucine 
zipper transcription factor 2 
ZNF18 zinc finger protein 18 
KCNAB2 potassium voltage-gated channel, shaker-
related subfamily, beta member 2 
UBE2G1 ubiquitin-conjugating enzyme E2G 1 (UBC7 
homolog, yeast) 
UFC1 ubiquitin-fold modifier conjugating enzyme 1 
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EIF2A eukaryotic translation initiation factor 2A, 
65kDa 
KCNK12 potassium channel, subfamily K, member 12 
LSM14A LSM14A, SCD6 homolog A (S. cerevisiae) 
HSF2 heat shock transcription factor 2 
USP12 ubiquitin specific peptidase 12 
USP11 ubiquitin specific peptidase 11 
GKAP1 G kinase anchoring protein 1 
CLDND1 claudin domain containing 1 
MASTL microtubule associated serine/threonine 
kinase-like 
DPP9 dipeptidyl-peptidase 9 
TWISTNB TWIST neighbor 
ERRFI1 ERBB receptor feedback inhibitor 1 
SERTAD1 SERTA domain containing 1 
FGF3 fibroblast growth factor 3 (murine mammary 
tumor virus integration site (v-int-2) oncogene 
homolog) 
SERTAD2 SERTA domain containing 2 
TTC32 tetratricopeptide repeat domain 32 
ZNF548 zinc finger protein 548 
EXOSC9 exosome component 9 
ARHGEF1 Rho guanine nucleotide exchange factor 
(GEF) 1 
BRF1 BRF1 homolog, subunit of RNA polymerase 
III transcription initiation factor IIIB (S. 
cerevisiae) 
EXOSC6 exosome component 6 
BRF2 BRF2, subunit of RNA polymerase III 
transcription initiation factor, BRF1-like 
GMEB2 glucocorticoid modulatory element binding 
protein 2 
SDK2 sidekick homolog 2 (chicken) 
SLC3A2 solute carrier family 3 (activators of dibasic 
and neutral amino acid transport), member 2 
MRPL9 mitochondrial ribosomal protein L9 
PAPD5 PAP associated domain containing 5 
GLCCI1 glucocorticoid induced transcript 1 
ZNF335 zinc finger protein 335 
LRPAP1 low density lipoprotein receptor-related 
protein associated protein 1 
CARD11 caspase recruitment domain family, member 
11 
PFDN1 prefoldin subunit 1 
BRWD1 bromodomain and WD repeat domain 
containing 1 
ZNF134 zinc finger protein 134 
BNIP1 BCL2/adenovirus E1B 19kDa interacting 
protein 1 
BNIP2 BCL2/adenovirus E1B 19kDa interacting 
protein 2 
EIF4A2 similar to eukaryotic translation initiation 
factor 4A2; eukaryotic translation initiation 
factor 4A, isoform 2 
IL12A interleukin 12A  
CAND2 cullin-associated and neddylation-dissociated 
2 (putative) 
OSBPL10 oxysterol binding protein-like 10 
KCNH8 potassium voltage-gated channel, subfamily H 
(eag-related), member 8 
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ZNF551 zinc finger protein 551 
ARL4C ADP-ribosylation factor-like 4C 
ZNF484 zinc finger protein 484 
ASTE1 asteroid homolog 1 (Drosophila) 
GRASP GRP1 (general receptor for phosphoinositides 
1)-associated scaffold protein 
KIAA1429 KIAA1429 
ARL4A ADP-ribosylation factor-like 4A 
ZNF276 zinc finger protein 276 
MIDN midnolin 
EXOC8 exocyst complex component 8 
CREM cAMP responsive element modulator 
MKNK2 MAP kinase interacting serine/threonine 
kinase 2 
RPL36 ribosomal protein L36 
EEA1 early endosome antigen 1 
CBLL1 Cas-Br-M (murine) ecotropic retroviral 
transforming sequence-like 1 
CCL28 chemokine (C-C motif) ligand 28 
ZNF653 zinc finger protein 653 
ZNF34 zinc finger protein 34 
ITM2A integral membrane protein 2A 
PLEKHG4 pleckstrin homology domain containing, 
family G (with RhoGef domain) member 4 
WDR19 WD repeat domain 19 
SNRK SNF related kinase 
RPL32 small nucleolar RNA, H/ACA box 7A; small 
nucleolar RNA, H/ACA box 7B; ribosomal 
protein L32 
PPP3CC protein phosphatase 3 (formerly 2B), catalytic 
subunit, gamma isoform 
ARMCX2 armadillo repeat containing, X-linked 2 
TCEA2 transcription elongation factor A (SII), 2 
PCSK6 proprotein convertase subtilisin/kexin type 6 
GALNT11 UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-
acetylgalactosaminyltransferase 11 (GalNAc-
T11) 
GALNT12 UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-
acetylgalactosaminyltransferase 12 (GalNAc-
T12) 
EXOC2 exocyst complex component 2 
IL6 interleukin 6 (interferon, beta 2) 
SPTY2D1 SPT2, Suppressor of Ty, domain containing 1 
(S. cerevisiae) 
ZNF160 zinc finger protein 160 
EXPH5 exophilin 5 
ZNF24 zinc finger protein 24 
RPL24 ribosomal protein L24; ribosomal protein L24 
pseudogene 6 
ZNF668 zinc finger protein 668 
ETF1 eukaryotic translation termination factor 1 
5-Mar membrane-associated ring finger (C3HC4) 5 
PHYH phytanoyl-CoA 2-hydroxylase 
ZNF165 zinc finger protein 165 
FEM1C fem-1 homolog c (C. elegans) 
DUSP5 dual specificity phosphatase 5 
RLF rearranged L-myc fusion 
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MEF2D myocyte enhancer factor 2D 
P2RY10 purinergic receptor P2Y, G-protein coupled, 
10 
RASSF5 Ras association (RalGDS/AF-6) domain 
family member 5 
ZNF671 zinc finger protein 671 
DUSP2 dual specificity phosphatase 2 
TFRC transferrin receptor (p90, CD71) 
WDR26 WD repeat domain 26 
DUSP1 dual specificity phosphatase 1 
C21ORF2 chromosome 21 open reading frame 2 
RPL22 ribosomal protein L22 pseudogene 11; 
ribosomal protein L22 
PTP4A1 protein tyrosine phosphatase type IVA, 
member 1 
PTP4A2 protein tyrosine phosphatase type IVA, 
member 2 
WHSC1L1 Wolf-Hirschhorn syndrome candidate 1-like 1 
SLFN13 schlafen family member 13 
ZBTB5 zinc finger and BTB domain containing 5 
GAMT guanidinoacetate N-methyltransferase 
ZBTB3 zinc finger and BTB domain containing 3 
ZNF256 zinc finger protein 256 
WNT7A wingless-type MMTV integration site family, 
member 7A 
WDR20 WD repeat domain 20 
SRP14 signal recognition particle 14kDa 
(homologous Alu RNA binding protein) 
pseudogene 1; signal recognition particle 
14kDa (homologous Alu RNA binding 
protein) 
ZNF581 zinc finger protein 581 
PRC1 protein regulator of cytokinesis 1 
RBM3 RNA binding motif (RNP1, RRM) protein 3 
PASK PAS domain containing serine/threonine 
kinase 
TGFB3 transforming growth factor, beta 3 
LNX2 ligand of numb-protein X 2 
KIAA1328 KIAA1328 
SLC7A5 solute carrier family 7 (cationic amino acid 
transporter, y+ system), member 5 
SLC7A6 solute carrier family 7 (cationic amino acid 
transporter, y+ system), member 6 
TCEAL3 transcription elongation factor A (SII)-like 3 
IDH3G isocitrate dehydrogenase 3 (NAD+) gamma 
LRRC57 leucine rich repeat containing 57 
MFHAS1 malignant fibrous histiocytoma amplified 
sequence 1 
AAK1 AP2 associated kinase 1 
SLC2A1 solute carrier family 2 (facilitated glucose 
transporter), member 1 
PDE4B phosphodiesterase 4B, cAMP-specific 
(phosphodiesterase E4 dunce homolog, 
Drosophila) 
DDX24 DEAD (Asp-Glu-Ala-Asp) box polypeptide 
24 
EIF1 similar to eukaryotic translation initiation 
factor 1; eukaryotic translation initiation 
factor 1 
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PITPNC1 phosphatidylinositol transfer protein, 
cytoplasmic 1 
DDX20 DEAD (Asp-Glu-Ala-Asp) box polypeptide 
20 
ZNF446 zinc finger protein 446 
LONRF1 LON peptidase N-terminal domain and ring 
finger 1 
IMP4 IMP4, U3 small nucleolar ribonucleoprotein, 
homolog (yeast) 
IDUA iduronidase, alpha-L- 
NET1 neuroepithelial cell transforming 1 
RPL35A ribosomal protein L35a 
SPTLC1 serine palmitoyltransferase, long chain base 
subunit 1 
RELA v-rel reticuloendotheliosis viral oncogene 
homolog A (avian) 
RELB v-rel reticuloendotheliosis viral oncogene 
homolog B 
ENC1 ectodermal-neural cortex (with BTB-like 
domain) 
PDE4D phosphodiesterase 4D, cAMP-specific 
(phosphodiesterase E3 dunce homolog, 
Drosophila) 
YTHDF3 YTH domain family, member 3 
TATDN2 TatD DNase domain containing 2 
WEE1 WEE1 homolog (S. pombe) 
CCDC6 coiled-coil domain containing 6 
RCL1 RNA terminal phosphate cyclase-like 1 
PODXL2 podocalyxin-like 2 
IGBP1 chromosome 14 open reading frame 19; 
immunoglobulin (CD79A) binding protein 1 
VSNL1 visinin-like 1 
RNF138 ring finger protein 138 
TESK2 testis-specific kinase 2 
MFAP3 microfibrillar-associated protein 3 
VAMP2 vesicle-associated membrane protein 2 
(synaptobrevin 2) 
MFAP4 microfibrillar-associated protein 4 
ZNF586 zinc finger protein 586 
ARFGAP3 ADP-ribosylation factor GTPase activating 
protein 3 
HDLBP high density lipoprotein binding protein 
EID3 EP300 interacting inhibitor of differentiation 
3 
ADAMTSL
2 
similar to ADAMTS-like 2; ADAMTS-like 2 
MAPKAPK
5 
mitogen-activated protein kinase-activated 
protein kinase 5 
SETD1A SET domain containing 1A 
LRIG1 leucine-rich repeats and immunoglobulin-like 
domains 1 
BEX2 brain expressed X-linked 2 
LRIG2 leucine-rich repeats and immunoglobulin-like 
domains 2 
SESN1 sestrin 1 
RABGGTB Rab geranylgeranyltransferase, beta subunit 
ATF2 activating transcription factor 2 
ISYNA1 inositol-3-phosphate synthase 1 
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TUBB tubulin, beta; similar to tubulin, beta 5; 
tubulin, beta pseudogene 2; tubulin, beta 
pseudogene 1 
ZNF324 zinc finger protein 324 
ZNF326 zinc finger protein 326 
POLE3 polymerase (DNA directed), epsilon 3 (p17 
subunit) 
ICOS inducible T-cell co-stimulator 
SYAP1 synapse associated protein 1, SAP47 homolog 
(Drosophila) 
JUND jun D proto-oncogene 
RPL3 ribosomal protein L3; similar to 60S 
ribosomal protein L3 (L4) 
ZNF329 zinc finger protein 329 
RPL10A ribosomal protein L10a pseudogene 6; 
ribosomal protein L10a; ribosomal protein 
L10a pseudogene 9 
TRAF3 TNF receptor-associated factor 3 
B4GALT1 UDP-Gal:betaGlcNAc beta 1,4- 
galactosyltransferase, polypeptide 1 
PRAF2 PRA1 domain family, member 2 
OVGP1 oviductal glycoprotein 1, 120kDa 
HERPUD1 homocysteine-inducible, endoplasmic 
reticulum stress-inducible, ubiquitin-like 
domain member 1 
TAF6 TAF6 RNA polymerase II, TATA box 
binding protein (TBP)-associated factor, 
80kDa 
DOCK9 dedicator of cytokinesis 9 
TNFRSF13
C 
tumor necrosis factor receptor superfamily, 
member 13C 
NR4A1 nuclear receptor subfamily 4, group A, 
member 1 
DNHD1 dynein heavy chain domain 1 
RPL23A ribosomal protein L23a  
THUMPD2 THUMP domain containing 2 
CACNA2D2 calcium channel, voltage-dependent, alpha 
2/delta subunit 2 
MMAA methylmalonic aciduria (cobalamin 
deficiency) cblA type 
ATF4 activating transcription factor 4 (tax-
responsive enhancer element B67); activating 
transcription factor 4C 
CDKN1B cyclin-dependent kinase inhibitor 1B (p27, 
Kip1) 
DNAJB9 DnaJ (Hsp40) homolog, subfamily B, 
member 9 
PLK3 polo-like kinase 3 (Drosophila) 
ZNF419 zinc finger protein 419 
EAF1 ELL associated factor 1 
ARMC8 armadillo repeat containing 8 
CDC42SE2 CDC42 small effector 2 
GTF2F1 general transcription factor IIF, polypeptide 1, 
74kDa 
NDUFV1 NADH dehydrogenase (ubiquinone) 
flavoprotein 1, 51kDa 
GTF2F2 general transcription factor IIF, polypeptide 2, 
30kDa 
HIST1H3A histone cluster 1, H3a 
TUBD1 tubulin, delta 1 
FBXO30 F-box protein 30 
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RHBDL1 rhomboid, veinlet-like 1 (Drosophila) 
HIVEP1 human immunodeficiency virus type I 
enhancer binding protein 1 
ZNF414 zinc finger protein 414 
DNAJB1 DnaJ (Hsp40) homolog, subfamily B, 
member 1 
IER2 immediate early response 2 
USPL1 ubiquitin specific peptidase like 1 
IER5 immediate early response 5 
LRRC8A leucine rich repeat containing 8 family, 
member A 
HP1BP3 heterochromatin protein 1, binding protein 3 
DPH5 DPH5 homolog (S. cerevisiae) 
WWC2 WW and C2 domain containing 2 
DPH3 DPH3, KTI11 homolog (S. cerevisiae); 
DPH3B, KTI11 homolog B (S. cerevisiae) 
ALG9 asparagine-linked glycosylation 9, alpha-1,2-
mannosyltransferase homolog (S. cerevisiae) 
RPS3 ribosomal protein S3 pseudogene 3; 
ribosomal protein S3 
SPRY1 sprouty homolog 1, antagonist of FGF 
signaling (Drosophila) 
PAX7 paired box 7 
PTDSS1 phosphatidylserine synthase 1 
PPP2R1B protein phosphatase 2 (formerly 2A), 
regulatory subunit A, beta isoform 
ANKS1A ankyrin repeat and sterile alpha motif domain 
containing 1A 
SIT1 signaling threshold regulating transmembrane 
adaptor 1 
PTGER4 prostaglandin E receptor 4 (subtype EP4) 
ARID5A AT rich interactive domain 5A (MRF1-like) 
CCNL1 cyclin L1 
CDK9 cyclin-dependent kinase 9 
MID1IP1 MID1 interacting protein 1 (gastrulation 
specific G12 homolog (zebrafish)) 
RPS4X ribosomal protein S4X pseudogene 6; 
ribosomal protein S4X pseudogene 13; 
ribosomal protein S4, X-linked 
NCL nucleolin 
PMM1 phosphomannomutase 1 
SIGLEC6 sialic acid binding Ig-like lectin 6 
ZFAND2A zinc finger, AN1-type domain 2A 
RRAS2 related RAS viral (r-ras) oncogene homolog 
2; similar to related RAS viral (r-ras) 
oncogene homolog 2 
CA6 carbonic anhydrase VI 
UBC ubiquitin C 
SLC41A1 solute carrier family 41, member 1 
INPP4B inositol polyphosphate-4-phosphatase, type II, 
105kDa 
UBAP1 ubiquitin associated protein 1 
OTUD4 OTU domain containing 4 
BCLAF1 similar to Bcl-2-associated transcription 
factor 1 (Btf); BCL2-associated transcription 
factor 1 
CABP1 calcium binding protein 1 
NR3C2 nuclear receptor subfamily 3, group C, 
member 2 
BTN2A2 butyrophilin, subfamily 2, member A2 
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PPM1B protein phosphatase 1B (formerly 2C), 
magnesium-dependent, beta isoform 
TSPYL5 TSPY-like 5 
RNF125 ring finger protein 125 
RNF126 ring finger protein 126 
TFAM transcription factor A, mitochondrial 
HIC2 hypermethylated in cancer 2 
TSC22D2 TSC22 domain family, member 2 
TSPYL2 TSPY-like 2 
AP3M2 adaptor-related protein complex 3, mu 2 
subunit 
ECD ecdysoneless homolog (Drosophila) 
CD6 CD6 molecule 
SCNN1D sodium channel, nonvoltage-gated 1, delta 
GCHFR GTP cyclohydrolase I feedback regulator 
CD7 CD7 molecule 
CNNM2 cyclin M2 
MAF v-maf musculoaponeurotic fibrosarcoma 
oncogene homolog (avian) 
EBP emopamil binding protein (sterol isomerase) 
VHL von Hippel-Lindau tumor suppressor 
SNX25 sorting nexin 25 
GDPD5 glycerophosphodiester phosphodiesterase 
domain containing 5 
MAL mal, T-cell differentiation protein 
DRG2 developmentally regulated GTP binding 
protein 2 
FBL fibrillarin 
PWP1 PWP1 homolog (S. cerevisiae) 
ID2 inhibitor of DNA binding 2, dominant 
negative helix-loop-helix protein 
ZBED4 zinc finger, BED-type containing 4 
SDF2L1 stromal cell-derived factor 2-like 1 
BAX BCL2-associated X protein 
JAK1 Janus kinase 1 
UCKL1 uridine-cytidine kinase 1-like 1 
ID3 inhibitor of DNA binding 3, dominant 
negative helix-loop-helix protein 
GGA1 golgi associated, gamma adaptin ear 
containing, ARF binding protein 1 
SCAND1 SCAN domain containing 1 
NELL2 NEL-like 2 (chicken) 
SNIP1 Smad nuclear interacting protein 1 
BBX bobby sox homolog (Drosophila) 
RNASEH1 ribonuclease H1 
LUZP1 leucine zipper protein 1 
CRY2 cryptochrome 2 (photolyase-like) 
H2AFV H2A histone family, member V 
CD44 CD44 molecule (Indian blood group) 
WWP2 WW domain containing E3 ubiquitin protein 
ligase 2 
TRAK1 trafficking protein, kinesin binding 1 
INSIG1 insulin induced gene 1 
COL12A1 collagen, type XII, alpha 1 
FAM53C family with sequence similarity 53, member C 
STAM signal transducing adaptor molecule (SH3 
domain and ITAM motif) 1 
FAM103A1 family with sequence similarity 103, member 
A1 
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FAM53B family with sequence similarity 53, member B 
DDX10 DEAD (Asp-Glu-Ala-Asp) box polypeptide 
10 
SUPT5H suppressor of Ty 5 homolog (S. cerevisiae) 
CRY1 cryptochrome 1 (photolyase-like) 
BCL7B B-cell CLL/lymphoma 7B 
CD3G CD3g molecule, gamma (CD3-TCR complex) 
CD3E CD3e molecule, epsilon (CD3-TCR complex) 
STRN3 striatin, calmodulin binding protein 3 
TBRG4 transforming growth factor beta regulator 4 
KRT10 keratin 10 
PIM3 pim-3 oncogene 
GCC1 GRIP and coiled-coil domain containing 1 
DEPDC5 DEP domain containing 5 
VEGFB vascular endothelial growth factor B 
CHRAC1 chromatin accessibility complex 1 
CCR7 chemokine (C-C motif) receptor 7 
PRDM4 PR domain containing 4 
ABT1 activator of basal transcription 1 
MLLT10 myeloid/lymphoid or mixed-lineage leukemia 
(trithorax homolog, Drosophila); translocated 
to, 10 
MNT MAX binding protein 
TGFBRAP1 transforming growth factor, beta receptor 
associated protein 1 
RAB12 RAB12, member RAS oncogene family 
BIN1 bridging integrator 1 
MRPL46 mitochondrial ribosomal protein L46 
CDV3 CDV3 homolog (mouse) 
ELL elongation factor RNA polymerase II 
GPBP1L1 GC-rich promoter binding protein 1-like 1 
PFKFB3 6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 3 
AFAP1L2 actin filament associated protein 1-like 2 
ANGEL2 angel homolog 2 (Drosophila) 
COIL coilin 
TIPRL TIP41, TOR signaling pathway regulator-like 
(S. cerevisiae) 
TJAP1 tight junction associated protein 1 (peripheral) 
SLC11A2 solute carrier family 11 (proton-coupled 
divalent metal ion transporters), member 2 
EPHB6 EPH receptor B6 
STX18 syntaxin 18 
NGRN neugrin, neurite outgrowth associated 
MRPL54 mitochondrial ribosomal protein L54 
SUPV3L1 suppressor of var1, 3-like 1 (S. cerevisiae) 
FBXO8 F-box protein 8 
TSEN54 tRNA splicing endonuclease 54 homolog (S. 
cerevisiae) 
TP53BP2 tumor protein p53 binding protein, 2 
SMAD7 SMAD family member 7 
CRIP2 cysteine-rich protein 2 
CREBBP CREB binding protein 
ANKMY1 ankyrin repeat and MYND domain containing 
1 
SMYD3 SET and MYND domain containing 3 
CELSR1 cadherin, EGF LAG seven-pass G-type 
receptor 1 (flamingo homolog, Drosophila) 
ZBTB44 zinc finger and BTB domain containing 44 
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U2AF1L4 U2 small nuclear RNA auxiliary factor 1-like 
4 
OCIAD2 OCIA domain containing 2 
DLX3 distal-less homeobox 3 
EPHA4 EPH receptor A4 
CBLB Cas-Br-M (murine) ecotropic retroviral 
transforming sequence b 
TEX13A testis expressed 13A 
LAMA5 laminin, alpha 5 
DCP1A DCP1 decapping enzyme homolog A (S. 
cerevisiae) 
NIPSNAP1 nipsnap homolog 1 (C. elegans) 
ZIK1 zinc finger protein interacting with K protein 
1 homolog (mouse) 
COPS2 COP9 constitutive photomorphogenic 
homolog subunit 2 (Arabidopsis) 
HIP1R huntingtin interacting protein 1 related 
CCNT1 cyclin T1 
SPINK2 serine peptidase inhibitor, Kazal type 2 
(acrosin-trypsin inhibitor) 
UVRAG UV radiation resistance associated gene 
VPS37B vacuolar protein sorting 37 homolog B (S. 
cerevisiae) 
TERF2IP telomeric repeat binding factor 2, interacting 
protein 
SPINK7 serine peptidase inhibitor, Kazal type 7 
(putative) 
FLT3LG fms-related tyrosine kinase 3 ligand 
BAG4 BCL2-associated athanogene 4 
C4ORF36 chromosome 4 open reading frame 36 
ACTR6 ARP6 actin-related protein 6 homolog (yeast) 
BAG3 BCL2-associated athanogene 3 
SEMA3E sema domain, immunoglobulin domain (Ig), 
short basic domain, secreted, (semaphorin) 3E 
ATP5L ATP synthase, H+ transporting, mitochondrial 
F0 complex, subunit G 
COL11A2 collagen, type XI, alpha 2 
NT5E 5'-nucleotidase, ecto (CD73) 
TFIP11 tuftelin interacting protein 11 
ZFP36 zinc finger protein 36, C3H type, homolog 
(mouse) 
PRPF31 PRP31 pre-mRNA processing factor 31 
homolog (S. cerevisiae) 
ZBTB20 zinc finger and BTB domain containing 20 
ZCCHC10 zinc finger, CCHC domain containing 10 
POLR1E polymerase (RNA) I polypeptide E, 53kDa 
POGZ pogo transposable element with ZNF domain 
SLC25A5 solute carrier family 25 (mitochondrial 
carrier; adenine nucleotide translocator), 
member 5; solute carrier family 25 
(mitochondrial carrier; adenine nucleotide 
translocator), member 5 pseudogene 8 
FAM35A family with sequence similarity 35, member 
A 
POLR1C polymerase (RNA) I polypeptide C, 30kDa 
HERC2 hect domain and RLD 2 
ARRDC2 arrestin domain containing 2 
ZBTB24 zinc finger and BTB domain containing 24 
ZBTB25 zinc finger and BTB domain containing 25 
RHBDD2 rhomboid domain containing 2 
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RAB11FIP4 RAB11 family interacting protein 4 (class II) 
GZMM granzyme M (lymphocyte met-ase 1) 
CTNNBIP1 catenin, beta interacting protein 1 
RAB11FIP2 RAB11 family interacting protein 2 (class I) 
GZMK granzyme K (granzyme 3; tryptase II) 
C6ORF106 chromosome 6 open reading frame 106 
CHMP1B chromatin modifying protein 1B 
AVEN apoptosis, caspase activation inhibitor 
RBM38 RNA binding motif protein 38 
SUSD3 sushi domain containing 3 
GADD45B growth arrest and DNA-damage-inducible, 
beta 
FKBP11 FK506 binding protein 11, 19 kDa 
SLC27A5 solute carrier family 27 (fatty acid 
transporter), member 5 
NXT1 NTF2-like export factor 1 
BCAT2 branched chain aminotransferase 2, 
mitochondrial 
YPEL5 yippee-like 5 (Drosophila) 
POLR2J polymerase (RNA) II (DNA directed) 
polypeptide J, 13.3kDa 
STARD10 StAR-related lipid transfer (START) domain 
containing 10 
POLR2D polymerase (RNA) II (DNA directed) 
polypeptide D 
ZBTB17 zinc finger and BTB domain containing 17 
POLR2C polymerase (RNA) II (DNA directed) 
polypeptide C, 33kDa 
SUMO3 SMT3 suppressor of mif two 3 homolog 2 (S. 
cerevisiae) pseudogene; SMT3 suppressor of 
mif two 3 homolog 2 (S. cerevisiae); SMT3 
suppressor of mif two 3 homolog 3 (S. 
cerevisiae) 
ZFP36L2 zinc finger protein 36, C3H type-like 2 
C12ORF45 chromosome 12 open reading frame 45 
PLCL1 phospholipase C-like 1 
ZDHHC23 zinc finger, DHHC-type containing 23 
TOE1 target of EGR1, member 1 (nuclear) 
NR1D2 nuclear receptor subfamily 1, group D, 
member 2 
ANKRD39 ankyrin repeat domain 39 
BCL11B B-cell CLL/lymphoma 11B (zinc finger 
protein) 
BCL11A B-cell CLL/lymphoma 11A (zinc finger 
protein) 
APBA2 amyloid beta (A4) precursor protein-binding, 
family A, member 2 
BCL9L B-cell CLL/lymphoma 9-like 
BCAS2 breast carcinoma amplified sequence 2 
CSNK1A1 casein kinase 1, alpha 1 
JARID2 jumonji, AT rich interactive domain 2 
C10ORF35 chromosome 10 open reading frame 35 
BCKDHB branched chain keto acid dehydrogenase E1, 
beta polypeptide 
CD1C CD1c molecule 
BIRC6 baculoviral IAP repeat-containing 6 
ILF3 interleukin enhancer binding factor 3, 90kDa 
ITPR3 inositol 1,4,5-triphosphate receptor, type 3 
APRT adenine phosphoribosyltransferase 
KHK ketohexokinase (fructokinase) 
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MRPL22 mitochondrial ribosomal protein L22 
ILF2 interleukin enhancer binding factor 2, 45kDa 
HELB helicase (DNA) B 
IFT57 intraflagellar transport 57 homolog 
(Chlamydomonas) 
RBM15 RNA binding motif protein 15 
TOB1 transducer of ERBB2, 1 
PBX4 pre-B-cell leukemia homeobox 4 
CBX4 chromobox homolog 4 (Pc class homolog, 
Drosophila) 
SAE1 SUMO1 activating enzyme subunit 1 
MMP3 matrix metallopeptidase 3 (stromelysin 1, 
progelatinase) 
VIPR1 vasoactive intestinal peptide receptor 1 
KLHL3 kelch-like 3 (Drosophila) 
MRPS30 mitochondrial ribosomal protein S30 
DMPK dystrophia myotonica-protein kinase 
KLHL7 kelch-like 7 (Drosophila) 
DMXL1 Dmx-like 1 
GATA3 GATA binding protein 3 
SRRM2 serine/arginine repetitive matrix 2; 
hypothetical LOC100132779 
TARDBP TAR DNA binding protein 
TFB2M transcription factor B2, mitochondrial 
ROBO3 roundabout, axon guidance receptor, homolog 
3 (Drosophila) 
GABPB2 GA binding protein transcription factor, beta 
subunit 2 
SATB1 SATB homeobox 1 
CA11 carbonic anhydrase XI 
ERP29 endoplasmic reticulum protein 29 
SOCS6 suppressor of cytokine signaling 6 
MFGE8 milk fat globule-EGF factor 8 protein 
SLC25A36 solute carrier family 25, member 36 
C8ORF58 chromosome 8 open reading frame 58 
CLPP ClpP caseinolytic peptidase, ATP-dependent, 
proteolytic subunit homolog (E. coli) 
SNRPA small nuclear ribonucleoprotein polypeptide 
A 
RNF26 ring finger protein 26 
SLC38A1 solute carrier family 38, member 1 
AKAP8 A kinase (PRKA) anchor protein 8 
EMP2 epithelial membrane protein 2 
PRPS1 phosphoribosyl pyrophosphate synthetase 1; 
phosphoribosyl pyrophosphate synthetase 1-
like 1 
PACS1 phosphofurin acidic cluster sorting protein 1 
DERL2 Der1-like domain family, member 2 
MYL5 myosin, light chain 5, regulatory 
BLM Bloom syndrome, RecQ helicase-like 
ITGAE integrin, alpha E (antigen CD103, human 
mucosal lymphocyte antigen 1; alpha 
polypeptide) 
COX7C cytochrome c oxidase subunit VIIc 
GIPC1 GIPC PDZ domain containing family, 
member 1 
ZMYND8 zinc finger, MYND-type containing 8 
LLGL1 lethal giant larvae homolog 1 (Drosophila) 
KARS lysyl-tRNA synthetase 
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FXYD7 FXYD domain containing ion transport 
regulator 7 
RRAGC Ras-related GTP binding C 
DAZAP1 DAZ associated protein 1 
PRR7 proline rich 7 (synaptic) 
PPP1R16B protein phosphatase 1, regulatory (inhibitor) 
subunit 16B 
LAPTM5 lysosomal multispanning membrane protein 5 
UBE2D2 ubiquitin-conjugating enzyme E2D 2 
(UBC4/5 homolog, yeast) 
BLOC1S2 biogenesis of lysosomal organelles complex-
1, subunit 2 
MTCH1 mitochondrial carrier homolog 1 (C. elegans) 
HARS2 histidyl-tRNA synthetase 2, mitochondrial 
(putative); D-tyrosyl-tRNA deacylase 1 
homolog (S. cerevisiae) 
LMTK3 lemur tyrosine kinase 3 
BTF3 basic transcription factor 3; basic transcription 
factor 3, like 1 pseudogene 
NPM3 nucleophosmin/nucleoplasmin, 3 
GLO1 glyoxalase I 
RNF10 ring finger protein 10 
UBAP2L ubiquitin associated protein 2-like 
STRBP spermatid perinuclear RNA binding protein 
AXIN2 axin 2 
CTRL chymotrypsin-like 
PARD6A par-6 partitioning defective 6 homolog alpha 
(C. elegans) 
REEP6 receptor accessory protein 6 
OBSCN obscurin, cytoskeletal calmodulin and titin-
interacting RhoGEF 
GABARAP
L1 
GABA(A) receptors associated protein like 3 
(pseudogene); GABA(A) receptor-associated 
protein like 1 
GNRH1 gonadotropin-releasing hormone 1 
(luteinizing-releasing hormone) 
AK1 adenylate kinase 1 
PTPN4 protein tyrosine phosphatase, non-receptor 
type 4 (megakaryocyte) 
ZMYM5 zinc finger, MYM-type 5 
GALT galactose-1-phosphate uridylyltransferase 
EPHX2 epoxide hydrolase 2, cytoplasmic 
AK2 adenylate kinase 2 
TOMM40 translocase of outer mitochondrial membrane 
40 homolog (yeast) 
ABHD14B abhydrolase domain containing 14B 
EVL Enah/Vasp-like 
TSN translin 
FOXP4 forkhead box P4 
C8ORF33 chromosome 8 open reading frame 33 
ATF7IP2 activating transcription factor 7 interacting 
protein 2 
EIF4B similar to eukaryotic translation initiation 
factor 4H; eukaryotic translation initiation 
factor 4B 
PHF3 PHD finger protein 3 
TXNDC11 thioredoxin domain containing 11 
PHF1 PHD finger protein 1 
FCAR Fc fragment of IgA, receptor for 
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EIF4H eukaryotic translation initiation factor 4H 
CYFIP2 cytoplasmic FMR1 interacting protein 2 
GLMN glomulin, FKBP associated protein 
SPTBN1 spectrin, beta, non-erythrocytic 1 
CIRBP cold inducible RNA binding protein 
COQ10A coenzyme Q10 homolog A (S. cerevisiae) 
KIAA0355 KIAA0355 
PTPN1 protein tyrosine phosphatase, non-receptor 
type 1 
CD79A CD79a molecule, immunoglobulin-associated 
alpha 
SCMH1 sex comb on midleg homolog 1 (Drosophila) 
HSP90AB1 heat shock protein 90kDa alpha (cytosolic), 
class B member 1 
HPS1 Hermansky-Pudlak syndrome 1 
ECHDC2 enoyl Coenzyme A hydratase domain 
containing 2 
HUS1B HUS1 checkpoint homolog b (S. pombe) 
CXCR3 chemokine (C-X-C motif) receptor 3 
UQCRFS1 ubiquinol-cytochrome c reductase, Rieske 
iron-sulfur polypeptide-like 1; ubiquinol-
cytochrome c reductase, Rieske iron-sulfur 
polypeptide 1 
RSRC2 arginine/serine-rich coiled-coil 2 
PDCD2 programmed cell death 2 
PHC3 polyhomeotic homolog 3 (Drosophila) 
CD96 CD96 molecule 
FOS v-fos FBJ murine osteosarcoma viral 
oncogene homolog 
PCGF2 polycomb group ring finger 2 
PLEKHB1 pleckstrin homology domain containing, 
family B (evectins) member 1 
KLHL26 kelch-like 26 (Drosophila) 
PCBP2 poly(rC) binding protein 2 
NECAP2 NECAP endocytosis associated 2 
NUDT16L1 nudix (nucleoside diphosphate linked moiety 
X)-type motif 16-like 1 
NECAP1 NECAP endocytosis associated 1 
CNTNAP1 contactin associated protein 1 
CDK10 cyclin-dependent kinase 10 
LTB lymphotoxin beta (TNF superfamily, member 
3) 
DUS1L dihydrouridine synthase 1-like (S. cerevisiae) 
PHC1 polyhomeotic homolog 1B (Drosophila); 
polyhomeotic homolog 1 (Drosophila) 
PSMD8 proteasome (prosome, macropain) 26S 
subunit, non-ATPase, 8 
PIGA phosphatidylinositol glycan anchor 
biosynthesis, class A 
PSMD9 proteasome (prosome, macropain) 26S 
subunit, non-ATPase, 9 
NRIP3 nuclear receptor interacting protein 3 
UBE2A ubiquitin-conjugating enzyme E2A (RAD6 
homolog) 
ALDH5A1 aldehyde dehydrogenase 5 family, member 
A1 
ZNF92 zinc finger protein 92 
MPP6 membrane protein, palmitoylated 6 (MAGUK 
p55 subfamily member 6) 
PRKCH protein kinase C, eta 
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PIGT phosphatidylinositol glycan anchor 
biosynthesis, class T 
LAS1L LAS1-like (S. cerevisiae) 
ARHGAP25 Rho GTPase activating protein 25 
NCR3 natural cytotoxicity triggering receptor 3 
MCM6 minichromosome maintenance complex 
component 6 
CCDC51 coiled-coil domain containing 51 
IFNAR2 interferon (alpha, beta and omega) receptor 2 
JOSD1 Josephin domain containing 1 
CTSK cathepsin K 
BTG2 BTG family, member 2 
BTG1 B-cell translocation gene 1, anti-proliferative 
BTG3 BTG family, member 3 
PEBP1 phosphatidylethanolamine binding protein 1 
KPNA5 karyopherin alpha 5 (importin alpha 6) 
PRNP prion protein 
PPP1R15B protein phosphatase 1, regulatory (inhibitor) 
subunit 15B 
C3ORF38 chromosome 3 open reading frame 38 
MATR3 matrin 3 
CTSF cathepsin F 
GLTSCR2 glioma tumor suppressor candidate region 
gene 2; glioma tumor suppressor candidate 
region gene 2 pseudogene 
GLTSCR1 glioma tumor suppressor candidate region 
gene 1 
SPOCK2 sparc/osteonectin, cwcv and kazal-like 
domains proteoglycan (testican) 2 
TNFRSF25 tumor necrosis factor receptor superfamily, 
member 25 
TRA2A transformer 2 alpha homolog (Drosophila) 
TIPARP TCDD-inducible poly(ADP-ribose) 
polymerase 
WBSCR22 Williams Beuren syndrome chromosome 
region 22 
DNAH1 dynein, axonemal, heavy chain 1 
HECA headcase homolog (Drosophila) 
CCDC59 coiled-coil domain containing 59 
SCARF2 scavenger receptor class F, member 2 
MOAP1 modulator of apoptosis 1 
CCDC66 coiled-coil domain containing 66 
FAM107B family with sequence similarity 107, member 
B 
SH3GLB2 SH3-domain GRB2-like endophilin B2 
SAFB scaffold attachment factor B 
MSI2 musashi homolog 2 (Drosophila) 
ENO3 enolase 3 (beta, muscle) 
PIK3R5 phosphoinositide-3-kinase, regulatory subunit 
5 
PLCD1 phospholipase C, delta 1 
YES1 v-yes-1 Yamaguchi sarcoma viral oncogene 
homolog 1 
DUS3L dihydrouridine synthase 3-like (S. cerevisiae) 
DTX1 deltex homolog 1 (Drosophila) 
L3MBTL3 l(3)mbt-like 3 (Drosophila) 
MAP1A microtubule-associated protein 1A 
DTX3 deltex homolog 3 (Drosophila) 
TUBGCP2 tubulin, gamma complex associated protein 2 
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CCDC69 coiled-coil domain containing 69 
RALGDS ral guanine nucleotide dissociation stimulator 
GPS2 G protein pathway suppressor 2 
ATXN7L2 ataxin 7-like 2 
CCDC77 coiled-coil domain containing 77 
TOX thymocyte selection-associated high mobility 
group box 
TDP1 tyrosyl-DNA phosphodiesterase 1 
ANXA11 annexin A11 
PSPC1 paraspeckle component 1; paraspeckle protein 
1 pseudogene 
SLC5A6 solute carrier family 5 (sodium-dependent 
vitamin transporter), member 6 
DUS4L dihydrouridine synthase 4-like (S. cerevisiae) 
RNF41 ring finger protein 41 
IGFBP5 insulin-like growth factor binding protein 5 
NKX3-1 NK3 homeobox 1 
HLA-DMA major histocompatibility complex, class II, 
DM alpha 
Table 23. Genes that are significantly expressed in PAH samples; and significantly correlated with ID3 in tissue samples (573 
genes) from the significant gene list provided from GEO PAH datasets. 
Gene 
Symbol 
Gene Name 
PDCD7 programmed cell death 7 
ADM adrenomedullin 
IGFBP5 insulin-like growth factor binding protein 
5 
KCNK17 potassium channel, subfamily K, member 
17 
DCUN1D2 DCN1, defective in cullin neddylation 1, 
domain containing 2 (S. cerevisiae) 
UBP1 upstream binding protein 1 (LBP-1a) 
C19orf25 chromosome 19 open reading frame 25 
ARMCX6 similar to armadillo repeat containing, X-
linked 6; armadillo repeat containing, X-
linked 6 
NOTCH4 Notch homolog 4 (Drosophila) 
ORAOV1 oral cancer overexpressed 1 
ADIPOR1 adiponectin receptor 1 
ZDHHC7 zinc finger, DHHC-type containing 7 
ADAMTS7 similar to hCG1991431; similar to 
COMPase; ADAM metallopeptidase with 
thrombospondin type 1 motif, 7 
LCE3D late cornified envelope 3D 
NES nestin 
PCDH10 protocadherin 10 
CLPTM1 cleft lip and palate associated 
transmembrane protein 1 
MCM3AP minichromosome maintenance complex 
component 3 associated protein 
ASB8 ankyrin repeat and SOCS box-containing 
8 
GIMAP6 GTPase, IMAP family member 6 
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DALRD3 DALR anticodon binding domain 
containing 3 
LOXL3 lysyl oxidase-like 3 
RHOT2 ras homolog gene family, member T2 
SORBS2 sorbin and SH3 domain containing 2 
ARHGEF10 Rho guanine nucleotide exchange factor 
(GEF) 10 
FADS3 fatty acid desaturase 3 
POLR2C polymerase (RNA) II (DNA directed) 
polypeptide C, 33kDa 
LRRC25 leucine rich repeat containing 25 
GFM1 G elongation factor, mitochondrial 1 
EXTL3 exostoses (multiple)-like 3 
NSD1 nuclear receptor binding SET domain 
protein 1 
STMN1 stathmin 1 
TMEM80 transmembrane protein 80 
MS4A3 membrane-spanning 4-domains, 
subfamily A, member 3 (hematopoietic 
cell-specific) 
ANK1 ankyrin 1, erythrocytic 
ETFB electron-transfer-flavoprotein, beta 
polypeptide 
NMUR1 neuromedin U receptor 1 
FOXA2 forkhead box A2 
FHOD1 formin homology 2 domain containing 1 
SEMA4G sema domain, immunoglobulin domain 
(Ig), transmembrane domain (TM) and 
short cytoplasmic domain, (semaphorin) 
4G 
HIST1H1E histone cluster 1, H1e 
PAOX polyamine oxidase (exo-N4-amino) 
IDH3B isocitrate dehydrogenase 3 (NAD+) beta 
DNAL4 dynein, axonemal, light chain 4 
PRRG1 proline rich Gla (G-carboxyglutamic 
acid) 1 
RASSF3 Ras association (RalGDS/AF-6) domain 
family member 3 
PKP4 plakophilin 4 
SNX1 sorting nexin 1 
AMPH amphiphysin 
USP21 ubiquitin specific peptidase 21 
COL4A3 collagen, type IV, alpha 3 (Goodpasture 
antigen) 
LUC7L LUC7-like (S. cerevisiae) 
DUT deoxyuridine triphosphatase 
CWF19L1 CWF19-like 1, cell cycle control (S. 
pombe) 
IL2 interleukin 2 
ZNF503 zinc finger protein 503 
ARHGAP6 Rho GTPase activating protein 6 
TNFSF10 tumor necrosis factor (ligand) 
superfamily, member 10 
IER2 immediate early response 2 
B3GALNT1 beta-1,3-N-
acetylgalactosaminyltransferase 1 
(globoside blood group) 
MRPL45 mitochondrial ribosomal protein L45 
IDH2 isocitrate dehydrogenase 2 (NADP+), 
mitochondrial 
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AFF2 AF4/FMR2 family, member 2 
ZFP37 zinc finger protein 37 homolog (mouse) 
SOX13 SRY (sex determining region Y)-box 13 
RGL2 ral guanine nucleotide dissociation 
stimulator-like 2 
GUCY1B3 guanylate cyclase 1, soluble, beta 3 
CSF3R colony stimulating factor 3 receptor 
(granulocyte) 
SSU72 SSU72 RNA polymerase II CTD 
phosphatase homolog (S. cerevisiae) 
MAPKAP1 mitogen-activated protein kinase 
associated protein 1 
PARVB parvin, beta 
GNAI1 guanine nucleotide binding protein (G 
protein), alpha inhibiting activity 
polypeptide 1 
RAC1 ras-related C3 botulinum toxin substrate 
1 (rho family, small GTP binding protein 
Rac1) 
AKR7A3 aldo-keto reductase family 7, member A3 
(aflatoxin aldehyde reductase) 
NOTCH1 Notch homolog 1, translocation-
associated (Drosophila) 
FBXO17 F-box protein 17 
OTOS otospiralin 
TBX4 T-box 4 
MRE11A MRE11 meiotic recombination 11 
homolog A (S. cerevisiae) 
ZNF117 zinc finger protein 117 
PAXIP1 PAX interacting (with transcription-
activation domain) protein 1 
EFNA4 ephrin-A4 
FGF12 fibroblast growth factor 12 
DCAKD dephospho-CoA kinase domain 
containing 
TRAF3IP3 TRAF3 interacting protein 3 
STAT5B signal transducer and activator of 
transcription 5B 
HEXA hexosaminidase A (alpha polypeptide) 
FAM127B family with sequence similarity 127, 
member B 
REM1 RAS (RAD and GEM)-like GTP-binding 
1 
NKD1 naked cuticle homolog 1 (Drosophila) 
NRG2 neuregulin 2 
STAB1 stabilin 1 
DAP death-associated protein 
ACSS2 acyl-CoA synthetase short-chain family 
member 2 
FKBP8 FK506 binding protein 8, 38kDa 
RNASE3 ribonuclease, RNase A family, 3 
(eosinophil cationic protein) 
RABEP1 rabaptin, RAB GTPase binding effector 
protein 1 
CDH24 cadherin-like 24 
CLK2 CDC-like kinase 2 
AHNAK AHNAK nucleoprotein 
LDOC1 leucine zipper, down-regulated in cancer 
1 
GNL3 guanine nucleotide binding protein-like 3 
(nucleolar) 
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ANGPT1 angiopoietin 1 
EIF2B1 eukaryotic translation initiation factor 
2B, subunit 1 alpha, 26kDa 
ZNF687 zinc finger protein 687 
USP5 ubiquitin specific peptidase 5 
(isopeptidase T) 
GABBR1 gamma-aminobutyric acid (GABA) B 
receptor, 1 
DLGAP3 discs, large (Drosophila) homolog-
associated protein 3 
CSRP1 cysteine and glycine-rich protein 1 
PRKCDBP protein kinase C, delta binding protein 
EXTL2 exostoses (multiple)-like 2 
RFC4 replication factor C (activator 1) 4, 
37kDa 
FBXW4 F-box and WD repeat domain containing 
4 
FOXK1 forkhead box K1 
TMEM98 similar to transmembrane protein 98; 
transmembrane protein 98 
GPRC5C G protein-coupled receptor, family C, 
group 5, member C 
BCL9L B-cell CLL/lymphoma 9-like 
ADCY6 adenylate cyclase 6 
RERE arginine-glutamic acid dipeptide (RE) 
repeats 
SLC25A23 solute carrier family 25 (mitochondrial 
carrier; phosphate carrier), member 23 
AGER advanced glycosylation end product-
specific receptor 
CTTNBP2N
L 
CTTNBP2 N-terminal like 
MRGPRF MAS-related GPR, member F 
AKT1 v-akt murine thymoma viral oncogene 
homolog 1 
TSKS testis-specific serine kinase substrate 
ADCY4 adenylate cyclase 4 
TTLL7 tubulin tyrosine ligase-like family, 
member 7 
TAF1C TATA box binding protein (TBP)-
associated factor, RNA polymerase I, C, 
110kDa 
EHBP1 EH domain binding protein 1 
CAMK1 calcium/calmodulin-dependent protein 
kinase I 
MAN2A2 mannosidase, alpha, class 2A, member 2 
PIGO phosphatidylinositol glycan anchor 
biosynthesis, class O 
RNF43 ring finger protein 43 
TNRC6C trinucleotide repeat containing 6C 
TLCD1 TLC domain containing 1 
ZCCHC9 zinc finger, CCHC domain containing 9 
ATP5G3 ATP synthase, H+ transporting, 
mitochondrial F0 complex, subunit C3 
(subunit 9) 
TMCO3 transmembrane and coiled-coil domains 3 
PTDSS1 phosphatidylserine synthase 1 
XYLT2 xylosyltransferase II 
AGGF1 angiogenic factor with G patch and FHA 
domains 1 
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RAVER1 ribonucleoprotein, PTB-binding 1 
CDT1 chromatin licensing and DNA replication 
factor 1 
SLC35A5 solute carrier family 35, member A5 
TRIM32 tripartite motif-containing 32 
EPDR1 ependymin related protein 1 (zebrafish) 
RSPO2 R-spondin 2 homolog (Xenopus laevis) 
PPCDC phosphopantothenoylcysteine 
decarboxylase 
NEK3 NIMA (never in mitosis gene a)-related 
kinase 3 
NEDD4 neural precursor cell expressed, 
developmentally down-regulated 4 
AGTR1 angiotensin II receptor, type 1 
LDLRAP1 low density lipoprotein receptor adaptor 
protein 1 
ZNF429 zinc finger protein 429 
ZNF672 zinc finger protein 672; hypothetical 
LOC100130262 
POLE polymerase (DNA directed), epsilon 
IMPA2 inositol(myo)-1(or 4)-monophosphatase 2 
ZNF781 zinc finger protein 781 
GNPDA1 glucosamine-6-phosphate deaminase 1 
CDKN1C cyclin-dependent kinase inhibitor 1C 
(p57, Kip2) 
FCN3 ficolin (collagen/fibrinogen domain 
containing) 3 (Hakata antigen) 
TFAP4 transcription factor AP-4 (activating 
enhancer binding protein 4) 
MAGEH1 melanoma antigen family H, 1 
TINAGL1 tubulointerstitial nephritis antigen-like 1 
ELOVL5 ELOVL family member 5, elongation of 
long chain fatty acids (FEN1/Elo2, 
SUR4/Elo3-like, yeast) 
NFYB nuclear transcription factor Y, beta 
VPS26B vacuolar protein sorting 26 homolog B 
(S. pombe) 
UBE2Q1 ubiquitin-conjugating enzyme E2Q 
family member 1 
PECR peroxisomal trans-2-enoyl-CoA reductase 
SMG6 Smg-6 homolog, nonsense mediated 
mRNA decay factor (C. elegans) 
HIST1H4L histone cluster 1, H4l 
HIST1H4D histone cluster 1, H4d 
SCAMP2 secretory carrier membrane protein 2 
STX6 syntaxin 6 
LOXL4 lysyl oxidase-like 4 
GNPAT glyceronephosphate O-acyltransferase 
ATP5B ATP synthase, H+ transporting, 
mitochondrial F1 complex, beta 
polypeptide 
PEX16 peroxisomal biogenesis factor 16 
CDC25B cell division cycle 25 homolog B (S. 
pombe) 
GNS glucosamine (N-acetyl)-6-sulfatase 
METTL4 methyltransferase like 4 
IGF2R insulin-like growth factor 2 receptor 
DCN decorin 
GANAB glucosidase, alpha; neutral AB 
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AP2M1 adaptor-related protein complex 2, mu 1 
subunit 
CCL26 chemokine (C-C motif) ligand 26 
DNAJC15 DnaJ (Hsp40) homolog, subfamily C, 
member 15 
GPS2 G protein pathway suppressor 2 
SCAMP1 secretory carrier membrane protein 1 
ADRA1B adrenergic, alpha-1B-, receptor 
MMRN1 multimerin 1 
PCTP phosphatidylcholine transfer protein 
OBFC1 oligonucleotide/oligosaccharide-binding 
fold containing 1 
MRPS18A mitochondrial ribosomal protein S18A 
MRPS14 mitochondrial ribosomal protein S14 
TUBAL3 tubulin, alpha-like 3 
TXN2 thioredoxin 2 
MUS81 MUS81 endonuclease homolog (S. 
cerevisiae) 
STX10 syntaxin 10 
SF3B1 splicing factor 3b, subunit 1, 155kDa 
COG1 component of oligomeric golgi complex 
1 
SLC44A1 solute carrier family 44, member 1 
METAP1 methionyl aminopeptidase 1 
EVC Ellis van Creveld syndrome 
DOCK6 dedicator of cytokinesis 6 
GPR161 G protein-coupled receptor 161 
TK2 thymidine kinase 2, mitochondrial 
TCEAL4 transcription elongation factor A (SII)-
like 4 
RAB40C RAB40C, member RAS oncogene family 
DUSP7 dual specificity phosphatase 7 
SLCO4C1 solute carrier organic anion transporter 
family, member 4C1 
NSUN5 NOL1/NOP2/Sun domain family, 
member 5 
PARS2 prolyl-tRNA synthetase 2, mitochondrial 
(putative) 
C6orf106 chromosome 6 open reading frame 106 
TUSC2 tumor suppressor candidate 2 
OPN3 opsin 3 
CYP4F12 similar to cytochrome P450, family 4, 
subfamily F, polypeptide 12; cytochrome 
P450, family 4, subfamily F, polypeptide 
12 
TSPAN7 tetraspanin 7 
ZFP2 zinc finger protein 2 homolog (mouse) 
EPAS1 endothelial PAS domain protein 1 
ACTN4 actinin, alpha 4 
STRN4 striatin, calmodulin binding protein 4 
VPS41 vacuolar protein sorting 41 homolog (S. 
cerevisiae) 
IRF2 interferon regulatory factor 2 
SCN1B sodium channel, voltage-gated, type I, 
beta 
SEC14L3 SEC14-like 3 (S. cerevisiae) 
TPM1 tropomyosin 1 (alpha) 
SEMA3F sema domain, immunoglobulin domain 
(Ig), short basic domain, secreted, 
(semaphorin) 3F 
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VEGFB vascular endothelial growth factor B 
ZMAT2 zinc finger, matrin type 2 
TMEM11 transmembrane protein 11 
FMO2 flavin containing monooxygenase 2 (non-
functional) 
VAMP2 vesicle-associated membrane protein 2 
(synaptobrevin 2) 
SEMA6C sema domain, transmembrane domain 
(TM), and cytoplasmic domain, 
(semaphorin) 6C 
PTPRB protein tyrosine phosphatase, receptor 
type, B 
TMLHE trimethyllysine hydroxylase, epsilon 
TEX261 testis expressed 261 
TRIM44 tripartite motif-containing 44 
PHF2 PHD finger protein 2 
GGT6 gamma-glutamyltransferase 6 
ATP6V1E1 ATPase, H+ transporting, lysosomal 
31kDa, V1 subunit E1 
RBP1 retinol binding protein 1, cellular 
ZNF311 zinc finger protein 311 
CEP63 centrosomal protein 63kDa 
FASTKD3 FAST kinase domains 3 
IRS2 insulin receptor substrate 2 
TRIB2 tribbles homolog 2 (Drosophila) 
DSCR3 Down syndrome critical region gene 3 
DNASE1L1 deoxyribonuclease I-like 1 
RBM5 RNA binding motif protein 5 
ZNF512 zinc finger protein 512 
MAP3K11 mitogen-activated protein kinase kinase 
kinase 11 
DDX41 DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 41 
MORC3 MORC family CW-type zinc finger 3 
VPS52 vacuolar protein sorting 52 homolog (S. 
cerevisiae) 
TMUB2 transmembrane and ubiquitin-like 
domain containing 2 
APEX1 APEX nuclease (multifunctional DNA 
repair enzyme) 1 
MMACHC methylmalonic aciduria (cobalamin 
deficiency) cblC type, with 
homocystinuria 
COPS5 COP9 constitutive photomorphogenic 
homolog subunit 5 (Arabidopsis) 
MED12 mediator complex subunit 12 
ZFHX4 zinc finger homeobox 4 
BANF1 similar to barrier-to-autointegration 
factor; barrier to autointegration factor 1 
LZIC leucine zipper and CTNNBIP1 domain 
containing 
DYSF dysferlin, limb girdle muscular dystrophy 
2B (autosomal recessive) 
TTC13 tetratricopeptide repeat domain 13 
NFKBIL1 nuclear factor of kappa light polypeptide 
gene enhancer in B-cells inhibitor-like 1 
ANKRD49 ankyrin repeat domain 49 
CHD8 chromodomain helicase DNA binding 
protein 8 
CSN3 casein kappa 
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RALA v-ral simian leukemia viral oncogene 
homolog A (ras related) 
SPPL2B signal peptide peptidase-like 2B 
CASKIN1 CASK interacting protein 1 
RSRC1 arginine/serine-rich coiled-coil 1 
GPAA1 glycosylphosphatidylinositol anchor 
attachment protein 1 homolog (yeast) 
CAMKK2 calcium/calmodulin-dependent protein 
kinase kinase 2, beta 
CEP68 centrosomal protein 68kDa 
IL17RE interleukin 17 receptor E 
GMEB2 glucocorticoid modulatory element 
binding protein 2 
ZFP64 zinc finger protein 64 homolog (mouse) 
PLEKHA6 pleckstrin homology domain containing, 
family A member 6 
CPT1A carnitine palmitoyltransferase 1A (liver) 
ZW10 ZW10, kinetochore associated, homolog 
(Drosophila) 
NKTR natural killer-tumor recognition sequence 
LASP1 LIM and SH3 protein 1 
GJB1 gap junction protein, beta 1, 32kDa 
PPP1R3C protein phosphatase 1, regulatory 
(inhibitor) subunit 3C 
CXXC4 CXXC finger 4 
TOP2B topoisomerase (DNA) II beta 180kDa 
RBM23 RNA binding motif protein 23 
RETSAT retinol saturase (all-trans-retinol 13,14-
reductase) 
SPTBN1 spectrin, beta, non-erythrocytic 1 
DFFB DNA fragmentation factor, 40kDa, beta 
polypeptide (caspase-activated DNase) 
DMPK dystrophia myotonica-protein kinase 
GAB3 GRB2-associated binding protein 3 
TTC9C tetratricopeptide repeat domain 9C 
INPP5A inositol polyphosphate-5-phosphatase, 
40kDa 
THYN1 thymocyte nuclear protein 1 
RIMS3 regulating synaptic membrane exocytosis 
3 
PHB prohibitin 
DECR2 2,4-dienoyl CoA reductase 2, 
peroxisomal 
CANX calnexin 
ARHGAP9 Rho GTPase activating protein 9 
LRRC28 leucine rich repeat containing 28 
BSDC1 BSD domain containing 1 
STK38 serine/threonine kinase 38 
SIRT5 sirtuin (silent mating type information 
regulation 2 homolog) 5 (S. cerevisiae) 
PDE5A phosphodiesterase 5A, cGMP-specific 
SRP14 signal recognition particle 14kDa 
SLC12A4 solute carrier family 12 
(potassium/chloride transporters), 
member 4 
LHPP phospholysine phosphohistidine 
inorganic pyrophosphate phosphatase 
EPRS glutamyl-prolyl-tRNA synthetase 
NAT2 N-acetyltransferase 2 (arylamine N-
acetyltransferase) 
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DHX16 DEAH (Asp-Glu-Ala-His) box 
polypeptide 16 
ALG6 asparagine-linked glycosylation 6, alpha-
1,3-glucosyltransferase homolog (S. 
cerevisiae) 
TMEM109 transmembrane protein 109 
CENPB centromere protein B, 80kDa 
USP46 ubiquitin specific peptidase 46 
NOTUM notum pectinacetylesterase homolog 
(Drosophila) 
TCF12 transcription factor 12 
SPINT2 serine peptidase inhibitor, Kunitz type, 2 
SHPRH SNF2 histone linker PHD RING helicase 
OSGEPL1 O-sialoglycoprotein endopeptidase-like 1 
ATP10D ATPase, class V, type 10D 
ALDH1L2 aldehyde dehydrogenase 1 family, 
member L2 
TTC23 tetratricopeptide repeat domain 23 
KRT10 keratin 10 
ID3 inhibitor of DNA binding 3, dominant 
negative helix-loop-helix protein 
SH3KBP1 SH3-domain kinase binding protein 1 
SLC26A6 solute carrier family 26, member 6 
DLL4 delta-like 4 (Drosophila) 
MRPL46 mitochondrial ribosomal protein L46 
BFAR bifunctional apoptosis regulator 
SERINC3 serine incorporator 3 
CRNKL1 crooked neck pre-mRNA splicing factor-
like 1 (Drosophila) 
ST5 suppression of tumorigenicity 5 
LCMT2 leucine carboxyl methyltransferase 2 
ARHGEF2 Rho/Rac guanine nucleotide exchange 
factor (GEF) 2 
SCRN2 secernin 2 
CA4 carbonic anhydrase IV 
BPGM 2,3-bisphosphoglycerate mutase 
HAAO 3-hydroxyanthranilate 3,4-dioxygenase 
SLC7A9 solute carrier family 7 (cationic amino 
acid transporter, y+ system), member 9 
TCF19 transcription factor 19 
PPM1M protein phosphatase 1M (PP2C domain 
containing) 
WDR20 WD repeat domain 20 
HECW2 HECT, C2 and WW domain containing 
E3 ubiquitin protein ligase 2 
HIC2 hypermethylated in cancer 2 
PCSK7 proprotein convertase subtilisin/kexin 
type 7 pseudogene; proprotein convertase 
subtilisin/kexin type 7 
RPL8 ribosomal protein L8; ribosomal protein 
L8 pseudogene 2 
SH3BGRL SH3 domain binding glutamic acid-rich 
protein like 
GAPVD1 GTPase activating protein and VPS9 
domains 1 
SLC5A5 solute carrier family 5 (sodium iodide 
symporter), member 5 
SLC43A1 solute carrier family 43, member 1 
ADAMTS2 ADAM metallopeptidase with 
thrombospondin type 1 motif, 2 
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NGRN neugrin, neurite outgrowth associated 
CHRNB2 cholinergic receptor, nicotinic, beta 2 
(neuronal) 
CARD10 caspase recruitment domain family, 
member 10 
IKBKE inhibitor of kappa light polypeptide gene 
enhancer in B-cells, kinase epsilon 
ZNF211 zinc finger protein 211 
CTDSP2 similar to hCG2013701; CTD (carboxy-
terminal domain, RNA polymerase II, 
polypeptide A) small phosphatase 2 
SMOC1 SPARC related modular calcium binding 
1 
TMEM9 transmembrane protein 9 
COG2 component of oligomeric golgi complex 
2 
PLCD3 phospholipase C, delta 3 
CDYL chromodomain protein, Y-like 
ZNF630 zinc finger protein 630 
STARD3NL STARD3 N-terminal like 
TFEB transcription factor EB 
ATP11C ATPase, class VI, type 11C 
BBS1 Bardet-Biedl syndrome 1 
SAE1 SUMO1 activating enzyme subunit 1 
ACACB acetyl-Coenzyme A carboxylase beta 
FIS1 fission 1 (mitochondrial outer membrane) 
homolog (S. cerevisiae) 
OLFM4 olfactomedin 4 
NR3C1 nuclear receptor subfamily 3, group C, 
member 1 (glucocorticoid receptor) 
ALS2CL ALS2 C-terminal like 
FGD5 FYVE, RhoGEF and PH domain 
containing 5 
CASP2 caspase 2, apoptosis-related cysteine 
peptidase 
CCDC8 coiled-coil domain containing 8 
GATA2 GATA binding protein 2 
CPNE2 copine II 
PSRC1 proline/serine-rich coiled-coil 1 
KCTD15 potassium channel tetramerisation 
domain containing 15 
IL22RA1 interleukin 22 receptor, alpha 1 
CARD8 caspase recruitment domain family, 
member 8 
C11orf49 chromosome 11 open reading frame 49 
PECAM1 platelet/endothelial cell adhesion 
molecule 
MSC musculin (activated B-cell factor-1) 
CECR6 cat eye syndrome chromosome region, 
candidate 6 
CYP4V2 cytochrome P450, family 4, subfamily V, 
polypeptide 2 
NDRG4 NDRG family member 4 
SF3B2 splicing factor 3b, subunit 2, 145kDa 
RREB1 ras responsive element binding protein 1 
PKN1 protein kinase N1 
TTYH3 tweety homolog 3 (Drosophila) 
PTPN9 protein tyrosine phosphatase, non-
receptor type 9 
ILVBL ilvB (bacterial acetolactate synthase)-like 
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RPA2 replication protein A2, 32kDa 
COPS6 COP9 constitutive photomorphogenic 
homolog subunit 6 (Arabidopsis) 
NIF3L1 NIF3 NGG1 interacting factor 3-like 1 
(S. pombe) 
SYT17 synaptotagmin XVII; synaptotagmin VII 
TMEM69 transmembrane protein 69 
SYPL1 synaptophysin-like 1 
EMP1 epithelial membrane protein 1 
SAMM50 sorting and assembly machinery 
component 50 homolog (S. cerevisiae) 
CCT7 chaperonin containing TCP1, subunit 7 
(eta) 
TM7SF2 transmembrane 7 superfamily member 2 
GJA5 gap junction protein, alpha 5, 40kDa 
CYBRD1 cytochrome b reductase 1 
ARHGAP4 Rho GTPase activating protein 4 
TDRD10 tudor domain containing 10 
GPR107 G protein-coupled receptor 107 
ASF1A ASF1 anti-silencing function 1 homolog 
A (S. cerevisiae) 
HARS2 histidyl-tRNA synthetase 2 
VPS37D vacuolar protein sorting 37 homolog D 
(S. cerevisiae) 
GSTA4 glutathione S-transferase alpha 4 
PHACTR2 phosphatase and actin regulator 2 
TSSC1 tumor suppressing subtransferable 
candidate 1 
DNAJB12 DnaJ (Hsp40) homolog, subfamily B, 
member 12 
NRGN neurogranin (protein kinase C substrate, 
RC3) 
DRD4 dopamine receptor D4 
MAP3K13 mitogen-activated protein kinase kinase 
kinase 13 
CYP2R1 cytochrome P450, family 2, subfamily R, 
polypeptide 1 
DIXDC1 DIX domain containing 1 
NOSTRIN nitric oxide synthase trafficker 
LRMP lymphoid-restricted membrane protein 
ACOX3 acyl-Coenzyme A oxidase 3, pristanoyl 
TXNDC11 thioredoxin domain containing 11 
ZNF333 zinc finger protein 333 
ARHGAP1 Rho GTPase activating protein 1 
LHFP lipoma HMGIC fusion partner 
GTF2E1 general transcription factor IIE, 
polypeptide 1, alpha 56kDa 
RASGRP2 RAS guanyl releasing protein 2 (calcium 
and DAG-regulated) 
LBH limb bud and heart development homolog 
(mouse) 
PTPN6 protein tyrosine phosphatase, non-
receptor type 6 
CIDEB cell death-inducing DFFA-like effector b 
ARHGEF6 Rac/Cdc42 guanine nucleotide exchange 
factor (GEF) 6 
LTK leukocyte receptor tyrosine kinase 
DNAJC4 DnaJ (Hsp40) homolog, subfamily C, 
member 4 
UGDH UDP-glucose dehydrogenase 
147 
 
RASSF1 Ras association (RalGDS/AF-6) domain 
family member 1 
HYAL1 hyaluronoglucosaminidase 1 
HES7 hairy and enhancer of split 7 (Drosophila) 
LETMD1 LETM1 domain containing 1 
STON2 stonin 2 
SCARF1 scavenger receptor class F, member 1 
MANEA mannosidase, endo-alpha 
TOB2 transducer of ERBB2, 2 
C1orf116 chromosome 1 open reading frame 116 
COG4 component of oligomeric golgi complex 
4 
PPIE peptidylprolyl isomerase E (cyclophilin 
E) 
RCBTB1 regulator of chromosome condensation 
(RCC1) and BTB (POZ) domain 
containing protein 1 
C10orf10 chromosome 10 open reading frame 10 
RHBDF1 rhomboid 5 homolog 1 (Drosophila) 
CPS1 carbamoyl-phosphate synthetase 1, 
mitochondrial 
ABLIM3 actin binding LIM protein family, 
member 3 
RAPGEF1 Rap guanine nucleotide exchange factor 
(GEF) 1 
FADS2 fatty acid desaturase 2 
EXOC4 exocyst complex component 4 
SLC4A2 solute carrier family 4, anion exchanger, 
member 2 (erythrocyte membrane protein 
band 3-like 1) 
TNRC6B trinucleotide repeat containing 6B 
RGL1 ral guanine nucleotide dissociation 
stimulator-like 1 
BTG3 BTG family, member 3 
PURA purine-rich element binding protein A 
2-Mar membrane-associated ring finger 
(C3HC4) 2 
PTGIS prostaglandin I2 (prostacyclin) synthase 
COPS7A COP9 constitutive photomorphogenic 
homolog subunit 7A (Arabidopsis) 
KCNJ10 potassium inwardly-rectifying channel, 
subfamily J, member 10 
MPPE1 metallophosphoesterase 1 
H1FX H1 histone family, member X 
TMCO6 transmembrane and coiled-coil domains 6 
SLC16A11 solute carrier family 16, member 11 
(monocarboxylic acid transporter 11) 
ZNF76 zinc finger protein 76 (expressed in 
testis) 
AVPI1 arginine vasopressin-induced 1 
ZNF609 zinc finger protein 609 
FIGNL1 fidgetin-like 1 
TRAF7 TNF receptor-associated factor 7 
DVL3 dishevelled, dsh homolog 3 (Drosophila) 
MAN2C1 mannosidase, alpha, class 2C, member 1 
ADAT1 adenosine deaminase, tRNA-specific 1 
FOXF2 forkhead box F2 
RAB26 RAB26, member RAS oncogene family 
OR8B8 olfactory receptor, family 8, subfamily B, 
member 8 
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CTNS cystinosis, nephropathic 
RXRB retinoid X receptor, beta 
PEX11A peroxisomal biogenesis factor 11 alpha 
SNTA1 syntrophin, alpha 1 (dystrophin-
associated protein A1, 59kDa, acidic 
component) 
NISCH nischarin 
ATOH8 atonal homolog 8 (Drosophila) 
PRMT2 protein arginine methyltransferase 2 
CD1D CD1d molecule 
GRTP1 growth hormone regulated TBC protein 1 
RNF146 ring finger protein 146 
JAG2 jagged 2 
LAMA5 laminin, alpha 5 
DCTN1 dynactin 1 (p150, glued homolog, 
Drosophila) 
MMP2 matrix metallopeptidase 2 (gelatinase A, 
72kDa gelatinase, 72kDa type IV 
collagenase) 
ZSWIM1 zinc finger, SWIM-type containing 1 
ZFYVE19 zinc finger, FYVE domain containing 19 
PTPRM protein tyrosine phosphatase, receptor 
type, M 
SLC35D2 solute carrier family 35, member D2 
SLCO2A1 solute carrier organic anion transporter 
family, member 2A1 
ATG16L2 ATG16 autophagy related 16-like 2 (S. 
cerevisiae) 
SS18L2 synovial sarcoma translocation gene on 
chromosome 18-like 2 
ESD esterase D/formylglutathione hydrolase 
NPM2 nucleophosmin/nucleoplasmin, 2 
PIGC phosphatidylinositol glycan anchor 
biosynthesis, class C 
ANGEL1 angel homolog 1 (Drosophila) 
SFXN3 sideroflexin 3 
USP19 ubiquitin specific peptidase 19 
CCNB1IP1 cyclin B1 interacting protein 1 
SDS serine dehydratase 
PRKCH protein kinase C, eta 
C11orf71 chromosome 11 open reading frame 71 
PODXL podocalyxin-like 
ARRDC1 arrestin domain containing 1 
HDAC1 histone deacetylase 1 
CX3CR1 chemokine (C-X3-C motif) receptor 1 
TSPAN10 tetraspanin 10 
NEK8 NIMA (never in mitosis gene a)- related 
kinase 8 
SDHB succinate dehydrogenase complex, 
subunit B, iron sulfur (Ip) 
RB1 retinoblastoma 1 
MVD mevalonate (diphospho) decarboxylase 
ASH2L ash2 (absent, small, or homeotic)-like 
(Drosophila) 
CXXC1 CXXC finger 1 (PHD domain) 
INPP5B inositol polyphosphate-5-phosphatase, 
75kDa 
WDR45 WD repeat domain 45 
MYH9 myosin, heavy chain 9, non-muscle 
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HPS3 Hermansky-Pudlak syndrome 3 
JAM3 junctional adhesion molecule 3 
PPP2R5A protein phosphatase 2, regulatory subunit 
B', alpha isoform 
ZFAND2B zinc finger, AN1-type domain 2B 
CHMP2A chromatin modifying protein 2A 
ETV5 ets variant 5 
PDE9A phosphodiesterase 9A 
GLO1 glyoxalase I 
TEX264 testis expressed 264 
SYNCRIP synaptotagmin binding, cytoplasmic 
RNA interacting protein 
PHKB phosphorylase kinase, beta 
CYFIP1 cytoplasmic FMR1 interacting protein 1 
CCS copper chaperone for superoxide 
dismutase 
ZBTB4 zinc finger and BTB domain containing 4 
HLF hepatic leukemia factor 
DPF2 D4, zinc and double PHD fingers family 
2 
AES amino-terminal enhancer of split 
EIF4B similar to eukaryotic translation initiation 
factor 4H; eukaryotic translation 
initiation factor 4B 
TACC3 transforming, acidic coiled-coil 
containing protein 3 
SDF4 stromal cell derived factor 4 
ZCCHC3 zinc finger, CCHC domain containing 3 
NR2F1 nuclear receptor subfamily 2, group F, 
member 1 
RAVER2 ribonucleoprotein, PTB-binding 2 
CRYZL1 crystallin, zeta (quinone reductase)-like 1 
PTGDR prostaglandin D2 receptor (DP) 
DDX21 DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 21 
ADARB1 adenosine deaminase, RNA-specific, B1 
(RED1 homolog rat) 
PAX4 paired box 4 
CDC37 cell division cycle 37 homolog (S. 
cerevisiae) 
PUM2 pumilio homolog 2 (Drosophila) 
LSS lanosterol synthase (2,3-oxidosqualene-
lanosterol cyclase) 
CNNM3 cyclin M3 
SPSB3 splA/ryanodine receptor domain and 
SOCS box containing 3 
MGAT1 mannosyl (alpha-1,3-)-glycoprotein beta-
1,2-N-acetylglucosaminyltransferase 
RACGAP1 Rac GTPase activating protein 1 
pseudogene; Rac GTPase activating 
protein 1 
GOT2 glutamic-oxaloacetic transaminase 2, 
mitochondrial (aspartate 
aminotransferase 2) 
PDE7A phosphodiesterase 7A 
PON3 paraoxonase 3 
DNASE1L2 deoxyribonuclease I-like 2 
TIMP3 TIMP metallopeptidase inhibitor 3 
TMEM42 transmembrane protein 42 
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CACNA1E calcium channel, voltage-dependent, R 
type, alpha 1E subunit 
LRP6 low density lipoprotein receptor-related 
protein 6 
FARP1 FERM, RhoGEF (ARHGEF) and 
pleckstrin domain protein 1 
(chondrocyte-derived) 
UROD uroporphyrinogen decarboxylase 
Table 24. Common genes between (significantly expressed genes in PAH and ID3 correlated, blood samples), and 
((significantly expressed genes in PAH and ID3 correlated, tissue) (28 genes) from the significant gene list provided from 
GEO PAH datasets 
Gene 
Symbol 
Gene Name 
MRPL46 mitochondrial ribosomal protein L46 
HIC2 hypermethylated in cancer 2 
PTDSS1 phosphatidylserine synthase 1 
BCL9L B-cell CLL/lymphoma 9-like 
TXNDC11 thioredoxin domain containing 11 
IER2 immediate early response 2 
HARS2 histidyl-tRNA synthetase 2, mitochondrial 
(putative); D-tyrosyl-tRNA deacylase 1 
homolog (S. cerevisiae) 
SRP14 signal recognition particle 14kDa 
(homologous Alu RNA binding protein) 
pseudogene 1; signal recognition particle 
14kDa (homologous Alu RNA binding 
protein) 
BTG3 BTG family, member 3 
IGFBP5 insulin-like growth factor binding protein 
5 
POLR2C polymerase (RNA) II (DNA directed) 
polypeptide C, 33kDa 
SPTBN1 spectrin, beta, non-erythrocytic 1 
EIF4B similar to eukaryotic translation initiation 
factor 4H; eukaryotic translation initiation 
factor 4B 
GPS2 G protein pathway suppressor 2 
H1FX H1 histone family, member X 
VEGFB vascular endothelial growth factor B 
PRKCH protein kinase C, eta 
VAMP2 vesicle-associated membrane protein 2 
(synaptobrevin 2) 
DMPK dystrophia myotonica-protein kinase 
NGRN neugrin, neurite outgrowth associated 
C6orf106 chromosome 6 open reading frame 106 
SAE1 SUMO1 activating enzyme subunit 1 
GLO1 glyoxalase I 
KRT10 keratin 10 
ID3 inhibitor of DNA binding 3, dominant 
negative helix-loop-helix protein 
GMEB2 glucocorticoid modulatory element 
binding protein 2 
LAMA5 laminin, alpha 5 
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WDR20 WD repeat domain 20 
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Blood Results: (GeneOntology, pantherdb.org) 
For blood sample analysis, we imported the significant gene list including 701 
genes into the panther database. However, some genes had different matched IDs, and the 
database included both IDs. Thus, 735 gene IDs were included. To further evaluate the 
gene list, we performed different comprehensive functions analysis including biological 
process, cellular component, Molecular function, GO biological process, GO cellular 
component, GO molecular function, pathways, and protein class. In biological process, 
different functions were involved with the significant gene list provided from GEO PAH 
datasets including cellular process, metabolic process, localization, developmental process, 
cellular component organization or biogenesis, response to stimulus, biological regulation, 
multicellular organismal process, immune system process, reproduction, biological 
adhesion, locomotion, cell killing (Figure 8). Cellular process and molecular process 
reported the most number of genes involved with 333 and 301 genes, respectively.  
 
Figure 8 Biological process functional analysis involved with the significant gene list 
provided from GEO PAH datasets – (Blood samples) from panther database gene 
ontology analysis.   
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In cellular component, the functional analysis: cell junction, membrane, 
macromolecular complex, extracellular matrix, cell part, organelle, and extracellular region 
were involved with the significant gene list provided from GEO PAH datasets; however, 
cell part and organelle had the highest number of genes involved with 192 and 134 genes, 
respectively (Figure 9).   
 
Figure 9 Cellular component functional analysis involved with the significant gene list 
provided from GEO PAH datasets – (Blood samples) from panther database gene 
ontology analysis. 
In GO molecular function analysis, rRNA binding, structural constituent of 
ribosome, RNA binding, nucleic acid binding, DNA binding, enzyme binding, heterocyclic 
compound binding, organic cyclic compound binding, protein binding, binding, molecular 
function, G-protein coupled receptor activity were involved with the significant gene list 
provided from GEO PAH datasets (Figure 10). Moreover, molecular function, binding, and 
protein binding were the most functions with number of genes involved 684, 632, and 531 
genes, respectively. Interestingly, molecular functions with small number of genes 
associated had higher fold enrichment.  
0 50 100 150 200
cell junction (GO:0030054)
membrane (GO:0016020)
macromolecular complex (GO:0032991)
extracellular matrix (GO:0031012)
cell part (GO:0044464)
organelle (GO:0043226)
extracellular region (GO:0005576)
4
45
82
5
192
134
18
Cellular Component - Blood
Percent of gene hit against total # genes # genes
154 
 
 
Figure 10 GO Molecular functional analysis involved with the significant gene list 
provided from GEO PAH datasets – (Blood samples) from panther database gene 
ontology analysis.   
Pathways analysis reported 95 pathways to be involved in our significant gene list 
provided from GEO PAH datasets (Figure 11). Gonadotropin-releasing hormone receptor 
pathway, inflammation mediated by chemokine and cytokine signaling pathway, apoptosis 
signaling pathway, Wnt signaling pathway, Huntington disease, and CCKR signaling map 
represented the highest number of genes involved among all pathways with 17, 16, 12, 11, 
11, and 10 genes, respectively.  
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Figure 11 Pathways functional analysis involved with the significant gene list provided 
from GEO PAH datasets – (Blood samples) from panther database gene ontology 
analysis.   
Protein class reported that ribosomal protein, RNA binding protein, transcription 
factor, and nucleic acid binding were involved with the significant gene list provided from 
GEO PAH datasets (Figure 12). Number of genes reported in each class were 25, 74, 93, 
and 151, respectively. Although, ribosomal protein, the class with small number of genes 
associated, showed the highest fold enrichment.    
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Figure 1. Protein Class functional analysis involved with the significant gene list 
provided from GEO PAH datasets – (Blood samples) from panther database gene 
ontology analysis.   
String (Functional Enrichments) 
String database predict protein-protein interactions and provide functional 
enrichments for biological process, molecular function, cellular component and KEGG 
pathways associated with the significant gene list provided from GEO PAH datasets. For 
biological process, 180 GO terms were observed to have set of genes involved. Cellular 
process, metabolic process, organic substance metabolic process, primary metabolic 
process, and cellular metabolic process had the highest number of genes in their pathways, 
with 429, 370, 366, 365, and 357 genes, respectively (supplement 3).  
 
Figure 2. GO Molecular functional analysis involved with the significant gene list 
provided from GEO PAH datasets – (Blood samples) from STING functional enrichment 
database.   
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GO of molecular function observed 9 pathways to be involved including poly(A) 
RNA binding, nucleic acid binding, RNA binding, heterocyclic compound binding, organic 
cyclic compound binding, DNA binding, binding, structural constituent of ribosome, and 
enzyme binding to be involved with the significant gene list provided from GEO PAH 
datasets (Figure 13). Organic cyclic compound binding, heterocyclic compound binding, 
and nucleic acid binding reported the largest number of genes involved with 244, 243, and 
200 respectively (Supplement 4 for full gene list). Cellular component showed that 43 GO 
pathways to be involved with the significant gene list provided from GEO PAH datasets 
(supplement 5). KEGG pathways showed that 8 pathways to be associated with the 
significant gene list provided from GEO PAH datasets including Ribosome, HTLV-I 
infection, RNA degradation, Purine metabolism, RNA polymerase, MAPK signaling 
pathway, Pathways in cancer, and HIF-1 signaling pathway. Of these pathways, HTLV-I 
infection and Pathways in cancer reported 25 and 24 genes to be involved, respectively 
(Figure 14).   
 
Figure 3. Pathways description analysis involved with the significant gene list provided 
from GEO PAH datasets – (Blood samples) from STING functional enrichment database.    
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An interaction network map was generated based on protein-protein interaction 
data provided by the STRING database. It concludes functional interactions between each 
of the 701 core genes and generated the network map which represent the interactions of 
these genes and their protein products (Figure 15). Another network map was generated 
using the significant gene list provided from GEO PAH datasets, however, it represent the 
highest confidence level of interaction between these genes and their protein products 
(Figure 16).  
 
Figure 4. An interaction network map was generated based on protein-protein 
interaction data using the significant gene list provided from GEO PAH datasets – 
(Blood samples) from STING functional enrichment database.   
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Figure 5. An interaction network map was generated based on the highest confidence 
level of protein-protein interaction involved with the significant gene list provided from 
GEO PAH datasets – (Blood samples) from STRING functional enrichment database. 
Tissue Samples Results: 
For tissue sample analysis, we imported the significant gene list provided from 
GEO PAH datasets including 573 genes into the database. However, some genes had 
different matched IDs, and the database included both IDs. Thus, 602 gene IDs were 
included. To further evaluate the gene list, we performed different comprehensive 
functions analysis including biological process, cellular component, molecular function, 
GO biological process, GO cellular component, GO molecular function, pathways, and 
protein class. In biological process, different functions were involved with the significant 
gene list provided from GEO PAH datasets including cellular component organization or 
biogenesis, cellular process, localization, reproduction, biological regulation, response to 
stimulus, developmental process, multicellular organismal process, biological adhesion, 
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locomotion, metabolic process, and immune system process (Figure 17). Cellular process 
and metabolic process reported the most number of genes involved with 303 and 258 genes, 
respectively.  
 
Figure 6. Biological process functional analysis involved with the significant gene list 
provided from GEO PAH datasets – (Tissue samples) from panther database gene 
ontology analysis.   
In cellular component, synapse, cell junction, membrane, macromolecular 
complex, extracellular matrix, cell part, organelle, and extracellular region were involved 
with the significant gene list provided from GEO PAH datasets; however, cell part and 
organelle had the highest number of genes involved with 163 and 90 genes, respectively 
(Figure 18). In GO biological process, small molecule metabolic process, cellular 
metabolic process, single-organism cellular process, organic substance metabolic process, 
metabolic process, primary metabolic process, cellular process, single-organism process, 
biological process, detection of stimulus involved in sensory perception, and sensory 
perception of chemical stimulus were involved with the significant gene list provided from 
GEO PAH datasets. Moreover, cellular process and single-organism process were the most 
functions with number of genes involved 510 and 433 genes, respectively. Small molecule 
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metabolic process, cellular metabolic process reported the highest fold enrichment among 
other biological process with 1.69 and 1.28 fold enrichment, respectively (Figure 18). 
 
Figure 7. Cellular component functional analysis involved with the significant gene list 
provided from GEO PAH datasets – (Tissue samples) from panther database gene 
ontology analysis.   
 
Figure 8. GO Biological Process functional analysis involved with the significant gene 
list provided from GEO PAH datasets – (Tissue samples) from panther database gene 
ontology analysis.   
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organelle, organelle, cell part, cell, and cellular component were involved with the 
significant gene list provided from GEO PAH datasets (Figure 20). Moreover, cell and cell 
part, intracellular, and intracellular part represented the highest number of gene involved 
with 543, 500, and 486 genes, respectively. Cytosol and intracellular organelle part were 
the highest in fold enrichment with 1.32 and 1.3, respectively.  
 
Figure 20. GO of Cellular component functional analysis involved with the significant 
gene list provided from GEO PAH datasets – (Tissue samples) from panther database 
gene ontology analysis.   
In GO molecular functional analysis, cation binding, metal ion binding, protein 
binding, catalytic activity, binding, and molecular function were involved with the 
significant gene list provided from GEO PAH datasets (Figure 21). Moreover, protein 
binding and catalytic activity represented the highest number of genes involved with 417 
and 220 genes, respectively.  Cation binding and metal ion binding were the highest in fold 
enrichment with 1.37 and 1.36, respectively. In molecular function, translation regulator 
activity, binding, receptor activity, structural molecule activity, signal transducer activity, 
catalytic activity, antioxidant activity, and transporter activity were involved with the 
significant gene list provided from GEO PAH datasets (Figure 22). Molecular function of 
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binding and catalytic activity reported 194 and 190 genes to be involved, respectively. 
Pathway analysis reported 90 pathways to be involved in the significant gene list provided 
from GEO PAH datasets (Figure 23). Gonadotropin-releasing hormone receptor pathway, 
Angiogenesis, Wnt signaling pathway, inflammation mediated by chemokine and cytokine 
signaling pathway, and EGF receptor signaling pathway represented the highest number of 
genes involved among all pathways with 13, 11, 10, 10, and 7 genes, respectively.  
 
Figure 21. GO of Molecular functional analysis involved with the significant gene list 
provided from GEO PAH datasets – (Tissue samples) from panther database gene 
ontology analysis.   
 
Figure 22. Molecular functional analysis involved with the significant gene list provided 
from GEO PAH datasets – (Tissue samples) from panther database gene ontology 
analysis.   
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Figure 23 Pathway functional analysis involved with the significant gene list provided 
from GEO PAH datasets – (Tissue samples) from panther database gene ontology 
analysis.   
Protein class analysis reported 20 protein class to be involved with the significant 
gene list provided from GEO PAH datasets (Figure 24). Nucleic acid binding, enzyme 
modulator, hydrolase, transferase, and transcription factor represented the highest number 
of genes involved with 91, 54, 51, 46, and 45 genes respectively.   
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Figure 9. Protein Class functional analysis involved with the significant gene list 
provided from GEO PAH datasets – (Tissue samples) from panther database gene 
ontology analysis.   
Analyzing tissue samples using STRING database for biological process reported 
23 pathways to be involved in the significant gene list provided from GEO PAH datasets 
(Figure 25). GO Cellular process, single-organism cellular process, single-organism 
process, and metabolic process showed the highest number of gene with 367, 313, 310, and 
295 genes, respectively. GO of Enrichment component showed 16 components to be 
involved with the significant gene list provided from GEO PAH datasets (Figure 26). Cell 
part, intracellular part, and organelle represented the highest number of genes involved 
with 429, 395, and 367 genes, respectively. GO of molecular function observed 8 pathways 
to be involved including binding, ion binding, catalytic activity, protein binding, cation 
binding, metal ion binding, transition metal ion binding, and phosphoric ester hydrolase 
activity. Binding, ion binding, and catalytic activity reported the largest number of genes 
involved with 320, 205, and 180, respectively (Figure 27) (Supplement attached for full 
gene list). 
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Figure 25. Biological process reported 23 pathways involved with the significant gene 
list provided from GEO PAH datasets – (Blood samples) from STING functional 
enrichment database.   
 
Figure 26. GO of Enrichment component reported 16 components to be involved with the 
significant gene list provided from GEO PAH datasets – (Blood samples) from STING 
functional enrichment database.  
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Figure 27. GO of molecular function observed 8 pathways to be with the significant gene 
list provided from GEO PAH datasets – (Blood samples) from STING functional 
enrichment database.   
An interaction network map was generated based on protein-protein interaction 
data provided by the STRING database. It concludes functional interactions between each 
of the 573 core genes and generated the network map which represent the interactions of 
with the significant gene list provided from GEO PAH datasets and their protein products 
(Figure 28). Another network map was generated; however, it represents the highest 
confidence level of interaction between these genes and their protein products (Figure 29). 
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Figure 28. An interaction network map was generated based on protein-protein 
interaction data provided of the significant gene list provided from GEO PAH datasets – 
(Blood samples) from STING functional enrichment database.   
 
 
Figure 29. An interaction network map for Tissue samples was generated based on the 
highest confidence level of protein-protein interaction. 
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We searched through panther web-tool gene ontology for pathways associated with 
blood samples and tissue samples, and compared these pathways from STRING database. 
Common pathways were selected for further analysis. Also, we searched the literature for 
PAH associated pathways and genes associated with PAH. We searched through all 
pathways, and pathways with 3< genes involved were included, and common genes were 
included in a separate gene list.  
29 genes found to be common in blood samples, and 18 genes in tissue samples 
(Table 28 and Table 29). This gene list was imported into Bene software to find out and 
validate the association between these genes with PAH in blood and tissue samples in a 
structure of BN which represent the best score in association between variables. The best 
structure of BN of tissue samples including genes associated with PAH in Figure 30.   
Table 25 Genes associated with PAH; and PAH pathways from Gene Ontology, 
STRING, and literature (Blood Samples) (29 genes) 
Gene Symbol Gene Name 
ATF4 activating transcription factor 4(ATF4) 
AXIN2 axin 2(AXIN2) 
BAX BCL2 associated X, apoptosis regulator(BAX) 
CD3E CD3e molecule(CD3E) 
CREM cAMP responsive element modulator(CREM) 
ATF2 activating transcription factor 2(ATF2) 
CREBBP CREB binding protein(CREBBP) 
FKBP11 FK506 binding protein 11(FKBP11) 
SNIP1 Smad nuclear interacting protein 1(SNIP1) 
BAG3 BCL2 associated athanogene 3(BAG3) 
BAG4 BCL2 associated athanogene 4(BAG4) 
FOS Fos proto-oncogene, AP-1 transcription factor subunit(FOS) 
JUND JunD proto-oncogene, AP-1 transcription factor subunit(JUND) 
SMAD7 SMAD family member 7(SMAD7) 
LTB lymphotoxin beta(LTB) 
EIF2A eukaryotic translation initiation factor 2A(EIF2A) 
GADD45B growth arrest and DNA damage inducible beta(GADD45B) 
MAPK6 mitogen-activated protein kinase 6(MAPK6) 
PRKCH protein kinase C eta(PRKCH) 
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PPP3CC protein phosphatase 3 catalytic subunit gamma(PPP3CC) 
DCP1A decapping mRNA 1A(DCP1A) 
EXOC2 exocyst complex component 2(EXOC2) 
RELA RELA proto-oncogene, NF-kB subunit(RELA) 
RELB RELB proto-oncogene, NF-kB subunit(RELB) 
RALGDS ral guanine nucleotide dissociation stimulator(RALGDS) 
SUMO3 small ubiquitin-like modifier 3(SUMO3) 
TGFB3 transforming growth factor beta 3(TGFB3) 
RRAS2 related RAS viral (r-ras) oncogene homolog 2(RRAS2) 
PIK3R5 phosphoinositide-3-kinase regulatory subunit 5(PIK3R5) 
Table 26 Genes associated with PAH and PAH pathways from Gene Ontology, STRING, 
and literature (Tissue Samples) (18 genes) 
Gene 
Symbol 
Gene Name 
TNFSF10 tumor necrosis factor superfamily member 10(TNFSF10) 
AES amino-terminal enhancer of split(AES) 
AKT1 AKT serine/threonine kinase 1(AKT1) 
ARHGAP
1 
Rho GTPase activating protein 1(ARHGAP1) 
AP2M1 adaptor related protein complex 2 mu 1 subunit(AP2M1) 
DVL3 dishevelled segment polarity protein 3(DVL3) 
HDAC1 histone deacetylase 1(HDAC1) 
IGF2R insulin like growth factor 2 receptor(IGF2R) 
PCDH10 protocadherin 10(PCDH10) 
LRP6 LDL receptor related protein 6(LRP6) 
PRKCH protein kinase C eta(PRKCH) 
PPP2R5A protein phosphatase 2 regulatory subunit B'alpha(PPP2R5A) 
CDH24 cadherin 24(CDH24) 
RALA RAS like proto-oncogene A(RALA) 
RGL2 ral guanine nucleotide dissociation stimulator like 2(RGL2) 
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RAC1 ras-related C3 botulinum toxin substrate 1 (rho family, small GTP binding 
protein Rac1)(RAC1) 
NKD1 naked cuticle homolog 1(NKD1) 
RGL1 ral guanine nucleotide dissociation stimulator like 1(RGL1) 
 
 
 
 
Figure 30. The best structure of BN of tissue samples including genes associated with 
PAH using Bene software (20 variables) 
 
We searched the Comparative Toxicogenomics Database (http://ctdbase.org/) for 
association between the identified PAH and ID3 target genes and PCBs associated genes. 
We used the gene list of PAH and ID3 target genes (701 genes) in blood samples and PCBs 
associated genes curated from CTD (648). The common genes in blood sample analysis 
were 34 genes (Table 27). We used the gene list of PAH and ID3 target genes (573 genes) 
in tissue samples and PCBs associated genes curated from CTD (648). The common genes 
in tissue sample analysis were 19 genes (Table 27). 
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Table 27 Common (34) genes between PAH and ID3 target genes (701 genes) in blood 
samples and PCBs associated genes (648). Common (19) genes between PAH and ID3 
target genes (573 genes) in tissue samples and PCBs associated genes (648) using CTD 
database.  
Common (34) genes between PAH and ID3 
target genes (701 genes) in blood samples and 
PCBs associated genes (648) 
Common (19) genes between PAH and ID3 
target genes (573 genes) in tissue samples and 
PCBs associated genes (648) 
ALDH5A1, BTG1, CDKN1B, CIRBP, CLK1, 
COL12A1, CTSK, DNAJB9, DUSP1, EBP, 
EMP2, ENC1, FOS, HSP90AB1, ID3, IL6, 
ILF2, LNX2, MASTL, MCM6, MMP3, 
NECAP1, PEBP1, PFKFB3, PLEKHB1, 
PRC1, PRNP, PTGER4, RAD23B, 
RNASEH1, SAFB, TNFRSF25, TSEN54, 
YPEL5 
AKT1, ARHGEF10, CASP2, CDT1, CLK2, 
CSF3R, HIST1H4L, ID3, IL2, MAN2C1, 
NR3C1, POLE, RACGAP1, NF146, SMG6, 
STMN1, TACC3, TIMP3, UROD 
 
 
Figure 31 Common (34) genes between PAH and ID3 target genes (701 genes) in blood 
samples and PCBs associated genes (648).  
 
 
Figure 32 Common (19) genes between PAH and ID3 target genes (573 genes) in tissue 
samples and PCBs associated genes (648). 
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We used the gene list of PAH-associated genes; and genes associated with PAH 
pathways in literature and we found 5 genes to be common among different pathways 
including VEGFB, PRKCH, VAMP2, POLR2C, and LAMA5. Then, we used the 
expression data we have for VEGFB, PRKCH, VAMP2, POLR2C, LAMA5, location, and 
PAH; and we run it into Genie software to see how these genes are expressed in the data 
and what would be the relationship between them. We run the analysis many times and 
each we changed the status of one of the variables. For genes (low, normal, and high 
expression), location (blood and tissue), and PAH (control and Disease) (Figure 33-37).   
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Figure 33 Genie software analysis: A) Original expression of genes, PAH, and location variables using our meta-analyzed 
microarray datasets. B) We overexpressed PAH variable to see the effect on its parent variable. C) We knockdown PAH 
variable to be all control sample expression. 
A 
B C 
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Figure 34 Genie software analysis: A) Normal expression of VAMP2 gene and its effect on other variable using our meta-
analyzed microarray datasets. B) We overexpressed VAMP2 variable to see the effect on other variables. C) We knockdown 
VAMP2 variable to see the effect on other variables. 
                               
Figure 35 Genie software analysis: A) Normal expression of POLR2C gene and its effect on other variable using our meta-
analyzed microarray datasets. B) We overexpressed POLR2C variable to see the effect on other variables. C) We knockdown 
POLR2C variable to see the effect on other variables 
C 
B 
A 
A B C 
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Figure 36 Genie software analysis: A) Normal expression of VEGFB gene and its effect on other variable using our meta-
analyzed microarray datasets. B) We overexpressed VEGFB variable to see the effect on other variables. C) We knockdown 
VEGFB variable to see the effect on other variables. 
A B C 
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Figure 37 Genie software analysis: A) Normal expression of PRKCH gene and its effect on other variable using our meta-
analyzed microarray datasets. B) We overexpressed PRKCH variable to see the effect on other variables. C) We knockdown 
PRKCH variable to see the effect on other variables 
 
 
C B A 
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DISCUSSION 
Our meta-analysis of PAH microarray datasets published in GEO would be the first 
meta-analysis on PAH microarray expression data. We identified the key gene network 
that significantly associated with PAH and different biological material including blood 
and tissues. We used those genes involved in pathways associated with PAH using different 
sources including literature, PANTHER gene Ontology, and STRING web tools. All 
pathways that had more than 3 genes involved were used, and genes were combined 
together.  
Many pathways and genes are known to be associated with PAH. ACVRL1, ALK1, 
BMPR1B, BMPR2, CAV1, CBLN2, EIF2AK4, ENG, KCNA5, KCNK3, SMAD9, TBX, 
TBX, CYP1B1, ACE, 5-HTT, PGIS, MMP2, MMP9, Bax, TGFBR2, VIP, ET1, and 
angiopoietin 1. While using STRING database, many pathways showed an association with 
PAH through gene association, and the most significant pathways were Apoptosis 
signaling pathway, p53 pathway, Ras Pathway, T cell activation, TGF-beta signaling 
pathway, VEGF signaling pathway, Wnt signaling pathway.  
In blood sample analysis using STRING database, apoptosis signaling pathway 
reported that ATF2, EIF2A, FOS, PRKCH, RELA, RELB, LTB, BAX, ATF4, BAG4, 
BAG3, and CREM to be associated with PAH. p53 pathway reported that PIK3R5, 
CREBBP, GADD45B, BAX, and SUMO3 to be associated with PAH. Moreover, Ras 
Pathway reported that ATF2, RRAS2, RALGDS, and EXOC2 to be associated with PAH. 
T cell activation reported that CD3, FOS, PPP3CC, and CD3E to be associated with PAH. 
TGF-beta signaling pathway reported ATF2, RRAS2, CREBBP, TGFB3, SMAD7, 
DCP1A, JUND, SNIP1, and FKBP11 to be associated with PAH. VEGF signaling pathway 
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reported PRKCH, MAPK6, and RRAS2 to be associated with PAH. Wnt signaling pathway 
reported that ATF2, RRAS2, CREBBP, TGFB3, SMAD7, DCP1A, JUND, SNIP1, 
FKBP11, AXIN2, and PRKCH to be associated with PAH.  
In tissue sample analysis using STRING database, Wnt signaling pathway reported 
that AES AP2M1, CDH24, DVL3, HDAC1, LRP6, NKD1, PCDH10, PPP2R5A, and 
PRKCH to be associated with PAH. Ras Pathway reported that RAC1, RGL2, AKT1, 
RALA, and RGL1 to be associated with PAH. Apoptosis signaling pathway reported that 
PRKCH, IGF2R, TNFSF10, and AKT1 to be associated with PAH. VEGF signaling 
pathway reported that RAC1, PRKCH, AKT1, and ARHGAP1 to be associated with PAH. 
p53 pathway and T cell activation reported that HDAC1 and AKT1; RAC1 and AKT1 to 
be associated with PAH, respectively.  
PRKCH is a gene that encodes the η isozyme of protein kinase C (PKCη) and it is 
known to play a significant role in signal transduction that control T-cell activation 
(Teixeira et al., 2008). PRKCH showed significant association with rheumatoid arthritis as 
it was expressed in lower levels than normal control. Our results showed that Low 
expression of PRKCH resulted in higher probability of PAH, and high expression of 
PRKCH decreases the probability of PAH (Figure 34 B and C). 
VEGF reported to be increased in lung tissue with PAH and VEGFB is another 
isoform of it (Malenfant et al., 2013). VEGFB controls many non-angiogenic functions 
such as facilitating fatty acid transport in EC and preventing angiotension 2 (which increase 
cardiac diastolic dysfunction) (Voelkel & Gomez-Arroyo, 2014). Low expression of 
VEGFB was found in the right ventricle of SuHx rats (Al-Husseini et al., 2015). Our results 
showed that knock-down VEGFB is significantly associated with decrease the expression 
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of VAMP2, POLR2C, and PRKCH. Whereas, over expression of VEGFB, cases increase 
in expression of same genes. However, it causes decrease in probability of PAH status 
comparing with normal and low expression of VEGFB. In summary, our meta-analysis 
showed that different expression in VAMP2, LAMA5, POLR2C, VEGFB, and PRKCH 
are the most significantly associated genes with PAH and PAH regulated pathways. 
Although, these genes suggested to be highly influencing the pathogenesis of PAH.  
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CHAPTER 6 
OVERALL CONCLUSIONS 
The main goal of this dissertation was to study the molecular determinant of PAH 
and to evaluate the exposure to EDC (PCB) and their association with the risk of PAH in 
a representative NHANES 1999-2004 data of the U.S population. Molecular level 
interactions that are associated with PAH were studied by meta-analyzing 6 microarray 
gene expression datasets of PAH from GEO. The resulted gene list was used to determine 
gene ontology and PAH-associated pathways using Panther and string database. Combined 
results from our meta-analysis, Panther and String databases were used to determine the 
plausible markov blanket genes network using Bayesian network analysis.  
Meta-analysis of gene expression microarray datasets from GEO resulted in 10,716 
genes to be common in all PAH studied in blood and tissue samples. ID3 correlated genes 
were matched with 701 and 573 genes from blood and tissue samples, respectively. GO 
pathway analysis showed that Gonadotropin-releasing hormone receptor pathway, 
inflammation mediated by chemokine and cytokine signaling pathway, and apoptosis 
signaling pathway had the highest number of gene involved from blood samples. However, 
Gonadotropin-releasing hormone receptor pathway, Angiogenesis, and Wnt signaling 
pathway had the highest number of genes involved from tissue samples. Common genes in 
pathways associated with PAH from gene ontology databases resulted in 29 genes and 18 
genes common for blood and tissue samples, respectively. These genes were matched with 
literature PAH pathway associated genes and resulted in 5 genes to be common among 
different pathways including VEGFB, PRKCH, VAMP2, POLR2C, and LAMA5.      
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Supported with information that females have higher risk of PAH, we evaluated 
PCBs serum concentrations and their association with risk of PAH using NHANES 1999-
2004 survey data. All 6 PCBs (74, 99, 118, 138, 153, and 180) concentration were higher 
in people at risk of PAH than people not at risk of PAH in the U.S. population > 20 years 
old. Also, higher risk of PAH was reported in the sum of dioxin-like PCBs (PCB 74 and 
118), and non-dioxin-like PCBs (PCB 118, 138, 153, and 180) concentration in the U.S. 
population > 20 years old. All confounders (gender, age, BMI, annual family income, 
educational level, smoking, and alcohol use) were associated with the higher risk of PAH 
except older age groups. Different LOD of PCBs (> LOD, > 50%, 50-75%, and >75%) 
were significantly higher in people at risk of PAH except PCB 180.    
Overall, we are representing genes (VEGFB, PRKCH, VAMP2, POLR2C, and 
LAMA5) that were associated with PAH risk factors using bioinformatics and gene-
ontology. Also, we provide plausible gene network pathway that could lead to PAH. 
Additionally, we evaluated different PCBs serum concentrations and their association with 
the risk of PAH in the U.S population.  
LIMITATIONS 
Risk of PAH variable that was created using PAH associated risk factors remains a 
limitation in our study. Also, small number of people at risk of PAH in NHANES 1999-
2004 data, resulted in decreasing the significance risk of PAH and exposure to PCBs 
results.    
Future Studies  
Even though our results showed association between PCBs and risk of PAH, 
epidemiologic studies need to be conducted to report the association between exposure to 
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EDCs and development of PAH. Multiple pathways associated with PAH, its related 
estrogen toxicity, and at the same time continuous exposure to EDCs, support the needs to 
conduct epidemiological studies. Lastly, RNA sequence studies need to update findings of 
such deep level analysis and its association of development of PAH; and further validate 
by what mechanism estrogen would increase risk of females.    
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